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Chapter 1 - General introduction
Inflammation-based diseases, such as chronic inflammation (e.g., inflammatory 
bowel disease (IBD) and Type 2 diabetes Mellitus (T2DM)), auto-immune diseases 
(rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)), hypertension and 
severe cancer (myeloma, neuroendocrine tumors, lung and breast cancer) (1–3) are 
major health problems. For instance, two million people in the United States suffer 
from IBD, which includes patients with Crohn’s disease (CD) and ulcerative colitis (UC) 
(4). Moreover, 415 million adults were globally affected by T2DM in 2015 and this 
caused 5.0 million deaths (5). For RA the current mortality rate is 2.2 million (6) and 
for SLE comorbidities including infection and cardiac malfunction account for 29% 
of all deaths (5,7). The second leading cause of death worldwide is cancer and 1 in 
6 people die of cancer, accounting for 8.8 million deaths in 2015 (5). The prevalence 
of all these diseases is increasing and, in many cases, sufficient therapies are not 
available. Recently, an interest in utilizing the body’s own molecules to treat these 
diseases arose. An interesting candidate for this is the pro-hormone chromogranin A 
(CgA), which contributes to a balanced immune response (8,9). CgA is proteolytically 
cleaved, both intracellularly as well as extracellularly after its release, and this gives 
rise to several bioactive peptides that can be released locally by endocrine cells in 
for example the pancreas or the gut (10,11). Moreover, CgA has been detected in 
other secretory vesicles of endocrine, neuroendocrine and neuronal tissues (12–15) 
as well as in keratinocytes (16), myocardial cells (17–19), endothelial cells (20,21), 
and macrophages (20). The bioactive peptides exert a broad spectrum of regulatory 
functions among the metabolic, endocrine, cardiovascular and immune systems 
(22). It is becoming increasingly clear that one of these cleavage products, the bio-
active peptide catestatin (CST: hCgA352-372) (23,24), is particularly of interest, since it 
suppresses tissue inflammation and affects the immune system. Indeed, the concept is 
emerging that CST plays an immunomodulatory role in the regulation of macrophages, 
metabolism, hypertension, insulin resistance and in gut homeostasis(8,9). Therefore, 
we investigated the new concept of modulating innate immunity by targeting CST, by 
examining the effect of CST on gut homeostasis and infiltrating immune cells and the 
role of CST in inflammatory bowel disease (IBD). 
Gut homeostasis and chronic inflammation in the gut
The protection against pathogens, viruses and bacteria, already starts on the outside 
of our body. Invaders are stopped by several physical barriers including the skin, 
mucus and environment with a low pH, such as the stomach. The gastro-intestinal 
tract itself also contains beneficial bacteria that help to take up food and nutrients and 
complement the mucus layer(25). However, the balance between these ‘good’ and ‘bad’ 
bacteria in the gut is very important since an increase in for example, the negative 
bacteria Bacteroidetes, can disturb the protective mucus layer because Bacteroidetes 
metabolize the mucin glycans (26)(Fig. 1). Normally, the mucus layer prevents 
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the bacteria to reach the intestinal epithelial lining of the villi, which separates the 
lumen with bacteria from the underlying gut tissue (27). There are several cell types 
present in these intestinal villi such as goblet cells, which produce the mucus, and 
enteroendocrine cells (EECs). EECs are cells in the intestine helping the epithelium 
to regulate nutrient absorption, secretion and motility by producing several pro-
hormones, including CgA (28,29). Hormones, such as glucagon-like peptide 1 and 
ghrelin, produced by EECs can access the central nervous system to regulate digestive 
processes, immune regulation, immune cell migration and gut motility (27,30). A 
dysregulation in these hormones contributes to intestinal inflammation (31,32), such 
as found in IBD.
IBD is a chronic inflammatory disorder with an incompletely understood pathogenesis, 
that is potentially linked to the gastrointestinal endocrine system (GES)(27). The 
two main forms of IBD are Ulcerative colitis (UC) and Crohn’s disease (CD). UC is 
characterized by inflammation of the mucosa in the rectum and colon, whereas CD 
involves inflammation in all layers of the intestinal wall. In contrast to UC, CD is mainly 
found in the ileum, but can affect the whole gastrointestinal tract (27). In the colon 
of IBD patients, the epithelial layer is more permeable and leakier resulting in more 
exposure to pathogens which can lead to inflammation of the gut (Fig. 1). Monocytes, 
granulocytes and T cells are attracted from the blood to the inflamed area, followed by 
infiltration in the intestinal tissue. 
Tissue macrophages such as liver Kupffer cells, spleen red-pulp and large peritoneal 
macrophages develop during embryogenesis, where they originate from precursors in 
the yolk sac, fetal liver and bone marrow (33). These embryonically-derived macrophages 
become tissue-resident macrophages that can propagate via self-renewal (33,34). Later 
in life, the hematopoietic stem cells in the bone marrow give rise to LY6C+ monocytes in 
mice or CD14+CD16+ monocytes in human, which  can subsequently be recruited from 
the blood into the tissues, such as sites of infection or tumors, to either promote further 
inflammation or tissue repair (34–36). Upon arrival, these monocytes can either remain 
monocytes, exerting for example antigen-presenting roles (37), and/or differentiate into 
macrophages upon external signals, PRR signaling, growth factors, and cytokines present 
in the tissue (38–40)these monocytes can differentiate into pro- or anti-inflammatory 
monocyte-derived macrophages, depending on the PRR signaling, growth factors and 
cytokines present in the tissue. Both monocytes and macrophages, (tissue-resident or 
monocyte-derived) can release inflammatory cytokines, including interleukin-1β (IL-1β), 
IL-6, IL-8, Tumor necrosis factor-alpha (TNF-α) as well as chemokines, such as CCL2 and 
CCL3 (38–40), which normally contribute to the elimination of pathogens. However, in 
the case of IBD the intestinal inflammation is not completely resolved, which eventually 
results in chronic inflammation.
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So far, no cure has been found for IBD and regulation of gut homeostasis remains 
partly unknow. Since IBD is characterized by chronic inflammation and a dysregulated 
intestinal immune system (27), it is possible that the immunomodulatory pro-hormone 
CgA and its bioactive cleavage product CST are involved in the pathogenesis of IBD.
Chromogranin and its cleavage product Catestatin
The plasma (nM)  and high local (μM) CgA or CST levels seem to change in health 
and disease  (8). The CgA plasma levels range from 0.5 to 1  nM (22), whereas the 
physiological blood levels of CST range from 0.03 to 1.5 nM in healthy subjects (22,41). 
To understand the role of CgA and CST in colon homeostasis we will first take a more 
detailed look into the location and production of CgA and its cleavage products 
resulting in detectable plasma levels.
Fig. 1 Healthy vs inflamed colon. (A) Healthy colon: good (green) and bad (red) bacteria, shielded 
from intestinal cells by the mucus layer (pink), which is produced by goblet cells (purple), and 
includes enteroendocrine cells that produce hormones such as chromogranin A. Tissue resident 
macrophages (blue) and T cells (grey) (B) Inflamed colon: the bacteria composition has changed 
and the mucus layer is thinner. As a result, the bacteria can now infiltrate into the intestinal tissue. 
To eliminate the bacteria monocytes, monocyte-derived macrophages and T cells are attracted to 
the affected area.
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Cleavage products of the pro-hormone Chromogranin A (CgA)
The human CgA gene is located on chromosome 14 (42,43) and codes for a 439 amino 
acids long protein (44). As member of the granin family, CgA is characterized by an 
acidic pI, heat stability, and 8-10 pairs of dibasic cleavage sites (45). Moreover, this 
49 kDa protein has the capacity to form aggregates and the ability to bind calcium 
(Ca2+) with a high capacity, but low affinity (46). CgA was first identified as an acidic 
protein co-stored and co-released with ATP and catecholamines in chromaffin 
granules of neuroendocrine cells in the adrenal medulla (47,48). CgA facilitates the 
storage in these granules of catecholamines and ATP at hyperosmotic concentrations 
in a non-diffusible form (47–51). Thereby CgA contributes to the biogenesis of 
secretory granules packed with condensed proteins, mostly (pro) hormones (52,53) 
via recruitment of proteins involved in the formation and trafficking of vesicles, 
such as cytoskeleton-, GTP-, and Ca2+-binding proteins (54). The secretory granules 
route toward the cell periphery, where they mature and undergo calcium-controlled 
exocytosis (55–57). Upon an increase in Ca2+ concentration, CgA is co-released 
simultaneously with the stored hormones of the secretory granules via exocytosis 
(55–57). CgA is not only present in chromaffin cells, but has been detected in other 
secretory vesicles of endocrine, neuroendocrine and neuronal tissues (12–15) as 
well as in keratinocytes (16), myocardial cells (17–19), endothelial cells (20,21), and 
macrophages (20). Interestingly, CgA is also present in cells of the pancreatic islet, 
secretory granules of glucagon containing α-cells and insulin producing β-cells, and 
may thereby modulate glucose metabolism (15,58–62). This makes CgA particularly 
interesting in the context of metabolic diseases such as diabetes. Patients suffering 
from carcinoids or other neuroendocrine tumors (55,63–67), heart failure, renal failure, 
hypertension, RA, and IBD (32,68–73) display increased levels of circulating CgA, 
implicating an important role of CgA to influence human health and disease (3). These 
functions indicate that the role of CgA is more general as a pro-hormone and is not 
only restricted to the storage of catecholamines.
Cleavage products of CgA
CgA can be proteolytically processed in various tissues and thereby serves as a 
precursor for several biological active peptides (Fig. 2). The cleavage of CgA at its 
dibasic sites is performed by intra-granular and extra-cellular proteases such as 
prohormone convertases 1 (PC1) (74), PC2 (74), furin (74), cysteine protease cathepsin 
L (CTSL) (75), the serine proteases plasmin (76,77) and thrombin (78), as well as by 
kallikrein (79). Depending on the cleavage sites, post-translational modifications 
(glycosylation and phosphorylation) and proteolytic processing, CgA can result 
in the following six biological active peptides (22,80). The first peptide identified 
was pancreastatin (PST) (hCgA250-301), which has an opposing effect to insulin 
(62,81,82). WE-14 (hCgA324-337) was identified in midgut carcinoid tumors and acts 
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as an antigen for the highly diabetogenic CD4+ T cell clones (83–85). Chromofungin 
(hCgA47-66) has antimicrobial effects as well as effects on innate immune regulation 
(86,87). Vasostatin (hCgA1-76) has a vasodilative and anti-angiogenic as well as 
antiadrenergic functions (88–90). Serpinin (hCgA402-439) regulates granule biogenesis 
(91) and acts as a myocardial ß agonist (92). Finally, the pleotropic peptide CST 
(hCgA352-372) has mainly anti-inflammatory effects (11,93) and is the central focus 
of this thesis. Cleavage of CST results in Cateslytin (hCgA344-358), which is the active 
domain of CST (94,95). CgA is unique as several of its peptides exhibit opposing 
counter-regulatory effects for fine-tuning and maintaining metabolic homeostasis. 
As for cardiac function, this is regulated in rodents by the pro-adrenergic peptide 
serpinin (92) and both antiadrenergic peptides vasostatin and CST (96,97). Likewise, 
angiogenesis is controlled by the antiangiogenic peptide vasostatin (98,99) and the 
proangiogenic peptide CST (98,100). Similarly, glucose homeostasis is maintained 
by the anti-insulin peptide pancreastatin (62,81,82,101), and the pro-insulin peptide 
CST (102). Although CgA processing has been reported to occur intracellularly inside 
the hormone-storage vesicles and extracellularly after its release in the blood, no 
systematic studies have been conducted to determine whether several proteolytic 
enzymes act at the same time to liberate all of the CgA peptides or act at different 
sites at different times in a tissue-specific manner. In addition, no attempts have been 
made so far to assess whether CgA peptides are generated in equal molar amounts 
or generated in response to physiological demands in different tissues. However, it 
has been reported that circulating concentrations of CgA peptides are different. As for 
example, plasma vasostatin level varies from 0.3 to 0.4 nM and CST circulates at 0.03 to 
1.5 nM  concentrations (22), which might represent different degrees of processing or 
rate of clearance from the circulation. 
The pleotropic peptide catestatin (CST)
At first CST was identified as a potent inhibitor of nicotine induced catecholamine 
release. As CST is secreted together with catecholamines, it can thereby function 
as an autocrine negative feedback-loop self-limiting further catecholamine 
production (23,103–105). Later, CST was found to play a role in the regulation of 
hypertension(97,106–108) and cardiac functions (11,109–114), as well as in promoting 
angiogenesis (100,107), decreasing obesity(115) and regulating innate immunity 
(11,16,20,28,102,116,117). In line with this, altered plasma levels of CST or its 
prohormone CgA have been observed in the context of various diseases. Plasma levels 
of CST are reduced in patients suffering from T2DM and hypertension (41,102,118), 
whereas elevated levels of the pro-hormone CgA have been detected in the plasma 
of patients with neuroendocrine tumors (55), hypertension(119,120) and various 
inflammatory diseases such as RA (7,121,122), SLE (7), IBD (31,32,73,123,124) as well 
as T1DM and T2DM (85,125–128). This suggests that the lower levels of CST are caused 
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by a dysregulation of proteolytic processing of CgA (118). The balance between 
other CgA cleaved products seems also important to counteract effects of CST. Since 
vasostatin has an anti-angiogenic effect (88–90), this might counteract the pro-
angiogenic effect of CST (100,107). Moreover, CgA-knockout (CgA-KO) mice develop 
an obese phenotype (62) as well as severe hypertension which could be rescued by 
intra-peritoneal injections of CST (106). Since hypertension is linked to diabetes, heart 
diseases and psoriasis (129), this indicates that CST might be important in various 
severe diseases. These findings support the hypothesis that the impaired processing 
of CgA might lead to lower CST levels which contributes to disease development. They 
also warrant further studies to elucidate the effects and mechanisms of CgA and its 
bio-active peptide products. 
CST contributes to maintenance of metabolic and immune 
homeostasis
CST regulates immune homeostasis
CST contributes to the defense against infections in several ways (116,117,130). 
An early study utilized 15 amino acids from the N-terminal end of bovine CST or 
cateslytin to demonstrate the antimicrobial activities (116). Thus, CST can directly 
act on invading microbes, as CST can penetrate the membrane of bacteria and fungi. 
At relatively high concentrations (>µM) it thereby directly can impair the growth of 
fungal pathogens (116). Moreover, CST can induce lysis of bacteria and helps to 
protect against infections following skin injuries in mice (16). Second, at least in vitro, 
CST can result in activation of neutrophils and mast cells which contribute to innate 
immune responses to infections (28,116,117,130,131). These effects may be restricted 
to locally high CST concentrations, whereas systemic anti-inflammatory effects of CST 
have been best described in autoimmune diseases (Fig. 3). 
In Diet-induced obese (DIO) mice, the intra-peritoneal injection of CST inhibited the 
infiltration of monocytes in the liver and reduced CC-chemokine ligand 2 (CCL2)-
induced chemotaxis of peritoneal macrophages (102). The molecular mechanisms 
by which CST affects monocyte and macrophage migration are still unclear. One 
possibility is that CST directly affects leukocyte migration. This is shown for monocytes, 
although in this case already low concentrations of CST (nM) promoted migration in 
an in vitro chemotaxis assay (132). The reasons underlying this discrepancy between 
in vitro and in vivo experiments is unclear, but could be due to CST affecting other 
chemokines (such as CCL-2) present in the in vivo situation. Moreover, CST is also pro-
angiogenic (100,107) which might reduce its anti-inflammatory effect when present 
on its own. Another possibility is that CST affects the integrins that affect leukocyte 
extravasation. This possibility is supported by the finding that CST can reduce 
expression levels of the integrin ligands intracellular adhesion molecule 1 (ICAM-1) 
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and vascular CAM-1 (VCAM-1) in endothelial cells, which correlate with lymphocyte 
extravasation (20). Finally, CST might reduce monocyte infiltration in inflammatory 
tissues by lowering the production of pro-inflammatory cytokines and chemokines by 
macrophages due to altered macrophage differentiation (28,102). 
Considering the effects of CST on THP-1 cells (a human monocyte cell line), it seems 
that CST does not affect the overall differentiation of monocytes to macrophages. 
This was shown by consistent expression of the macrophage marker CD68 by THP-
1 cells cultured with CST. However, CST steers the polarization of differentiation 
into less pro- and more anti-inflammatory phenotypes (20). CST treatment of THP-1 
derived macrophages resulted in elevated levels of anti-inflammatory macrophage 
markers (mannose receptor C-type 1, MRC1) and reduced levels of pro-inflammatory 
macrophage markers (macrophage receptor with collagenous domain, MARCO) (20). 
Moreover, a reduction of pro-inflammatory gene expression (TNF-α, F4/80, Itgam, 
Itgax, Ifng, Nos2 and Ccl2) was detected in isolated Kupffer cells and monocyte derived 
macrophages of DIO mice after intra-peritoneal injections with CST, whereas the 
levels of anti-inflammatory genes were increased (IL-10, Mgl1, IL-4, Arg1 and Mrc1)
(102). These results could be confirmed in isolated macrophages treated in vitro 
with CST (102). In the DIO mouse model, intra-peritoneal injections with CST also 
reduced plasma levels of pro-inflammatory cytokines and chemokines (TNF-α, INF-γ 
and CCL2) (102). Taken together, these findings indicate that CST shifts macrophage 
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differentiation from a pro- to a more anti-inflammatory phenotype. Since adipose 
tissue macrophages (ATMs) have antigen-presenting capacities this shift could 
influence the adaptive immune response (133). Interestingly, CD8 deficient mice show 
a decrease in macrophage infiltration and adipose tissue (134), suggesting that CD8+ T 
cell infiltration precedes macrophage accumulation in inflammation. So, CST reduces 
inflammation, macrophage infiltration and might even influence the adaptive immune 
response by affecting T cell infiltration, but that would need to be validated in future 
experiments.
CST in intestinal inflammation
CST seems to have a specific anti-inflammatory effect in chronic gut inflammation as 
shown by several studies in IBD mouse models. In a colitis mouse model, intra-rectal 
injections with CST resulted in decreased serum levels of the acute phase reactant 
C-reactive protein (CRP) (28,135) and suppressed activity of myeloperoxidase (MPO), 
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which is a marker for granulocyte infiltration (28). As a result of these injections, the 
tissue architecture of the colon improved (28,136). Moreover, in atherosclerotic mice 
(apolipoprotein E-deficient mice), intraperitoneal injection followed by continuous 
subcutaneous CST infusion significantly retarded atherosclerotic lesions by 40% in the 
entire surface area of the aorta (20). In both colitis and atherosclerosis models, the 
prevalence of macrophages and monocytes in inflamed tissues was reduced following 
administration of CST (20,28,136), thereby supporting the anti-inflammatory effects 
of CST. Additionally, the gene expression levels of the pro-inflammatory macrophage 
markers inducible nitric oxygen synthase (iNOS) and monocyte chemoattractant 
protein 1 (Mcp1) were reduced upon intra-rectal injection of CST in a reactivated colitis 
mouse model, as well as in vitro in LPS stimulated peritoneal and colon macrophages 
(28,136). In both, the mouse model and in vitro, CST treatment resulted in decreased 
levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) (28,136). In the reactivated 
colitis mice model, CST promoted expression of several anti-inflammatory genes 
(IL-10, Arg1 and Ym1) of the macrophages in the colon (136). 
The pro-hormone chromogranin A (CgA) is produced by the endocrine cells of the GES 
that line the epithelium of the gastrointestinal tract (137). CgA is used as endocrine 
cell and serum marker in cancers(63), and might have a role in inflammatory and 
metabolic diseases such as diabetes (126,138) and IBD (32,73,123,124). CST mainly 
has anti-inflammatory properties, as exemplified by its ability to reduce inflammation 
in mouse models of UC (28,136,139) and other inflammatory diseases (8). Despite 
the counteracting activities of CgA and CST, blood plasma levels of both CgA 
(32,73,123,124) and CST (140) are increased in IBD patients. This raises the question 
how CgA and CST affect IBD pathology.
CST effects on metabolism
In addition to its anti-inflammatory effects, CST also affects metabolism. Opposite 
to insulin, CST inhibits lipogenesis and increases lipolysis in adipose tissue by 
inhibition of the α2-adrenergic receptor and by enhancing leptin signalling (115). 
Simultaneously, it stimulates fatty acid uptake and breakdown in the liver, as reflected 
by increased expression of the genes involved in fatty acid oxidation upon intra-
peritoneal CST injections in mice (115). In line with this, CST injections in CgA-KO mice 
resulted in decreased triglyceride levels in the plasma and reduced fat depot sizes by ~ 
25% (115). These findings indicate that CST promotes lipid flux from adipose tissue to 
the liver for beta oxidation, which might explain the frequently observed weight gain 




Besides the effect on lipid metabolism, intra-peritoneal administration of CST improved 
glucose and insulin tolerance in Diet-induced obese (DIO) mice and insulin-resistant 
systemic CST-KO mice, that express a truncated version of CgA (102). This could be 
due to CST inhibiting gluconeogenesis in the liver, thereby lowering the production 
and release of glucose in the blood (102). This effect of CST could be mediated by the 
modulation of Kupffer-cells and monocyte-derived macrophages, since the effects of 
their cytokines are linked to glucose and insulin metabolism (102,141) and for instance 
neutralization of TNF-α improves insulin sensitivity (142). Thus, CST can promote lipid 
and glucose metabolism, and thereby might help to prevent obesity and maintain 
homeostasis of metabolic functions (10,102,115). Although CST immunoreactivity 
has been detected in carcinoid tumours of the appendix, bronchus, stomach, small 
bowel and large bowel (143), its effects on cancer metabolism is yet to be investigated. 
However, insulin has been reported to promote cancer metabolism by upregulating 
pyruvate kinase M2 isoform (PKM2) expression and decreasing its activity, eventuating 
in amplification of cancer-metabolism-specific parameters like glucose uptake, lactate 
production, glycolytic pooling and macromolecular synthesis (144). In addition, several 
reports reveal increased cancer risk under hyperinsulinemic condition (145,146). Since 
CST decreases insulin level in hyperinsulinemic as well as insulin-resistant DIO and 
CST-KO mice (102), we expect that CST would decrease tumour growth by decreasing 
expression of PKM2 and increasing its activity, which requires experimental validation. 
Interestingly, PST, another cleavage product of CgA counteracts the metabolic and 
insulin sensitizing effects of CST (102). These anti-insulin actions of PST are likely 
important in maintaining homeostasis in glucose metabolism (10,62,101). The exact 
regulation of the proteolytic generation of CST and PST remains to be elucidated, but 
it could be coupled to metabolism via glycosylation because hyper-glycosylation of 
CgA is known to lead to reduced levels of CST (147). Thereby, the generation of CgA 
cleavage products might be regulated by sugar levels and this might play a role in 
progression of metabolic diseases, as for instance the increased blood glucose levels 
in T2DM might promote glycosylation of CgA. 
Although it is increasingly clear that CST exerts anti-inflammatory effects on 
macrophages, the underlying mechanisms are still largely unknown. A key open 
question is to which receptor CST binds to exert its effect. This could either be a 
plasma membrane receptor as well as an intracellular target, since CST can penetrate 
the cell membrane of neutrophils (116,117). Another question is which signaling 
pathways are influenced by CST. Based on experiments with inhibitors in mast cells, 
CST treatment leads to cellular activation by mobilizing intracellular Ca2+ and inducing 
the production of pro-inflammatory cytokines/chemokines (GM-CSF, CCL2, CCL3 
and CCL4) via a mechanism possibly involving G-proteins, phospholipase C and the 
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mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) (131). 
However, it is unknown whether these pathways are also responsible for the anti-
inflammatory signaling in macrophages by CST. 
Clinical implications of CST
Given its roles in metabolic regulation and immune homeostasis, CST has potential 
clinical applications as a diagnostic marker and even as a therapeutic target. For 
example, lower levels of CST have been reported in the blood of patients suffering from 
T2DM, suggesting that it might be a diagnostic marker for this disease (41,102,118). 
However, it might be more useful to study CST levels relative to other cleavage 
products of CgA, considering that some of these cleavage products counteract the 
activities of CST. For instance, PST exerts opposing effects on insulin sensitivity and 
glucose metabolism compared to CST (81), and increased levels of PST can contribute 
to T2DM (61). The observed lower levels of CST might well be caused by dysregulation 
of proteolytic processing of CgA (118), since this could result in a higher ratio of PST to 
CST. Indeed, an altered processing of CgA has been observed in the microenvironment 
of tumors. Here CgA cleavage products lead to proangiogenic activity, as cleavage 
of the N- and C-terminal regions of CgA can activate antiangiogenic (vasostatin) and 
proangiogenic sites (CST), respectively (1). Further supporting the notion that CgA and 
its cleavage products can be diagnostic markers for various diseases, is that elevated 
levels of CgA have been detected in the plasma of patients with neuroendocrine 
tumors(55), hypertension(119,120) and various inflammatory diseases such as RA 
(7,121,122), SLE (7), IBD (31,32,73,123,124) as well as T1DM and T2DM (85,125–128). 
However, not all assays used in the aforementioned studies allow to discern full-length 
from proteolytically processed CgA (148) and it would be very interesting to compare 
this to levels of unprocessed CgA and its cleavage products.
As discussed above, CST can decrease inflammation by reducing immune infiltration 
in inflamed tissues and altering macrophages differentiation into an anti-
inflammatory phenotype (28,62,102,118,136,148). These effects are already observed 
at concentrations in the nM range, which corresponds to physiological concentration 
levels of circulating CST (22). By lowering the production of pro-inflammatory 
cytokines, CST may suppress inflammatory immune responses and/or might promote 
the dissolvement of inflammation. As a result, CST could prevent chronic states of 
inflammation and inhibit exaggerated inflammatory responses normally leading 
to tissue damage. Although CST exerts primarily anti-inflammatory effects, other 
cleavage products of CgA have opposing pro-inflammatory effects. Disbalances in 
the levels of circulating CgA-derived peptides might therefore contribute to various 
diseases including IBD (3). 
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Scope of this thesis
In this thesis, we investigated the relatively new concept of modulating innate 
immunity by targeting CST, which may find applications in treatment of various 
inflammatory based diseases and cancer (1–3). Here, we examined the effect of CST on 
gut homeostasis, infiltrating immune cells and the role of CST in inflammatory bowel 
disease (IBD). 
In chapter 2, we examined the role of CgA and CST on intestinal barrier function and 
inflammation, by investigating the influence of CST and CgA on tight junctions and 
permeability, using ultrastructural studies and plasma FITC-dextran assays in knockout 
mice for CgA or CST. The observed leaky gut in CST-KO mice was associated with a 
higher ratio of Firmicutes to Bacteroidetes, a dysbiotic pattern commonly encountered 
in IBD. Supplementation of CST-KO mice with recombinant CST reversed this leakiness 
and key readouts. Supplementation of CgA-KO mice with either CST alone, or with the 
pro-inflammatory proteolytic CgA fragment pancreastatin (PST: CgA250-301) showed that 
gut permeability is regulated by the antagonistic roles of these two peptide hormones: 
PST increases and CST reduces leakiness. We conclude that the enteroendocrine cell-
derived hormone, CgA regulates post-prandial gut permeability. CST is both necessary 
and sufficient to reduce the leakiness. CST acts primarily via antagonizing the effects 
of PST.
Moreover, in chapter 3 we took a closer look at the colon histology of CST-KO mice 
and patients with IBD to observe the beneficial effects of CST in an inflammatory 
environment. Here we show that bone-marrow derived immune cells regulate the 
colonic mucus layer by production of CST, a bioactive peptide derived from the pro-
hormone CgA. Since IBD patients have elevated stool CST this might contribute to the 
reduced mucus layer in inflamed colon regions. Additionally, in chapter 4, we report 
that CST blocks leukocyte migration towards inflammatory chemokines. By in vitro and 
in vivo migration assays, we show that although CST itself is weakly chemotactic, it 
blocks migration of monocytes and granulocytes to inflammatory attracting factor CC-
chemokine ligand 2 (CCL2) and macrophage inflammatory protein 2 (MIP-2). Moreover, 
it directs CX3CR1
+ macrophages away from pancreatic islets. These findings support 
the emerging notion that CST is a key anti-inflammatory modulator.
In the second part of this thesis, we focus more on the information exchange between 
antigen-presenting cells and cytolytic T cells. We will introduce this topic in chapter 
5 & 6, followed by the actual research on the immunological synapse in chapter 7. 
In chapter 5 we briefly discuss the role of macrophage antigen cross-presentation 
to the activation of cytolytic T cells for immune defenses against tumors, viruses and 
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intracellular pathogens. Here we provide an overview of in vitro and in vivo evidence 
on cross-presentation by various types of tissue-resident and circulating macrophages 
via similar cellular pathways as DCs. Since macrophages can cross-present and thereby 
might aid in CTL responses, stimulating macrophages to cross-present might be a 
promising strategy for anti-tumor or anti-viral therapies. Hereafter, in chapter 6, we 
give an overview of mechanism as well as the function of MHC-I reverse signalling, 
which is involved in the defense regulation against malignancies and viral or bacterial 
infections. We discuss and compare this signalling in multiple cell types, ranging 
from immune cells such as macrophages, natural killer (NK) cells, T- and B-cells to 
non-immune cells like endothelial, smooth muscle cells and cancer cells. Followed 
by chapter 7, where we examined the effects of MHC-I on immunological synapse 
formation in dendritic cells. Here, we used electron microscopy to visualize the 
microtubule organizing center (MTOC) at the immunological synapse between the DC 
and T cell. Followed by bead assays coated with various T cell receptors showing that 
MHC-I drives IL-12 release via MTOC polarization.
Chapter 8 provides a brief summary of the main findings of this thesis as well as an 
extensive discussion about the possible working mechanism of CST in macrophages 
and neuroendocrine cells via autocrine/paracrine signaling. Moreover, we will discuss 
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Abstract 
Aim: A ‘leaky’ gut barrier has been implicated in the initiation and progression of a 
multitude of diseases, e.g. inflammatory bowel disease (IBD), irritable bowel syndrome 
and celiac disease. Here we show how pro-hormone Chromogranin A (CgA), produced 
by the enteroendocrine cells, and Catestatin (CST: hCgA352-372), the most abundant 
CgA-derived proteolytic peptide, affect the gut barrier.
Methods Colon tissues from region-specific CST-knockout (CST-KO) mice, CgA-
knockout (CgA-KO) and WT mice were analyzed by immunohistochemistry, Western 
blot, ultrastructural and flowcytometry studies. FITC-dextran assays were used 
to measure intestinal barrier function. Mice were supplemented with CST or CgA 
fragment pancreastatin (PST: CgA250-301). The microbial composition of cecum was 
determined. CgA and CST levels were measured in blood of IBD patients. 
Results: Plasma levels of CST were elevated in IBD patients. CST-KO mice displayed 
(i) elongated tight, adherens junctions and desmosomes similar to IBD patients, (ii) 
elevated expression of Claudin 2, and (iii) gut inflammation. Plasma FITC-dextran 
measurements showed increased intestinal paracellular permeability in the CST-
knockout mice. This correlated with a higher ratio of Firmicutes to Bacteroidetes, a 
dysbiotic pattern commonly encountered in various diseases. Supplementation of CST-
knockout mice with recombinant CST restored paracellular permeability and reversed 
inflammation, whereas CgA-knockout mice supplementation with CST and/or PST 
in CgA-KO mice showed that intestinal paracellular permeability is regulated by the 
antagonistic roles of these two peptides: CST reduces and PST increases permeability.
Conclusion: The pro-hormone CgA regulates the intestinal paracellular permeability. 





The intestinal tract harbors 103-1011 bacteria/ml 1 that in aggregate can constitute >1 
g of endotoxin 2. Endotoxins stimulate immune cells in the lamina propria, which can 
trigger mucosal inflammation 3. Such inflammation can result in luminal dysbiosis 4 
and gut barrier defects 5-8. The gut barrier is comprised of a surface mucus layer which 
separates intact bacteria and large particulates from the mucosa 9 and the colonic 
epithelium which provides a physical and immunological barrier separating the body 
from the luminal contents (e.g. dietary antigens, a diverse intestinal microbiome, and 
pathogens) 10-12. Mucosal homeostasis is maintained by the delicate and complex 
interactions between epithelial cells, immune cells, and luminal microbiota 10.
The gastrointestinal epithelium not only forms the body’s largest interface with the 
external environment, but also establishes a selectively permeable epithelial barrier; it 
allows nutrient absorption and waste secretion while preventing the entry of luminal 
contents. The epithelial barrier is regulated by a series of intercellular junctions 
between polarized cells: an apical tight junction (TJ), which guards paracellular 
permeability, the subjacent adherens junction (AJ) and desmosomes; the AJs and 
desmosomes do not seal the paracellular space but provide essential adhesive and 
mechanical properties that contribute to paracellular barrier functions 11. 
The permeability of the barrier is regulated by many factors such as the immune 
system. For example, tumor necrosis factor (TNF)-α increases the flux of larger 
molecules, such as proteins and other macromolecules, through the leak pathway, and 
interleukin (IL)-13 selectively enhances the flux of small molecules and ions via the 
pore pathway 5. TNF-α plays crucial roles in the Caveolin-1-mediated internalization 
of Occludin (OCLN), which elevates gut permeability. Conversely, overexpression of 
OCLN alleviates the cytokine-induced increase in gut permeability 6. Interferon (IFN)-γ 
increases gut permeability by reducing the expression of Tight junction protein ZO-1 
(TJP1) and OCLN as well as by modulating actin-myosin cytoskeleton interactions with 
TJ proteins 7. The simultaneous presence of TNF-α and IFN-γ deteriorates intestinal 
integrity by dissociating TJ proteins 8.
Here we show that the permeability of the gut barrier is regulated by the pro-hormone 
Chromogranin A (CgA). CgA is an acidic secretory proprotein 13 that is abundantly 
expressed in enteroendocrine cells (EECs) of the gut and serves as a common marker 
for the EECs of the gut 14. Originally, CgA was identified as a cellular packaging factor 
15-17. However, the pro-hormone CgA is proteolytically cleaved, both intracellularly as 
well as extracellularly after its secretion, giving rise to seven bioactive peptides that 
exert a wide variety of regulatory functions among the metabolic 18-21, cardiovascular 
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22-25 and immune systems 26-30. Among these bioactive peptide hormones are catestatin 
(CST: hCgA352-372) 
31,32 and pancreastatin (PST: hCgA250-301) 
33. Blood plasma levels of both 
intact CgA 34-36 and CST 37 are increased in patients with inflammatory bowel disease 
(IBD). We show that CST is abundantly generated in the gut. Unexpectedly, we found 
that CgA regulates the paracellular permeability of the gut via the antagonistic actions 
of its two peptides, PST and CST; while PST is a pro-inflammatory, pro-obesigenic 
and anti-insulin peptide 20 which loosens the barrier, CST acts as anti-inflammatory, 
antiobesigenic, anti-microbial, and proinsulin peptide 25,27,29 that appears to be 
necessary and sufficient to neutralize the actions of PST and tighten the barrier. Using 
knockout (KO) mice in conjunction with recombinant proteins, we show that CST 
exerts its actions via counteracting PST. 
Results 
CgA is extensively processed to CST 
To study the role of CgA and its peptides in the regulation of the gut barrier, we 
used systemic CgA-KO (deletion of exon 1 and ~1.5 kbp proximal promoter, thereby 
completely inactivating the Chga allele) 22 and CST-KO mice (the 63 bp CST domain 
of CgA was deleted from Exon VII of the Chga gene) 38. CST-KO mice show low grade 
inflammation in the heart, pancreas, and liver and have an elevated blood pressure, are 
obese and suffer from insulin resistance 27,38. We analyzed the function and morphology 
of the gut barrier in CST-KO mice. We used transmission electron microscopy (TEM) to 
resolve the ultrastructure of EECs and to evaluate the subcellular compartment where 
hormones are stored and released, i.e., dense core vesicles (DCVs). While DCV numbers 
were reduced in both CgA-KO and CST-KO mice, DCV areas were smaller in CgA-KO 
mice but larger in CST-KO mice (Fig. 1A&B). WT colon showed a lower concentration 
of CgA (average 0.019 nmol/mg protein) than of CST (average 0.37 nmol/mg protein), 
indicating extensive processing of CgA to CST (Fig. 1C). As anticipated, in CST-KO 
mice the levels of CgA in the colon were similar to that in WT mice, but those of CST 
were undetectable (Fig. 1C). Consistent with enhanced processing of CgA, we found 
increased expression of the proteolytic enzymes Cathepsin L (Ctsl, which cleaves CST 
from CgA) and Plasminogen (Plg, the precursor of plasmin, which is involved in CgA 
processing) in CST-KO and CgA-KO, respectively (Fig. 1D) 39,40. 
Because the processing of CgA to CST is compromised in several diseases 41-43, we 
determined plasma CgA and CST levels in patients with Crohn’s disease and with 
ulcerative colitis, both with active disease and in remission (Fig. 1E&F). In line with 
previous findings 34-36, we found higher CgA levels in plasma of patients with active 
Crohn’s disease but not in patients in remission. In contrast, we found higher plasma 
37
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Fig. 1. CgA is efficiently processed to CST in the colon and CST levels correlate with Crohn’s 
disease activity. (A) TEM micrographs (n=3) showing enteroendocrine cell DCV in colon of WT, CgA-
KO and CST-KO mice, (B) fewer DCV in CgA-KO and CST-KO mice (1-way ANOVA) but enlarged DCV 
in CST-KO mice and smaller DCV in CgA-KO mice (>500 vesicles from 30 micrographs) (Kolmogorov-
Smirnov test). DCV, dense core vesicles; Nuc, nucleus. (C) CgA protein and CST peptide levels in colon 
of WT and CST-KO mice. CgA levels were comparable between WT and CST-KO mice. CST level was 
markedly higher in WT mice and was undetectable in CST-KO mice (n=6; Welch’s t test). (D) Expression 
of proteolytic genes (n=7). Ctsl and Plg are differentially expressed in colon of CgA-KO and CST-KO 
mice (n=8; 1-way ANOVA). (E) CgA and CST levels in EDTA-plasma of healthy donors (Control) and 
Crohn’s disease patients (N=89) in remission or flare-up (2-way ANOVA). Ns, not significant; †, p<0.01; 
‡, p<0.001.
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F I G U R E  1  CgA is efficiently processed to CST in the colon and CST levels correlate with Crohn's disease activity. A, TEM micrographs 
(n = 3) showing enteroendocrine cell DCV in colon of WT, CgA- KO and CST- KO mice; B, fewer DCV in CgA- KO and CST- KO mice (one- way 
ANOVA) but enlarged DCV in CST- KO mice and smaller DCV in CgA- KO mice (>500 vesicles from 30 micrographs) (Kolmogorov- Smirnov 
test). DCV, dense core vesicles; Nuc, nucleus. C, CgA protein and CST peptide l vels in colon of WT and CST- KO mice. CgA levels were 
comparable between WT and CST- KO mice. CST level was markedly higher in WT mice and was undetectable in CST- KO mice (n = 6; Welch's t 
test). D, Expression of proteolytic genes (n = 7). Ctsl and Plg are differentially expressed in colon of CgA- KO and CST- KO mice (n = 8; one- way 
ANOVA). E, CgA and CST levels in EDTA- plasma of healthy donors (Control) and Crohn's disease (CD) and ulcerative colitis (UC) patients 
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CST levels in Crohn’s disease regardless of disease activity, indicating that the 
processing of CgA to CST is more efficient in active disease. Patient characteristics are 
provided in Supplemental Table S1&S2.
CST-KO mice have a ‘leaky’ gut
Ultrastructural evaluation of the gut epithelium revealed that the TJs, AJs and 
desmosomes are significantly different in CST-KO mice compared to wild-type (WT): 
the TJs, AJs and desmosomes were elongated, as also observed in IBD patients (Fig. 
2A, C-E, Fig. 3H-L). We determined whether this altered morphology was caused 
by an altered expression of proteins involved in these epithelial junctions. Gene 
expression studies showed a trend towards mRNA expression of multiple TJ-markers 
such as Occludin (Ocln), MARVEL domain-containing protein 2 (Marveld2, also called 
Tricellulin), Junctional adhesion molecule A (JAM-A; F11r) Tight junction protein 
ZO-1 (Tjp1) 44 and the desmosomal protein Desmoglein 2 (Dsg2), which is required 
for maintenance of intestinal barrier function 45. We observed concomitant elevated 
mRNA expression of the genes coding for TJ components Claudin 1 and 2 (Cldn1 and 
Cldn2), TJ protein ZO-2 and 3 (Tjp2 and Tjp3), and AJ genes coding for alpha-E-Catenin 
(Ctnna1), Cadherin-associated protein (Ctnnb1), and Cadherin 1 (Cdh1) (Fig. 2F&G). 
Primer sequences are provided in Supplemental Table S3. For Occludin, ZO-1, alpha-
E-Catenin, Cadherin 1, Claudin 1, we did not observe significantly altered protein 
levels. However, we did find expression at both the mRNA and protein levels of Cldn2 
(Fig. 2F, Fig. 3A&G), a specific claudin that is known to increase the paracellular flux 
of cations and water through the pore pathway 46. In order to assess the functional 
consequence of the altered cellular junctions, we determined the flux through the 
leak pathway, which is responsible for the paracellular movement of larges molecules, 
including microbial proteins and other macromolecules. Compared to WT mice, we 
observed a more than 10-fold increase in leakage of plasma FITC-dextran (4 kDa) in the 
CST-KO mice (Fig. 2B). This confirms that the intestine in CST-KO mice has a strongly 
diminished paracellular barrier via the leak pathway, although the large magnitude of 
leakage might even suggest direct epithelial damage.
CST-KO mice and IBD patients show comparable ultrastructural 
changes in tight junctions, adherens junctions, and desmosomes.
Ultrastructural analyses of colonic mucosa revealed increased lengths of TJ, AJ, and 
desmosomes in IBD patients compared to healthy controls (Fig. 3H-L). Unlike CST-KO 
mice, IBD patients displayed a decrease in AJ diameter (Fig. 3H&K).
39
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Fig. 2. Impaired epithelial paracellular barrier function in CST-KO mice. (A) TEM micrographs 
(n=3) showing tight junction (TJ), adherens junction (AJ), and desmosomes (Des). MV, microvillus. (B) 
Increased gut permeability as measured by FITC-dextran level in CST-KO compared to WT mice (n=8; 
Welch’s t test). (C-E) Morphometrical analyses (n=20-54) showing increased length and diameter of TJ 
(C), AJ (D) and Des (E) in CST-KO mice (Welch’s t test). (F-H) Differential expression of genes in TJ (Cldn1, 
Cldn2, Cldn6, Ocln, Marveld2, F11r, Tjp1, Tjp2, and Tjp3), AJ (Ctnna1, Ctnnb1, and Cdh1) and Des (Dsg2) in 
colon of CST-KO mice compared to WT mice. Supplementation of CST-KO mice with CST reversed the 
expression of the above genes (n=8; 2-way ANOVA or Welch’s t test). *, p<0.05; †, p<0.01; ‡, p<0.001.
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exon 1 and ~1.5 kbp proximal promoter, thereby completely 
inactivating the Chga allele)22 and CST- KO mice (the 63 bp 
CST domain of CgA was deleted from Exon VII of the Chga 
gene).38 CST- KO mice show low grade inflammation in the 
heart, pancreas, and liver and have an elevated blood pressure, 
are obese and suffer from insulin resistance.27,38 We analysed 
the function and morphology of the gut barrier in CST- KO 
mice. We used transmission electron microscopy (TEM) to 
resolve the ultrastructure of EECs and to evaluate the subcel-
lular compartment where hormones are stored and released, 
that is, dense core vesicles (DCVs). While DCV numbers 
were reduced in both CgA- KO and CST- KO mice, DCV 
areas were smaller in CgA- KO mice but larger in CST- KO 
mice (Figure 1A,B). WT colon showed a lower concentration 
of CgA (average 0.019 nmol/mg protein) than of CST (aver-
age 0.37 nmol/mg protein), indicating extensive processing 
F I G U R E  2  Impaired epithelial paracellular barrier function in CST- KO mice. A, TEM micrographs (n = 3) showing tight junction (TJ), 
adherens junction (AJ) and desmosomes (Des). MV, microvillus. B, Increased gut permeability as measured by FITC- dextran level in CST- KO 
compared to WT mice (n = 8; Welch's t test). C- E, Morphometrical analyses (n = 20- 54) showing increased length and diameter of TJ (C), AJ 
(D) and Des (E) in CST- KO mice (Welch's t test). F- H, Differential expression of genes in TJ (Cldn1, Cldn2, Cl n6, Ocln, Marveld2, F11r, Tjp1, 
Tjp2 and Tjp3), AJ (Ctnna1, Ct nb1 and Cdh1) and Des (Dsg2) in colon of CST- KO mice compared to WT mice. Supplementation of CST- KO 
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of CgA to CST (Figure  1C). As anticipated, in CST- KO 
mice the levels of CgA in the colon were similar to that in 
WT mice, but those of CST were undetectable (Figure 1C). 
Consistent with enhanced processing of CgA, we found in-
creased expression of the proteolytic enzymes Cathepsin L 
(Ctsl, which cleaves CST from CgA) and Plasminogen (Plg, 
the precursor of plasmin, which is involved in CgA process-
ing) in CST- KO and CgA- KO respectively (Figure 1D).39,40
Because the processing of CgA to CST is compro-
mised in several diseases,41- 43 we determined plasma CgA 
and CST levels in patients with Crohn's disease and with 
ulcerative colitis, both with active disease and in remis-
sion (Figure  1E,F). In line with previous findings,34- 36 
we found higher CgA levels in plasma of patients with 
active Crohn's disease but not in patients in remission. 
In contrast, we found higher plasma CST levels in Crohn's 
disease regardless of disease activity, indicating that the 
processing of CgA to CST is more efficient in active 
disease. Patient characteristics are provided in Tables S1 
and S2.
F I G U R E  3  Elevated levels of Claudin- 2 in colon of CST- KO mice and elongated epithelial junctions in IBD patients. (A) Western blots and 
(B) densitometric analyses of Claudin- 1 (B), Claudin- 2 (C), Occludin (D), Tjp1 (E), Catenin 1 (F) and Cadherin 1 (G). H and I, TEM micrographs 
(n = 3) showing tight junction (TJ), adherens junction (AJ) and desmosomes (Des) in healthy control and IBD patients. Microvillus (MV). J- L, 







(C) (D) (E) (F) (G)
Fig. 3. Elevated levels of Claudin-2 in colon of CST-KO mice and elongated epithelial junctions 
in IBD patients. (A) Western blots and (B) densitometric analyses of Claudin-1 (B), Claudin-2 (C), 
Occludin (D), Tjp1 (E), Catenin 1 (F), and Cadherin 1 (G). (H&I) TEM micrographs (n=3) showing tight 
junction (TJ), adherens junction (AJ), and desmosomes (Des) in healthy control and IBD patients. 
Microvillus (MV). (J-L) Morphometrical analyses (n=20-54) showing increased lengths and diameter of 
TJ (J), AJ (K) and Des (L) in IBD patients. *, p<0.05; †, p<0.01; ‡, p<0.001.
41
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That the leaky gut of CST- KO mice is inflamed and har-
bours dysbiotic luminal contents implies that CST is required 
for maintaining gut barrier integrity and preventing dysbio-
sis and gut inflammation. This is important because a “leaky 
gut”,53 dysbiosis54 and hyperactivated immunity55 are all well 
known to play a role in IBD. It is also consistent with others’ 
observation that administration of exogenous CST can ame-
liorate colitis in mice.55
2.5 | CST is sufficient to tighten the leaky 
gut barrier in CST- KO mice and reduce 
inflammation
To test whether CST is sufficient to regulate gut perme-
ability, we supplemented CST- KO mice with recombinant 
CST (intraperitoneal injections of 2 µg/g body weight once 
daily for at least 15  days), which reversed paracellular 
F I G U R E  4  Increased infiltration of immune cells in colon of CST- KO mice. A- C, haematoxylin and eosin- stained histological micrographs 
of colon in WT (A), CST- KO (B), and CgA- KO (C) mice. Arrows indicate immune cells. D, Immunohistological micrographs showing increased 
infiltration of Emr+ cells in CST- KO mice. E, TEM micrographs (n = 3) showing increased number of immune cells in colon of CST- KO mice. 
Mϕ, macrophage; Cap, capillary; Ec, enterocytes; Gc, goblet cells; LP, lamina propria. F, Flow cytometry study (n = 5- 10) shows increased 
number of macrophages (CD45+CD11b+Emr1+) and T cells (CD45+CD4+) in colon of CST- KO mice (n = 5- 10; Welch's t test). G, Increased 
expression of proinflammatory genes (Tnfa, Ifng, Cxcl1, Ccl2, Emr1, Il12b, Nos2, Itgam and Itgax), which returned to WT levels after treatment 







Fig. 4. Increased infiltration of immune cells in colon of CST-KO mice. (A-C) hematoxylin and 
eosin-stained histological micrographs of colon in WT (A), CST-KO (B), and CgA-KO (C) mice. Arrows 
indicate immune cells. (D) Immunohistological micrographs showing increased infiltration of Emr+ 
cells in CST-KO mice. (E) TEM micrographs (n=3) showing increased number of immune cells in colon 
of CST-KO mice. Mf, macrophage; Cap, capillary; Ec, enterocytes; Gc, goblet cells; LP, lamina propria. 
(F) Flow cytometry study (n=5-10) shows increased number of macrophages (CD45+CD11b+Emr1+) 
and T cells (CD45+CD4+) in colon of CST-KO mice (n=5-10; Welch’s t test). (G) Increased expression of 
proinflammatory genes (Tnfa, Ifng, Cxcl1, Ccl2, Emr1, Il12b, Nos2, Itgam, and Itgax), which returned to 
WT levels after treatment with CST (n=8; 2-way ANOVA). (n=8; 2-way ANOVA). *, p<0.05; †, p<0.01; 
 ‡, p<0.001.
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The leaky gut in CST-KO mice is accompanied by mucosal 
inflammation and dysbiosis 
Because inflammation regulates the epithelial cellular junctions 5-8 and an increased 
gut permeability is often associated with mucosal inflammation, we investigated the 
immune cell populations in the colons of CST-KO mice by histochemical analysis (Fig. 
4A-C). Indeed, the colon of CST-KO mice displayed signs of mucosal inflammation, 
such as elevated immune cell infiltration (Fig. 4D&E), increased fibrosis (Fig. 5D&E), 
and increased apoptosis (Fig. 6A). In addition, there was increased abundance of 
macrophages (CD45+11b+Emr1+) and helper CD4+ T cells in the colon of CST-KO mice 
as confirmed by flow cytometry (Fig. 4F). Moreover, CST-KO mice showed increased 
expression of the following proinflammatory genes: TNF-α (Tnfa), IFN-γ (Ifng), 
Chemokine CXC motif ligand 1 (Cxcl1 aka Kc/Gro1), Chemokine CC motif ligand 2 
(Ccl2 aka Mcp1), Egg-like module-containing mucin-like hormone receptor 1 (Emr1 
aka F4/80), Integrin alpha-M (Itgam aka Cd11b), and Integrin alpha-X (Itgax aka Cd11c) 
(Fig. 4G). Increased expression of Tnfa, Ifng, Cxcl1, and Ccl2 genes correlated with 
increased protein levels (Fig. 5A). Upregulation of proinflammatory cytokines is in 
line with prior work demonstrating a positive correlation of IFN-γ 47 and TNF-α 44 with 
intestinal leakiness. The decreased expression of anti-inflammatory cytokines, such as 
interleukin 4 (Il4) and interleukin 10 (Il10), in CST-KO mice is also in congruence with 
the reported role of anti-inflammatory cytokines in gut permeability (Fig. 5C) 48. The 
decreased Il10 mRNA levels correlated with a decreased protein level of IL-10 (Fig. 5C). 
Furthermore, the expression of S100a9 gene (forming Calprotectin in complex with 
S100a8) was increased in colon of CST-KO mice and Calprotectin protein levels were 
increased in plasma, colon and feces of CST-KO mice (Fig. 5B); increased Calprotectin, 
a protein secreted by activated neutrophils and macrophages, has been shown to be 
associated with increased intestinal permeability 49. The increased inflammation in 
the gut of CST-KO mice is consistent with the known anti-inflammatory roles of CST 
29,50 and with our previous observation of low-grade systemic inflammation in the 
CST-KO mice 27. 
Because a leaky gut may either cause or be the consequence of altered luminal 
microbes 51, we investigated whether the microbial population in CST-KO mice was 
altered. We found that the microbiome in CST-KO mice was indeed quite different in 
composition than its WT littermates (Fig. 6B-E&7). Most prominently, CST-KO mice 
showed a higher ratio of Firmicutes to Bacteroidetes (Fig. 6C-E), which is opposite 
to the decreased ratio observed in WT mice intra-rectally infused with CST 52, and 
supports the idea that a low ratio of Firmicutes to Bacteriodetes could be beneficial to 
dampen intestinal inflammation 52. 
43
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F I G U R E  5  Elevated levels of pro- inflammatory proteins and fibrosis in colon of CST- KO mice. A, Increased expression of proinflammatory 
proteins (Tnfα, Ifnγ, Cxcl1 and Ccl2) in colon of CST- KO mice (n = 8; two- way ANOVA). B, Increased expression of proinflammatory 
Calprotectin gene s100A9 in colon and Calprotectin protein in plasma, colon and faeces of CST- KO mice, which were reversed upon administration 
of CST for 15 d (n = 5; one- way ANOVA). C, Decreased expression of anti- inflammatory genes (Arg1, Il4, Tgfb1, Il10, Mrc1, Clec7a and 
Clec10a) (n = 8; two- way ANOVA), and anti- inflammatory protein (Il10) (n = 8; Welch's t test) in colon of CST- KO mice. CST treatment 
increased expression of anti- inflammatory genes in CST- KO mice. D, Masson's trichrome- stained histological micrographs showing increased 
fibrosis in CST- KO and CgA- KO colon. E, TEM micrographs showing increased presence of collagen fibers in CST- KO and CgA- KO mice. Coll, 






Fig. 5. Elevat  levels f pro-inflammatory proteins and fibrosis in colon of CST-KO mice. (A) 
Increased expression of proinflammatory proteins (Tnfa, Ifng, Cxcl1, and Ccl2) in colon of CST-KO 
mice (n=8; 2-way ANOVA). (B) Increased expression of proinflammatory Calprotectin gene s100A9 in 
colon and Calprotectin protein in plasma, colon, and feces of CST-KO mice, which were reversed upon 
administration of CST for 15 days (n=5; 1-way ANOVA). (C) Decreased expression of anti-inflammatory 
genes (Arg1, Il4, Tgfb1, Il10, Mrc1, Clec7a, and Clec10a) (n=8; 2-way ANOVA), and anti-inflammatory 
protein (Il10) (n=8; W lch’s t test) in colon of CST-KO mice. CST treatment increased expression of anti-
inflammatory genes in CST-KO mice. (D) Masson’s trichrome-stained histological micrographs showing 
increased fibrosis in CST-KO and CgA-KO colon. (E) TEM micrographs showing increased presence of 
collagen fibers in CST-KO and CgA-KO mice. Coll, collagen; CV, clear cholinergic vesicles; MP, Meissner’s 
plexus; PV, dense core peptidergic vesicles. *p<0.05; **p<0.01; ***p<0.001.
44
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F I G U R E  6  Increased apoptosis and ratio of Firmicutes to Bacteriodetes in gut of CST- KO mice. A, increased numbers of Caspase- 3 positive 
apoptotic cells in colon of CST- KO mice. B, Principal CoordiNATE Analysis (PCoA) of microbiome data using Bray- Curtis distance of species 
composition and abundance in individual WT (blue) and CST- KO (red) mice. C- E, Microbiota composition of cecum of WT and CST- KO mice for 





Fig. 6. Increased apoptosis and ratio of Firmicutes to Bacteriodetes in gut of CST-KO mice. 
(A) increased numbers of Caspase-3 positive apoptotic cells in colon of CST-KO mice. (B) Principal 
CoordiNATE Analysis (PCoA) of microbiome data using Bray-Curtis distance of species composition 
and abundance in individual WT (blue) and CST-KO (red) mice. (C-E) Microbiota composition of cecum 




10 of 20 |   MUNTJEWERFF ET al.
leakiness of FITC- dextran and the associated abnormalities 
such as: (a) reduced plasma FITC- dextran even lower than 
WT level (Figure 2B), (b) increased mRNA expression of 
Ocln, Marveld2, F11r, Tjp1 and Dsg2 (Figure 2F,H), (c) 
decreased mRNA expression of Cldn1, Cldn2, Tjp2, Tjp3, 
Ctnna1, Ctnnb1 and Cdh1, as well as increased protein 
expression of Claudin- 2 (Figures 2F,G and 3A,C), (d) de-
creased mRNA expression of proinflammatory genes (Tnfa, 
Ifng, Cxcl1, Ccl2, Emr1, Il12b, Nos2, Itgam and Itgax) 
(Figure 4G), (e) increased expression of anti- inflammatory 
genes (Arg1, Il4, Tgfb1, Il10, Mrc1, Clec7a and Clec10a) 
(Figure 5C), (f) decreased expression of Calprotectin gene 
F I G U R E  7  Detailed microbial composition of WT, CST- KO and CgA- KO mice. Graphs show complete microbiota composition in cecum of 




Fig. 7. Detailed microbial composition of WT, CST-KO, and CgA-KO mice. Graphs show complete 
microbiota composition in cecum of WT (A), CST-KO (B), and CgA-KO (C) mice. Circles from inside to 
outside show kingdom, phylum, class, der, family and genus.
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CST promotes the epithelial paracellular barrier function by 
counteracting PST. Nevertheless, the baseline gut perme-
ability in CST- KO mice was higher than in CgA- KO mice 
supplemented with PST. This might suggest that there are 
other cleavage fragments of CgA that regulate the intestinal 







Fig. 8. Increased epithelial paracellular barrier function and lower inflammation in CgA-KO mice. 
(A) Electron microscopy micrographs of colon of WT and CgA-KO mice. TJ: tight junction. AJ: adherens 
junction. Des: desmosomes. (B) Gut permeability as measured by FITC-Dextran plasma level in WT 
and CgA-KO mice (n=7; Welch’s t test). (C) Relative mRNA expression of genes in tight junction (Cldn2, 
Ocln, Marveld2, F11r, and Tjp1) (n=8, 2-way ANOVA), adherens junction (Ctnna1, Ctnnb1, and Cdh1) 
(n=8; 2-way ANOVA), and desmosome (Dsg2) (n=8; Welch’s t test) in colon of WT and CgA-KO mice. 
Comparable expression of (D) proinflammatory genes (Tnfa, Ifng, Cxcl1, Ccl2, Emr1, Itgam, and Itgax), 
and (E) proinflammatory proteins (Tnfα, Ifnγ, Cxcl1, and Ccl2) in colon of WT and CgA-KO mice (n=8, 
2-way ANOVA). Increased expression of (F) anti-inflammatory genes (Arg1, Tgfb1, Clec7a, and Clec10a) 
and comparable expression of anti-inflammatory genes (Il4, Il10, and Mrc1), and (G) anti-inflammatory 
protein (Il10) in colon of WT and CgA-KO mice (n=8; 2-way ANOVA or Welch’s t test). (H) Comparable 
expression of s100a9 gene and decreased expression of calprotectin protein in CgA-KO colon (n=5; 
Welch’s t test). †, P<0.01; ‡, P<0.001.
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That the leaky gut of CST-KO mice is inflamed and harbors dysbiotic luminal contents 
implies that CST is required for maintaining gut barrier integrity and preventing dysbiosis 
and gut inflammation. This is important because a “leaky gut” 53, dysbiosis 54, and 
hyperactivated immunity 55 are all well known to play a role in IBD. It is also consistent 
with others’ observation that administration of exogenous CST can ameliorate colitis 
in mice 55.
CST is sufficient to tighten the leaky gut barrier in CST-KO mice 
and reduce inflammation 
To test whether CST is sufficient to regulate gut permeability, we supplemented CST-
KO mice with recombinant CST (intraperitoneal injections of 2 µg/g body weight once 
daily for at least 15 days), which reversed paracellular leakiness of FITC-dextran and 
the associated abnormalities such as: (i) reduced plasma FITC-dextran even lower 
than WT level (Fig. 2B), (ii) increased mRNA expression of Ocln, Marveld2, F11r, Tjp1, 
and Dsg2 (Fig. 2F&H), (iii) decreased mRNA expression of Cldn1, Cldn2, Tjp2, Tjp3, 
Ctnna1, Ctnnb1, and Cdh1, as well as increased protein expression of Claudin-2 (Fig. 
2F&G, 3A&C), (iv) decreased mRNA expression of proinflammatory genes (Tnfa, Ifng, 
Cxcl1, Ccl2, Emr1, Il12b, Nos2, Itgam, and Itgax) (Fig. 4G), (v) increased expression of 
anti-inflammatory genes (Arg1, Il4, Tgfb1, Il10, Mrc1, Clec7a, and Clec10a) (Fig. 5C), (vi) 
decreased expression of Calprotectin gene (subunit S100a9) and protein levels (Fig. 
5B). These findings demonstrate that CST reduces intestinal inflammation, and that 
CST is not only required for the integrity of the paracellular gut barrier, but is also 
sufficient to maintain the integrity of this barrier during homeostasis.
The paracellular permeability of the gut is intact in CgA-KO mice
Next, we carried out the gut barrier studies in CgA-KO mice, which not only lack CST, 
but also lack all other peptides derived from CgA. Ultrastructural studies showed no 
structural changes in TJ, AJ and desmosomes in CgA-KO mice compared to WT mice 
(Fig. 8A). To our surprise, we found that despite the absence of CST in these mice, 
the gut permeability for FITC-dextran was not increased (Fig. 8B); if anything, the 
paracellular barrier was even tighter than WT control mice. This decreased permeability 
was not accompanied by changes in CgA-KO mice in genes coding for components of 
TJ, AJ and desmosomes, except that Ocln and Dsg2 gene expression were decreased 
in CgA-KO mice compared to WT mice (Fig. 8C). Likewise, proinflammatory gene and 
protein expressions were not affected in CgA-KO mice (Fig. 8D-E). In line with this, 
histology and EM revealed some fibrosis, but no excessive immune cell infiltration 
in the colon of CgA-KO mice (Fig. 5D&E). In contrast to the CST-KO mice, the CgA-
KO mice even showed increased colonic expression of anti-inflammatory genes and 
proteins (Fig. 8F-G). The decreased colon levels of Calprotectin were also consistent 
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Fig. 9. Altered microbiome composition in CgA-KO mice and CST and PST oppositely regulate gut 
permeability. (A) Microbiota composition of cecum of WT and CgA-KO mice for main bacteria phyla 
and the geni within the Bacteriodetes and Firmicutes. (B) Scheme of CgA indicating the positions of 
the peptide products vasostatin 1, PST, CST and serpinin. (C) Gut permeability as measured by FITC-
Dextran plasma levels in WT, CST-KO and CgA-KO mice treated with saline or CST (n=8; 2-way ANOVA) 
and in CgA-KO mice treated with PST or a combination of PST and CST (n=8; 1-way ANOVA). (D) Model 
of gut barrier regulation by CST and PST. ‡, P<0.001.
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conditions like insulin resistance and obesity. Firmicutes 
(eg, Lactobacillus, Clostridium and Enterococcus) and 
Bacteroidetes (eg, Bacteroides) constitute the major bacte-
rial phyla in the gut.73 Toxigenic bacteria cause diarrhoea via 
increased ion permeability of the pore pathway,51 but gut mi-
crobes might also affect the leak pathway. Enteric pathogenic 
bacteria such as Escherichia coli and Salmonella typhimurium 
alter the intestinal epithelial TJ barrier and cause intestinal 
F I G U R E  9  Altered microbiome composition in CgA- KO mice and CST and PST oppositely regulate gut permeability. A, Microbiota 
composition of cecum of WT and CgA- KO mice for main bacteria phyla and the geni within the Bacteriodetes and Firmicutes. B, Scheme of CgA 
indicating the positions of the peptide products vasostatin 1, PST, CST and serpinin. C, Gut permeability as measured by FITC- Dextran plasma 
levels in WT, CST- KO and CgA- KO mice treat d with saline or CST (n = 8; two- way ANOVA) and in CgA- KO mice treated with PST or a 







with decreased gut permeability (Fig. 8H). Compared to CST-KO mice, Firmicutes and 
Bacteroidetes bacteria populations in CgA-KO mice were more comparable to WT mice 
(Fig. 7&9A). 
These findings suggest that CST is not essential in the absence of CgA. Because a leaky 
and inflamed gut was seen in the CST-KO mice which specifically lack the proteolytic 
fragment of CST, but not in CgA-KO mice which lack CST and all other peptides that are 
generated proteolytically from CgA, these findings raised the possibility that CST may 
be required to antagonize the actions of some other peptide hormone that is also a 
product of CgA.
Gut permeability is regulated by the antagonistic effects of two 
CgA peptides: CST and Pancreastatin (PST)
Among the various proteolytic peptides, we hypothesized that CST could be acting to 
balance the impact of PST, another peptide fragment of CgA (Fig. 9B). This hypothesis 
was guided by prior work 43 alluding to PST’s deleterious impact on the gut mucosa, 
causing macrophage infiltration and inflammation. To test the nature of contribution 
of PST and CST on the gut paracellular barrier function, we supplemented the CgA-
KO mice with either CST alone (2 µg/g body weight for 15 days), or PST alone (2 µg/g 
body weight for 15 days), or both PST and CST co-administered at equimolar ratio for 
15 days. CST alone did not change leakiness of FITC-dextran in CgA-KO mice (Fig. 9C). 
By contrast, PST alone increased the leakiness in CgA-KO mice and this leakiness was 
markedly reduced when the CgA-KO mice received both PST and CST at equimolar 
concentration (Fig. 9C). These findings indicate that PST increases the paracellular gut 
permeability, and that CST antagonizes this action. Together, these data lead us to 
propose a working model (Fig. 9D) in which the intestinal epithelial paracellular barrier 
is finetuned by the EECs via a major gut hormone, CgA. Our data show that CgA is 
proteolytically processed into two peptides, CST and PST, which tighten and loosen 
the gut barrier, respectively.
Discussion
The major finding in this work is the discovery of a molecular mechanism that involves 
a major EEC-derived gut hormone that has a balanced action on the paracellular gut 
barrier; two hormone derivatives of CgA, i.e., CST and PST, which either tighten or 
loosen the barrier, respectively. Because CgA-KO mice had unimpaired leakage of FITC-
dextran, which was increased by exogenous administration of PST but not reduced by 
exogenous CST alone, findings also indicate that the barrier-homeostatic mechanism(s) 
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is contained within and converge at a molecular level on the prohormone CgA and 
its processing into counteracting peptide hormones. These findings are important 
because CST is a major peptide hormone in EEC which is proteolytically produced from 
CgA by proprotein convertase 1 (PC1) 55, cathepsin L 56, plasmin 40 and kallikrein 57. Its 
abundance in the gut suggests that the permeability of the gut barrier is regulated by 
CST. 
CgA is unique in having peptide domains that antagonize several functions including 
inflammation (CST suppresses while PST promotes), obesity (CST inhibits while 
PST stimulates) and sensitivity to insulin (CST increases while PST diminishes) 20,27,58. 
Since CgA-KO mice lack both CST and PST, and we observed increased permeability 
in CST-KO mice and decreased permeability in CgA-KO mice, we reasoned that these 
opposing phenotypes are probably caused by the lack of PST in the CgA-KO mice. 
Indeed, the increased permeability in PST-treated CgA-KO mice and its reversal by 
co-treatments of PST and CST lead us to conclude that CST promotes the epithelial 
paracellular barrier function by counteracting PST. Nevertheless, the baseline gut 
permeability in CST-KO mice was higher than in CgA-KO mice supplemented with PST. 
This might suggest that there are other cleavage fragments of CgA that regulate the 
intestinal permeability or that the effects cannot be completely reversed.
While PST exerts deleterious impact on the gut mucosa, causing macrophage 
infiltration and inflammation 59, we found that lack of CST caused an increased 
expression of proinflammatory genes and proteins and treatment of CST-KO mice with 
CST reversed expression of those genes and proteins. These findings are in line the anti-
inflammatory roles of CST 27,29 and with the low-grade systemic inflammation present 
in the CST-KO mice 27,29. Our findings are also in congruence with the existing literature 
which showed increased TJ permeability in presence of increased proinflammatory 
cytokines such as TNF-α, IL-1β, and IFN-γ60. A reduced gut barrier function might 
facilitate the leakage of microbial components such as lipopolysaccharide (LPS) and 
peptidoglycan (PGN) from the lumen of the gut into the tissues, where they can bind to 
pattern recognition receptors and activate the immune system. In turn, the increased 
inflammation can result in further leakage of the gut. For instance, myosin light chain 
kinase (MLCK) plays critical roles in cytokine-mediated TJ regulation by disrupting 
the interaction between TJ proteins and the actin-myosin cytoskeleton 61 leading to 
damage of the TJ scaffold, which is crucial for the maintenance of barrier integrity 61. 
Inflammatory cytokine-induced intestinal barrier loss is also believed to be due to 
endocytosis of TJ proteins, which also requires MLCK transcription and activity at the 
TJ 6, although we did not observe decreased protein levels of TJ proteins in the colon 
of CST-KO mice. In addition to the above mechanisms, TNF-α suppresses TJ barrier 
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function by decreasing expression of TJP1 protein, increasing expression of Claudin-2, 
and activating the NF-KB pathway 62. IL-6 also increases expression of Claudin-2 63. In 
line with this, we observed elevated levels of Claudin-2 in the colon of CST-KO mice. 
In addition to these indirect effects on TJ protein expression and structure via the 
immune system, it might also be possible that CgA and/or its cleavage products exert 
direct effects on the epithelial cells and thereby more directly regulate the TJs. To 
investigate this, it will be interesting to perform in vitro experiments, e.g., epithelial 
monolayers in perfusion chambers co-cultured with or without immune cells 64.
An interesting question is how CST and PST affect the AJs and desmosomes. Not 
only TJ components, but also desmosome and AJ components are altered in CST-KO 
mice and these changes are reversible by administration of exogenous CST. It might 
be possible that the AJs and/or desmosomes are part of a feedback mechanism to 
compensate the altered TJ structure. Previously, by using Dsg2-KO mice, desmosomes 
have been shown to regulate the intestinal barrier 45. Moreover, Dsg2 modulates the 
production of glial cell-derived neurotrophic factor (GDNF) in inflammatory bowel 
disease patients 65. Therefore, a possible scenario is that CgA-derived peptides regulate 
the release of GDNF from enteric glial cells in the gut wall, which in turn affects the 
epithelial junctions. 
The present study unequivocally demonstrates that CST is a key regulator of 
paracellular gut permeability since the absence of CST (CST-KO) is accompanied 
by dysbiosis, increased gut permeability for FITC-dextran, increased infiltration of 
macrophages and CD4+ T cells, and higher local inflammatory gene and protein 
expression with the substitution of CST-KO mice with CST reversing many of the above 
abnormalities. Do gut hormones simulate the actions of CST? While Cholecystokinin 
(CCK) decreases mucosal production of proinflammatory cytokines induced by LPS 
and increases the expression of seal forming TJ proteins (OCLN, Claudins and JAM-A) 66, 
Ghrelin ameliorates sepsis-induced gut barrier dysfunction by activation of vagus nerve 
via central ghrelin receptors 53 as well as by decreasing production of TNF-α and IL-6 
67. Glucagon-like peptide 1 (GLP-1) has also been shown to decrease inflammation of 
enterocytes 68. Vasoactive intestinal peptide, a neuropeptide found in lymphocytes 69, 
mast cells 70, and enteric neurons of the gastrointestinal tract regulates both epithelial 
homeostasis 71 and intestinal permeability 72. The multitude of effects of CST on 
gut physiology and their recapitulation by these well-investigated gut hormones 
establishes CST as an important gastrointestinal peptide hormone.
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CST-KO mice (loss of barrier integrity) are hypertensive and insulin-resistant on normal 
chow diet 27,38 and CgA-KO mice (intact barrier integrity) have a normal blood pressure 
and are supersensitive to insulin in both normal chow and on high fat diet 18,20. Could 
metabolic endotoxemia explain the above phenotypes? Besides gastrointestinal 
peptide hormones and neuropeptides, TJ homeostasis is altered by proinflammatory 
cytokines, pathogenic bacteria, and pathological conditions like insulin resistance and 
obesity. Firmicutes (e.g., Lactobacillus, Clostridium, and Enterococcus) and Bacteroidetes 
(e.g., Bacteroides) constitute the major bacterial phyla in the gut 73. Toxigenic bacteria 
cause diarrhea via increased ion permeability of the pore pathway 51, but gut microbes 
might also affect the leak pathway. Enteric pathogenic bacteria such as Escherichia 
coli and Salmonella typhimurium alter the intestinal epithelial TJ barrier and cause 
intestinal inflammation 74. LPS alters expression and localization of TJ proteins such as 
TJP1 and OCLN 75. Therefore, it would be interesting to study whether the systemic LPS 
levels support the observed dysbiosis-related loss of gut barrier in the CST-KO mice. 
Since high fat diet-induced insulin-resistant mice and patients with obesity or diabetes 
display elevated levels of Firmicutes and Proteobacteria compared to the beneficial 
phylum Bacteroidetes 76, it is conceivable that dysbiosis (i.e., increased Firmicutes and 
decreased Bacteroidetes) in CST-KO mice is due to their resistance to insulin. This is 
further supported by the fact that Akkermansia muciniphila, which regulates intestinal 
barrier integrity, is less abundant in diabetic individuals 77. Furthermore, the daily 
administration of A. muciniphila is known to mitigate high fat-induced gut barrier 
dysfunction 78. Conversely, metabolic endotoxemia, resulting from the loss of barrier 
integrity, contributes to insulin resistance and obesity 76,79. The intact paracellular 
barrier function in CgA-KO mice could thus be due to their heightened sensitivity to 
insulin.
Human calprotectin, a 24 kDa dimer, is formed by S100A8 and S100A9 monomers 
and released from neutrophils and monocytes. In fact, this calprotectin complex 
constitutes up to 60% of the soluble proteins in the cytosol of neutrophils 80 and 
fecal calprotectin levels serve as a marker of intestinal inflammation 81,82. Because 
of the positive correlation between calprotectin concentration in gut lavage fluid 
and intestinal permeability 83, calprotectin levels are also used to assess intestinal 
permeability. Increased calprotectin levels have been reported to increase intestinal 
permeability 49. Therefore, increased gene and protein expressions in the colon of CST-
KO mice are in line with the increased permeability in CST-KO mice.
Elevated plasma CST levels in patients suffering from Crohn’s disease both in disease 
remission and flare-up as compared to elevated precursor CgA in Crohn’s disease flare-
ups only suggests that while CgA is generally upregulated in Crohn’s disease, it is only 
efficiently processed to CST during disease remission. Previous studies revealed higher 
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plasma CgA levels during flare-ups as compared to ulcerative colitis and Crohn’s 
disease patients in remission 34. An open question remains how the levels of PST and 
CST are regulated in ulcerative colitis and Crohn’s disease patients. For CST our findings 
suggest a proteolytic switch, where CgA and CST are excessively produced in Crohn’s 
disease regardless of the disease state, but CgA is converted more into the anti-
inflammatory CST in quiescent Crohn’s disease. The gut barrier dysfunction in CST-KO 
mice is reminiscent of active Crohn’s disease, because the gut permeability provided 
by cell-cell junctions is generally diminished in IBD patients 84. Based on our findings, 
we hypothesize that the higher levels of CST during Crohn’s disease remision promote 
anti-inflammatory responses and aid restoration of epithelial cellular junctions.
Material and Methods
Mice. Male wild type (WT), CST-knockout (KO) and CgA-KO mice (3 weeks old) on 
C57BL/6 background were kept in a 12 hr dark/light cycle on normal chow diet (NCD: 
13.5% calorie from fat; LabDiet 5001, Lab Supply, Fort Worth, TX). Experiments were 
conducted in a blinded fashion whenever possible. For terminal procedure, mice were 
deeply anesthetized (assessed by pinching toe response) with isoflurane followed by 
harvesting of tissues. Euthanasia was achieved through exsanguination. For rescue 
experiments with exogenous CST and PST, mice were injected intraperitoneally with 
CST (2 µg/g body weight) and/or PST (2 µg/g body weight) at 9:00 AM for 2-4 weeks 
before collecting feces or harvesting tissues. All mouse studies were approved by the 
UCSD and Veteran Affairs San Diego Institutional Animal Care and Use Committees 
and conform to relevant National Institutes of Health guidelines. 
Gut permeability assay. Fluorescein isothiocyanate conjugated dextran (FITC-
dextran-FD4, 4 kDa; MilliporeSigma, St. Louis, MO) was administered (44 mg/100 g 
body weight) to 8 hr fasting mice by oral gavage followed by collection of blood after 
4 hr of administration from the heart under deep isloflurane anesthesia 85. Plasma 
concentration of FITC was determined by comparison of fluorescence signals with a 
FITC-dextran standard curve.
Measurement of tissue cytokines, CST, CgA and calprotectin. A portion of the colon 
was homogenized in PBS and cytokines were measured in 20 µl of the homogenate 
using U-PLEX mouse cytokine assay kit (Meso Scale Diagnostics, Rockville, MD) via 
the manufacturer’s protocol. Mouse EIA kits from CUSABIO (CUSABIO Technology LLC, 
Houston, TX) were used to determine CgA (CSB-EL005344MO), CST (CSB-E17357m), 
and calprotectin (CSB-EQ013485MO).
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Determination of CgA and CST levels in human plasma. EDTA-plasma was 
collected from patients with Crohn’s disease (N=89) and ulcerative colitis (N=101) 
(Supplemental table S1) and healthy controls (N=50). Intestinal inflammation was 
assessed by colonoscopy. A flare-up was defined as histological and endoscopic 
disease activity, whereas remission entailed absence of endoscopic inflammation 
and histological disease activity. EDTA-plasma from healthy controls (Supplementary 
table S2) was obtained from the Mini Donor Service at the University Medical Center 
Utrecht. Samples were thawed and diluted 50-times with extraction buffer (PBS with 
0.5% Tween and 0.05% sodium azide), thoroughly vortexed followed by incubation at 
4°C for 20 min on a rolling device. Afterwards samples were centrifuged at 760 ×g for 
20 min at 4°C and the supernatant was collected for analysis. Samples were collected 
in compliance with the Declaration of Helsinki. EDTA plasma was used to quantify CgA 
and CST using ELISA (CUSABIO CSB-E17355h, CSB-E09153h). Informed consent was 
obtained, and the study was conducted in accordance with the Institutional Board 
Review of the University Medical Center Utrecht (approval number NL35053.041.11 & 
11-050).
Colon histological stains and immunohistochemistry. Mouse colon was isolated, 
washed in PBS and dehydrated in ethanol series, xylene and paraffin. Afterwards, the 
tissue was embedded in paraffin, formalin fixed, and paraffin embedded (FFPE) and 
sections of 5 µM were cut. Hematoxylin and eosin (HE) and Masson’s trichrome (MT) 
staining were performed using standard techniques. For the immunohistochemistry, 
the tissue was heated in citrate buffer (pH 6.0, 1.0 nM citric acid) and endogenous 
peroxidase activity was quenched with 3% H2O2 in methanol. Standard indirect 
immunoperoxidase procedures were used for detection (Vectastain and SK-4800, 
Vector Laboratories) with the antibody Rabbit-αKi-67 (1:100, Novus Biologicals), 
Rat-αF4/80 (1:500, Caltag laboratories and slides were counterstained with Mayer’s 
haematoxylin. Followed by mounting using Quick D mounting medium. For fluorescent 
staining, slides were incubated with Rabbit-αCASPIII antibody (1:100, ab2302, Abcam) 
and nuclear counterstain with DAPI using Fluoromount-G (0100-01, Southern Biotech). 
Slides were imaged using the PerkinElmer Vectra (Vectra 3.0.3; PerkinElmer, MA) at 20x 
magnification or imaged using the Leica SP8 with a water dipping objective.
Transmission Electron Microscopy (TEM) and morphometric analysis. To displace 
blood and wash tissues before fixation, mice were cannulated through the apex of 
the heart and perfused with a Ca2+ and Mg2+ free buffer composed of DPBS and 9.46 
mM KCl as described 73. Mouse and human colon fixation, embedding, sectioning and 
staining were done as described 73. Grids were viewed using a JEOL JEM1400-plus TEM 
(JEOL, Peabody, MA) and photographed using a Gatan OneView digital camera with 
4×4k resolution (Gatan, Pleasanton, CA). Morphometric analyses of the dense core 
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vesicles were determined as described 86. TJ length and diameter were determined 
by measuring the lengths and perpendicular widths using the line tool in NIH ImageJ 
software.
Tight junction protein analysis via immunoblotting. Mouse colon pieces were 
homogenized in a buffer containing phosphatase and protease inhibitors, as previously 
described 19. Colon lysates were subjected to SDS-PAGE and immunoblotted. Followed 
by staining with Rabbit-αOccludin (1:1000, ab216327, Abcam, Cambridge, MA, USA), 
Rabbit-αClaudin 1 (1:2000, ab180158, Abcam), Rabbit-αClaudin 2 (2µg/ml, 51-6100, 
Thermo Fisher Scientific, Waltham, MA, USA), Mouse-αE-cadherin (1:500, 610182, BD 
Biosciences, San Jose, CA, USA), Rabbit-αcatenin (1:1000, C2081, Sigma-Aldrich, St. 
Louis, MO, USA) or Rat-αZO-1 (1:500, R26.4C, DSHB, Iowa City, Iowa, USA).
Flow cytometry analysis. Isolated colon cells from digested mouse colon were stained 
with fluorescence-tagged antibodies to detect macrophages (CD45+CD11b+Emr1+) 
and helper T cells (CD45+CD4+). Data were analyzed using FlowJo. 
Microbiome analysis. DNA was extracted from cecum of WT, CST-KO and CgA-KO 
(normal chow diet (NCD), littermates) using the Zymobiomics miniprep kit. Isolated 
DNA was quantified by Qubit (Thermo Fisher Scientific). DNA libraries were prepared 
using the Illumina Nextera XT library preparation kit. Library quantity and quality was 
assessed with Qubit and Tapestation (Agilent Technologies). Libraries were sequenced 
on Illumina HiSeq platform 2×150bp. Unassembled sequencing reads were directly 
analyzed by CosmosID bioinformatics platform (CosmosID) 87 for multi-kingdom 
microbiome analysis and profiling of antibiotic resistance and virulence genes and 
quantification of organism’s relative abundance. This system utilizes curated genome 
databases and a high-performance data-mining algorithm that rapidly disambiguates 
hundreds of millions of metagenomic sequence reads into the discrete microorganisms 
engendering the particular sequences. Data mining, interpretation and comparison of 
taxonomic information from the metagenomic datasets were performed using Calyspo 
Bioinformatics software V.8.84.
Real Time PCR. Total RNA from colon tissue was isolated using RNeasy Mini Kit and 
reverse-transcribed using qScript cDNA synthesis kit. cDNA samples were amplified using 
PERFECTA SYBR FASTMIX L-ROX 1250 and analyzed on an Applied Biosystems 7500 Fast 
Real-Time PCR system. Primer sequences are in Supplemental table S3. All PCRs were 
normalized to Rplp0, and relative expression levels were determined by the ΔΔCt method 
as described 24.
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Statistics. Statistics were performed with PRISM 8 (version 8.4.3; San Diego, CA). Data 
were analyzed using either unpaired two-tailed Student’s t-test for comparison of two 
groups or one-way or two-way analysis of variance for comparison of more than two 
groups followed by Tukey’s post hoc test if appropriate. All data are presented as mean 
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Abstract
Background The pro-hormone chromogranin A (CgA) and its bioactive cleavage 
product catestatin (CST) are both associated with inflammatory bowel disease (IBD) 
and dysregulated barrier functions, but their exact role has remained elusive. Here, we 
demonstrate that CST regulates the colonic mucus layer.
Methods CST levels were measured in feces of IBD patients. The mucus layer, goblet 
cells, and immune cell infiltration were analyzed by histology and electron microscopy 
in colon tissue from IBD patients and mice with selective deletion of the CST-coding 
region of the CgA gene. 
Results CST levels were elevated in feces of IBD patients compared to healthy controls. 
The thickness of the mucus layer was increased in non-affected, but not in inflamed, 
regions of the colon in IBD patients. The thickness of the mucus layer and concomitant 
mucus production were also increased in the CST-KO mouse. This mucus phenotype in 
CST-KO mice could be reversed by bone marrow transplantation from wildtype mice.
Conclusions CST produced by bone-marrow derived immune cells reduces production 
of the mucus layer in the intestine. This might contribute to the reduced mucus layer 





Approximately two million people in the United States suffer from IBD, comprising 
Crohn’s disease (CD) and ulcerative colitis (UC)(1). In IBD patients the plasma levels of 
both the pro-hormone chromogranin A (CgA)(2–6) and its bioactive cleavage product 
catestatin (CST: human CgA352-372)(6–8) are increased. CST is generally considered 
anti-inflammatory(9,10) and treatment of UC mouse models with CST was found to 
reduce macrophage infiltration of the colon and attenuate inflammation(11–13). 
We recently showed that CST-KO mice, with a selective deletion of the CST-coding 
region of the Chga gene, display severely compromised intestinal permeability and 
inflammation in the colon(6). Additionally, the colon of CST-KO mice displays increased 
fibrosis, macrophage infiltration and a bacterial population reminiscent of IBD and/
or inflammatory bowel syndrome patients(6). These inflammatory and permeability 
phenotypes are reversible by administration of exogenous CST(6). However, the exact 
role of CST in mucus regulation has not yet been addressed.
In addition to the epithelial cellular junctions, the mucus layer contributes to the 
protective barrier function of the colon(14). The mucus is produced by the goblet 
cells and consists of antimicrobial enzymes, immunoglobulins, glycoproteins 
and mucins (MUC)(14), with the latter two components defining the mucus layer 
composition. MUC2 is particularly important for mucus organization in the colon, 
since it establishes the connection between the compact inner layer and outer, more 
loose, mucus layer(15). The outer layer interacts with bacteria, while the inner layer 
is impenetrable and protects the mucosa from bacterial infiltration(15). A damaged 
mucus layer exposes the intestinal epithelial cells to gut microbial components 
which might lead to colonic inflammation(14). In UC, the mucus barrier is damaged 
independently of local inflammation, suggesting an intrinsic defect of the mucus 
layer(16). Mucus production is generally less affected in CD, but patients still display 
bacterial infiltration, again indicating that the mucus composition is not sufficient to 
maintain (mucosal) homeostasis(14,17). 
Aim of this study was to identify how CST affects the colonic mucus layer. We 
characterized the thickness of the mucus layer in non- and inflamed regions of the 
colon of CD patients, inflamed colon of UC patients, and healthy controls. Moreover, 
we measured the CST concentrations in feces of IBD patients. We also characterized 
the thickness of the mucus layer in CST-KO and wildtype (WT) mice. Since we recently 
showed that macrophages (and possibly other bone-marrow derived immune cells) 
are major producers of CST(18,19), we determined the effect of bone-marrow transfer 
from WT mice into CST-KO mice on the colonic mucus layer.
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Results
Feces CST correlates with IBD activity
We recently showed that CST is elevated in plasma of CD patients regardless of disease 
state, flare-up or remission, compared to healthy controls(6). Here, we addressed 
whether CST is also elevated in the feces of IBD patients. We measured CgA and CST 
levels in feces samples from a cohort of long-standing CD and UC patients stratified 
for inflammation by colonoscopy and confirmed by calprotectin levels (Fig. S1A-B, 
Table S1). For CD, CgA feces levels were only increased in patients with flare-ups, 
whereas for both CD and UC, CST feces levels were increased regardless of disease 
state (Fig. 1, Table S1). These findings are reminiscent to our previous findings in 
plasma(6) and support the conclusion that CST is not only elevated in circulation, but 
also locally in the colon of IBD patients.
Mucus layer thickness depends on local inflammation
In order to address the relation between inflammation and the mucus layer, we 
compared non-inflamed and inflamed regions of colon biopsies of IBD patients (Fig. 
2A-B, Fig. S2). Using cytochemistry and electron microscopy, we observed an increased 
thickness of the mucus layer at non-inflamed sites of the colon in IBD patients, while 
the thickness in inflamed regions was unaltered compared to a healthy individual 
(Fig. 2C-G). Moreover, electron microscopy revealed that the microvilli were shorter in 
inflamed as compared to non-inflamed regions of the colon within the same patients 
(Fig. 2C-F). Especially for CD patients, non-inflamed regions displayed longer microvilli 
and increased mucus thickness (Fig. 2C-E, Table S2). The thickness of the protective 
mucus layer of CD patients thus depends on the inflammatory state of the mucosa.
CST affects goblet cells and promotes mucus production
In the next set of experiments, we addressed the question whether the altered mucus 
layer in IBD patients could be linked to elevated levels of CST. In the colon of 3 months 
old CST-KO mice, the thickness of the mucus layer and the length of the microvilli were 
increased when compared to WT mice (Fig. 3A-C). The number of goblet cells was also 
increased in the colon of CST-KO mice (Fig. 3D-E), and electron microscopy revealed 
an altered morphology of these goblet cells (Fig. 3F-H). Quantitative PCR showed that 
expression of MUC2 was increased in the CST-KO mice (Fig. 3I). This increased MUC2 
expression was fully reversible by intraperitoneal injection of CST (Fig. 3I).
Bone-marrow derived immune cells produce CST in the colon
We recently showed that macrophages are major producers of CST and that 
macrophage-produced CST is both sufficient and required for normalization of the 
blood pressure in CST-KO mice(19).CST-KO mice are hypertensive due to increased 
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Fig. 1. CST correlates with IBD activity. (A) CgA levels in feces of healthy donors (black) and 
Crohn’s disease (CD) patients in remission (grey) or flare-up (white). (B) Same as panel A, but now 
for CST levels in feces. (C) Same as panel A, but now CgA levels for Ulcerative Colitis (UC) patients. 
(D) Same as panel C, but now for CST. Kruskal-Wallis *: P<0.05; **: P<0.01; ***P<0.001.
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Fig. 2. IBD inflammation links to mucus layer thickness. (A-B) Representative images of periodic 
acid–Schiff (PAS) stained colon cross-sections of non-inflamed (A) and inflamed (B) colon tissue of 
Crohn’s disease (CD) patients with enlargement in black framework. M: mucus, C: crypt, *: goblet cell 
and arrows indicate immune cell infiltration. (C) Representative electron microscopy (EM) micrographs 
of colon showing mucus layer (M), microvilli (MV) and epithelial border (EB). (D-G) Quantification of 
microvilli length and mucus thickness in colon of Crohn’s disease (CD) (D-E) and Ulcerative Colitis (UC) 
(F-G) patients. Kruskal-Wallis *: P<0.05; **: P<0.01; ***P<0.001; ****P<0.0001.
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Fig. 3. CST affects goblet cells and mucus production. (A) Representative electron microscopy (EM) 
micrographs of colon from wildtype (WT), CST-KO and CST-KO mice that received a bone marrow 
transplant from WT mice (CST-KO-BMT). Images show mucus layer (M), microvilli (MV) and epithelial 
border (EB). (B-C) Quantification of microvilli length (B) and mucus thickness (C) from panel A. (D) 
Representative images of periodic acid–Schiff (PAS) stained colon cross-sections of WT and CST-KO mice. 
ME: muscularis externa, M: mucus, C: crypt, *: goblet cell. (E) Quantification of goblet cells per crypt from 
panel D. (F) Electron microscopy micrographs of colon showing goblet cells. (G-H) Quantification of 
goblet cell area (G) and circularity (H) from panel F. (I) Relative mRNA level of MUC2 for WT, CgA-KO, CST-
KO and CST-KO treated with CST. Kruskal-Wallis *: P<0.05; **: P<0.01; ***P<0.001; ****P<0.0001.
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production of catecholamines, and this hypertensive phenotype could be fully 
reversed by depletion of macrophages or by bone-marrow transfer from WT mice 
to CST-KO(19). Bone-marrow transfer in CST-KO mice was also found to restore the 
phenotype of the mucus layer by reducing its thickness and the length of the microvilli 
(Fig. 3A-C). These results indicate that CST produced by macrophages (or other bone-
marrow immune cells) regulates the colonic mucosa.
Discussion
In this study, we showed that CST is increased in the feces of IBD patients regardless 
of disease activity, whereas feces levels of its precursor CgA are only increased in CD 
patients with active disease. We also found that, compared to a healthy control, the 
thickness of the mucus layer and the length of the microvilli are increased in non-
inflamed colon regions of CD patients, whereas the mucus layer is unaltered and the 
microvilli are shorter in inflamed regions. CST-KO mice display an increased thickness 
of the colonic mucus layer as well, in line with the increased presence and altered 
morphology of the goblet cells and increased levels of transcription of Muc2, a major 
component of the mucus layer(15). These microvilli and mucus phenotypes could 
be fully reversed by bone-marrow transfer from WT cells. From these findings, three 
important conclusions can be drawn:
First, not only blood levels(6), but also feces levels of CgA and CST might be markers 
for disease severity of IBD, particularly CD. CST levels are increased both in plasma(6) 
and feces (this study) of IBD patients irrespective of disease activity, whereas levels 
of CgA, the precursor of CST, are only elevated during active CD. These findings 
suggest a proteolytic switch, where CgA and CST are excessively produced in IBD 
regardless of the disease state, but CgA is cleaved more into CST in quiescent disease. 
As we recently reported, CST inhibits colon inflammation and promotes the intestinal 
epithelial barrier function by counteracting pancreastatin, another cleavage product 
of CgA(6). Thereby, the elevated CST levels in IBD patients are suggestive of a feedback 
mechanism to counteract the disease state and might help to normalize the colon 
function(6).  
Second, we found that the mucus layer thickness and microvilli length in IBD patients 
depend on local disease activity in the colon. Between 1970 and 1980, several 
studies showed increased goblet cell numbers in the ileum and colon(20,21) and 
increased mucus secretion in the ileum of CD patients(21). In contrast, UC patients 
were characterized with decreased goblet cell presence and glycocalyx (inner mucus 
layer)(20,22,23). These outcomes are based on case reports and did not include non-
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inflamed intestine of the same patient. In our study, non-inflamed colon regions of 
CD patients were characterized with a thicker mucus layer than inflamed colon 
regions from the same patient, whereas we did not observe significant differences for 
UC patients. Since the patient biopsies were taken only a few centimeter apart, this 
indicates tight local mucosal regulation. Moreover, the mucus layer in non-affected 
colon regions of CD patients was even thicker than for healthy controls, indicating 
excessive mucus production, possibly as a compensatory mechanism to protect 
the colon from microbial infiltration. The length of the microvilli was affected in the 
same way: increased in non-inflamed tissue and shortened in inflamed colon tissue, a 
pattern observed before in pigs(24). Previously, electron microscopy studies reported 
destroyed colon microvilli in UC patients(20,23), whereas no consistent changes 
were found in CD patients(20,22). Moreover, in the ileum of CD patients, a decreased 
microvilli density has been reported, as well as downregulation of genes related to 
microvilli formation, F-actin bundling, membrane cytoskeleton cross-linking and 
intermicrovillar adhesion complex(25). Our data add to this and show that changes of 
the mucus layer and microvilli in the colon depend on the local inflammation state in 
CD patients. 
Third, we conclude that CST produced by bone-marrow derived cells regulates the 
production of the protective mucus layer. We found that the thickness of the mucus 
layer in the colon of CST-KO mice is increased, in line with the increased infiltration of 
immune cells reported previously(6)6. It seems contrasting that CST presence reduced 
the protective mucus layer, but at the same time reduces intestinal permeability 
as we showed previously(6). So far, we don’t know whether the composition of the 
decreased mucus layer in presence of CST would be more protective against bacterial 
infiltration. Another open question is whether the effects on mucus regulation might 
be caused by CST alone or by the balance between CST and pancreastatin (PST)(26), 
another cleavage product of CgA. Our previous research showed that the intestinal 
barrier permeability is regulated by the antagonistic role of CST and PST, where CST 
reduced while PST increased permeability(6). We found that the increased length of 
the microvilli and the increased thickness of the mucus layer in the colon of CST-KO 
mice were fully reversible by bone-marrow transfer from WT mice. Combined with our 
previous findings that macrophages produce CST themselves and that bone-marrow 
transfer from WT mice into CST-KO mice results in near-normal levels of CST in the 
plasma(6), this suggests that the macrophages (and possibly other bone-marrow-
derived cells) are major producers of CST in the colon. In line with our hypothesis that 
CST produced by infiltrating macrophages reduces mucus production, we found a 
reduced thickness of the mucus layer in inflamed regions of the colon of CD patients, 
which have a high density of infiltrated macrophages and other immune cells(27,28). 
Further supporting this hypothesis, intraperitoneal injection of CST in CST-KO mice 
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could reverse the expression of MUC2. Thus, based on the findings from this study, 
we expect that the elevated levels of CST produced by immune cells regulate the 
production of mucus in inflamed colon regions of CD patients. 
An open question is what drives the cleavage of CgA to produce CST. Candidates are 
cathepsin L, an endolysosomal protease expressed by endocrine cells that co-localizes 
with CgA in chromaffin granules(29), and plasmin, the main enzyme of the fibrinolytic 
cascade(30). The expression of cathepsin L is increased in macrophages during 
mucosal inflammation of IBD patients(31), as well as in the colon of CST-KO mice(6). 
For plasmin, it has been shown that its inhibition prevents disease progression in acute 
colitis mouse models(32). However, its expression is downregulated in CST-KO mice(6). 
Finally, it seems possible that CgA is not only converted to CST by a host protease, but 
also by proteases produced by the gut bacteria(33), which would mean that the micro-
environment in the gut defines the balance between CgA and CST. 
Overall, our finding that CST regulates the mucus layer in the gut strengthens the 
emerging concept(6,31,32) that CST could be a potential new biomarker and/or 
therapeutic target for treatment of IBD and other gastrointestinal diseases.
Conclusion
CST produced by bone-marrow derived immune cells reduces production of the 
mucus layer in the intestine. Compared to healthy controls, IBD patients have 
increased stool levels of CST. This might contribute to the reduced mucus layer in 
inflamed colon regions of IBD patients. CST feces levels might be a therapeutic target 
or biomarker for IBD.
Materials and Methods
Mice 
Male WT, CgA-KO and CST-KO mice (3 months old) on C57BL/6J background were used 
to study the intestine. All procedures relating to the WT and KO mice were approved 
by the Institutional Animal Care and Use Committee (UCSD) and all procedures and 
housing and handling of the animals were in accordance with National Institutes of 
Health animal care guidelines. CST-KO have been described before(19). CST-KO mice 
display hypertension, and a hyperadrenergic and insulin-resistant phenotype. Bone-
marrow transplant from WT to CST-KO mice was performed as described previously(18).
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Human colon biopsies and feces collection
Colon biopsies and feces samples were collected from patients with CD (N=39) and 
UC (N=36) (Table S1) in a cohort of long-standing CD and UC patients stratified for 
inflammation by colonoscopy. A flare-up or inflammation was defined as histological 
and endoscopic disease activity, whereas remission entailed absence of endoscopic 
inflammation and of histological disease activity. Non-inflamed biopsies were 
taken of the same colon segment > 2 cm from endoscopically visible disease. Feces 
from healthy controls (N=10) was also collected (average age 44 with range 38-54 
years, 7/10 female) (Table S1). Informed consent was obtained and the study was 
conducted in accordance with the Institutional Board Review of the University Medical 
Center Utrecht (approval number NL 35053.041.11 & 11-050 for the IBD cohort and 
NL40331.078 for the healthy controls). Samples were collected in compliance with the 
Declaration of Helsinki.
CgA, CST and calprotectin levels in human feces
Feces was used to determine CgA and CST levels using ELISA (CUSABIO CSB-E17355h, 
CSB-E09153h) and calprotectin (HycultBiotech HK379). 
Electron microscopy mouse colon
Human colon was fixed  with 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M 
cacodylate (pH 7.4) buffer overnight at 4°C. After washing in buffer tissue was 
postfixed for 1 h at RT in 1% osmium tetroxide and 1,5% potassium ferrocyanide in 
0.1 M cacodylate buffer, washed in MQ, followed by one hour staining in en bloc with 
2% uranyl acetate on ice. After washing in MQ, tissue was dehydrated in an ascending 
series of aqueous ethanol solutions and subsequently transferred via a mixture of 
aceton and Durcupan to pure Durcupan (Sigma) as embedding medium. Ultrathin 
sections (80 nm) were cut on a Leica Artros ultramicrotome, picked up on grids, stained 
with 2% uranyl acetate and lead citrate, air dried and examined in a JEOL JEM1400 
electron microscope operating at 80 kV.
Electron microscopy human colon
Human colon was fixed  with 2% glutaraldehyde in 0.1 M cacodylate (pH 7.4) buffer 
overnight at 4°C. Tissue was postfixed for 1 h at RT in 1% osmium tetroxide and 1.5% 
potassium ferrocyanide in 0.1 M cacodylate buffer, washed in MQ, followed by one hour 
staining in en bloc with 2% uranyl acetate on ice. After washing in MQ, dehydrated in 
an ascending series of aqueous ethanol solutions and subsequently transferred via a 
mixture of aceton and Durcupan to pure Durcupan (Sigma) as embedding medium. 
Ultrathin sections (80 nm) were cut on a Leica ultramicrotome, and picked up on grids, 
stained with 2% uranyl acetate and lead citrate, air dried and examined in a JEOL 
JEM1400 electron microscope (JEOL) operating at 80 kV.
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Processing and histology human & mouse colon  
Human colon was fixed in carnoy-methanol to preserve the mucus layer. Mouse colon 
was fixed with 2.5% glutaraldehyde in 0.15 M cacodylate buffer. Mouse and human 
colon was dehydrated in ethanol series, xylene and paraffin. Afterwards, the tissue 
was carefully embedded in paraffin (formalin fixed and paraffin embedded (FFPE)) 
and sections of 5 µM were cut. Hematoxylin and eosin (HE) and periodic acid-Schiff 
(PAS) staining were performed using standard techniques. Slides were mounted on 
silane coated glass slides (MUTO PURE CHEMICALS 511618) using Quick D mounting 
medium and imaged using the PerkinElmer Vectra (Vectra 3.0.3; PerkinElmer, MA) at 
20x magnification. 
Analysis Electron microscopy goblet cells and mucus layer in 
colon
The imageJ straight line tool was used to analyze the microvilli (from border till visible 
end in lumen) and mucus thickness (measured on top of microvilli). Additionally, the 
freehand drawing tool was used for measuring the goblet cell area.
Statistical data analysis
Data are expressed as mean ± SEM. D’Agostino & Pearson omnibus normality test was 
performed followed by one-way ANOVA with Bonferroni post-hoc tests or the Kruskal-
Wallis with Dunn’s. Significance is displayed in the graphs and a value of p < 0.05 was 
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Fig. S1. Calprotectin levels correlates with IBD activity. (A) Calprotectin levels detected in feces 
of healthy donors (black) and Crohn’s disease (CD) patients in remission (grey) or flare-up (white). 
(B) Same as panel A, but now for calprotectin levels in feces of ulcerative colitis (UC) patients. 
Kruskal-Wallis *: P<0.05; **: P<0.01; ***P<0.001. 
Fig. S2. HE stain colon Crohn’s disease patient. 
Representative images of hematoxylin and eosin 
(HE) stained colon cross-sections of non-inflamed 
(A) and inflamed (B) colon tissue of Crohn’s disease 
(CD) patients. Note the increased immune cell 















Female (n, %) 7 (70%) 18 (67%) 10 (52%) 13 (65%) 9 (45%)
Age (average, range) 44 (38-54) 50 (22-71) 45 (22-72) 45 (20-66) 48 (24-75)
Disease duration 
(average, range)
- 23 (9-51) 18.5 (9-48) 16.5 (6-29) 19 (3-38)
Montreal (n, %) - L1 1 (5.5%) 0 (0%) E1 3 (15%) 1 (5%)
L2 7 (39%) 7 (37%) E2 7 (35%) 5 (25%)
L3 9 (50%) 11 (58%) E3 10 (50%) 14 (70%)
L2 + L4 0 (0%) 1 (5%)
L3 + L4 1 (5.5%) 0 (0%)
IBD medication (%)
None
50 (100%) 3 (17%) 5 (26%) 3 (15%) 0 (0%)
Mesalazine preparations 2 (11%) 2 (10.5%) 12 (60%) 17 (85%)
Corticosteroids 0 (0%) 1 (5%) 0 (0%) 5 (25%)
Immunosuppressives 12 (67%) 4 (21%) 8 (40%) 5 (25%)
Biologicals 3 (17%) 9 (47%) 1 (5%) 0 (0%)
Table 1. Patient characteristics for feces measurements. Characteristics of the patients at 
time of inclusion for stool measurements. As an indication for the extent of disease, the location 
has been scored according to the Montreal classification. For CD; L1 is ileal disease, L2 is colonic 
disease, L3 is ileocolonic disease, and L4 is isolated upper gastro-intestinal tract. For UC; E1 is 
distal to the rectosigmoid junction (proctitis), E2 is distal to the splenic flexure (left-sided) and 
E3 is proximal to the splenic flexure (extensive). Medication entails therapeutic categories in use 
for IBD; other therapies are not included. Some patients use more then one drug which all have 
been scored separately. Biologicals comprised only anti-TNF-α compounds. CD: Crohn’s disease, 
IBD: inflammatory bowel disease, UC: ulcerative colitis.
Table 2. Patient characteristics for electron microscopy. Characteristics of the patient at time of 
inclusion for electron microscopy on colonic biopsies. Indication for colonoscopy for the healthy 
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Abstract 
Increased levels of the anti-inflammatory peptide catestatin (CST), a cleavage 
product of the pro-hormone chromogranin A, correlates with less severe outcomes 
in hypertension, colitis and diabetes. However, it is unknown how CST reduces the 
infiltration of monocytes and macrophages in inflamed tissues. Here, we report that 
CST blocks leukocyte migration towards inflammatory chemokines. By in vitro and 
in vivo migration assays, we show that although CST itself is weakly chemotactic, it 
blocks migration of monocytes and granulocytes to inflammatory attracting factor CC-
chemokine ligand 2 (CCL2) and macrophage inflammatory protein 2 (MIP-2). Moreover, 
it directs CX3CR1
+ macrophages away from pancreatic islets. These findings support 




As an immunological response to inflammation, monocytes, granulocytes and 
leukocytes are attracted to inflamed tissues by chemokines such as CC-chemokine 
ligand 2 (CCL2, a.k.a. MCP-1) and macrophage inflammatory protein 2 (MIP-2, a.k.a. 
CXCL2) (1). However, to avoid an excessive response, leukocyte infiltration should 
be halted for resolution of inflammation, but the mechanisms that govern this are 
unknown (2). Here, we addressed the potential chemotactic effect of chromogranin A 
(CgA)-derived peptide Catestatin (CST: hCgA352-372) (3). While CST circulates at low nM 
range, the local concentrations were detected in the µM range in mouse tissues (3–6). 
Being an anti-inflammatory peptide, CST reduces inflammation in cardiac and chronic 
inflammatory diseases (3,7–9). Despite the chemotactic effects of CST (7,10,11), 
administration of exogenous CST reduces monocyte and macrophage infiltration in the 
liver, heart and gut in mouse models of type II diabetes, hypertension, atherosclerosis 
and colitis (4,7,8,12,13). In a colitis model, CST also reduced granulocyte infiltration in 
the colon (8). In line with this, the adrenal gland, heart, and gut of CST knockout mice 
display increased macrophage infiltration (4,7,12). In this study, we show that while CST 
itself is weakly chemotactic, it blocks the extravasation and migration of phagocytes 
both in vitro and in vivo. Thus, the anti-inflammatory effects of CST are partly the result 
of redirecting monocytes and granulocytes away from the inflammation sites.
Results & Discussion
Although human blood monocytes migrated towards a high (but physiological) 
concentration of CST (5 µM), this was less efficient compared to the canonical 
inflammatory chemokine CCL2 (0.5 nM) (Fig. 1A-C), reinforcing a weak chemoattractive 
effect of CST (7,10,11). To confirm this in vivo, we performed imaging of the cremaster 
muscle (Fig. 1D) (14). Upon perfusion of the muscle with CST (5 µM), phagocytes 
(monocytes and granulocytes) decreased their speed and attached to the vessel 
wall with similar efficiency as of the inflammatory chemotactic agent MIP-2 (0.5 
nM) (Fig. 1D-F, Fig. S1). Thus, both our in vivo and in vitro migration assays show that 
CST is weakly chemotactic, raising the question how CST can reduce monocyte and 
granulocyte infiltration in inflamed tissues such as the liver (diet induced obese mice), 
intestine (colitis model), heart (hypertension model) and atheromatous plaques 
(atherosclerosis model) (4,7,8,12,13).
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To address how CST affects macrophage chemotaxis to inflamed tissues, we used the 
aortic ring vessel model (15) (Fig. 2A), which is based on the co-embedding of part 
of the aorta of Cx3cr1
+/gfptransgenic mice adjacent to isolated pancreatic islets (16). 
These islets secrete chemokines, such as vascular endothelial growth factor (VEGF)-A, 
resulting in the directional macrophage migration from the aortic ring as well as vessel 
growth towards the pancreatic islets. Migration of CX3CR1
+macrophages from the 
aortic ring was visualized by fluorescence microscopy (17) (Fig. 2B, S2). As expected, 
the CX3CR1-macrophages moved towards the pancreatic islets in absence of CST (Fig 
2B). However, perfusing the aortic ring with CST (5 µM) resulted in a lower number 
of CX3CR1
+GFP macrophages migrating towards the pancreatic islets (Fig 2B), indicating 
that CST blocked directional migration. Interestingly, we also observed that CST is pro-
angiogenic, as it increased both the amount and length of the sprouts and branches 
emanating from the aortic rings (Fig. 2C-D, S3).
The loss of directional cell migration to the pancreatic islets might be caused by 
blockage of chemokine-induced cell migration by CST. To investigate this possibility, 
we performed intravital imaging of the cremaster muscle, but this time for CST in 
combination with MIP-2. This resulted in the inverse effect compared to CST or MIP-2 
alone: release of attached cells from the vessel wall and reduced migration of cells into 
the tissue (Fig. 2E, S4), indicating that despite being weakly chemotactic, CST blocks 
MIP-2 elicited phagocyte recruitment. To further confirm this, we performed an in vitro 
migration assay, where human monocytes were stimulated with a gradient of CCL2 
in presence of CST (Fig. 2F). Similar to our findings with the intravital imaging, CST 
blocked monocyte migration towards the CCL2. 
Although CST counteracts the chemoattraction by inflammatory cytokines (Fig. 2G), 
the question remains open which receptor(s) CST utilize to exert these effects on 
cell migration. We speculate that this might be a G-protein coupled receptor (GPCR), 
Fig. 1: CST is weakly chemotactic. (A) Scheme showing set-up of Gradientech migration assay. 
Two syringes filled with buffer +/- chemoattractant were connected to the device (green) to 
create a flow (x-direction) and perpendicular (y) cytokine gradient. The inset shows migration of 
monocytes along the flow and towards the chemoattractant. (B) Representative tracks of human 
monocytes showing the x- and y-movement of individual cells upon exposure to the indicated 
buffer, 5 µM CST or 0.5 nM CCL2. (C) Quantification of panel B (N=3). (D) Scheme showing set-
up of cremaster muscle imaging in mice to visualize phagocyte (monocytes and granulocytes) 
extravasation in vivo. (E) Phagocyte rolling velocity (top) and attachment (bottom) upon 
overflowing the muscle with buffer (control, gray), 0.5 nM MIP-2 (blue) or 5 µM CST (black) (N=3, 
two-way ANOVA). (F) Representative images of granulocyte attachment as visualized by Ly6G-
mAb (green) to the vessel wall upon only buffer, MIP-2 or CST stimulation. *: P<0.05; **: P<0.01; 
***P<0.001; ns: not significant.
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since GPCRs are actively involved in leukocyte migration (18) coupled with expression 
of GPCRs in all cell types responsive to catestatin (e.g. monocytes (10), neutrophils 
(19,20), macrophages (4,7,8,12,13), endothelial (13,21) and mast cells (11)), we 
speculate that CST might act through this receptor type. We have not only shown 
how CST reduces the infiltration of monocytes and macrophages in inflamed tissues 
(4,7,8,12,13), but offer a possible mechanistic explanation for the correlation of CST 
levels with improved disease outcome in patients suffering from chronic diseases (4–
6), reinforcing CST as a therapeutic target for treatment of diseases associated with 
chronic inflammation.
Fig. 2: CST blocks migration induced by inflammatory chemokines and promotes 
angiogenesis. (A) Scheme showing set-up of aortic ring assay. Aortic ring was isolated from 
CX3CR1-GFP mice and embedded adjacent to pancreatic islets in collagen I. Image shows islets 
(blue), CD31 (red) and CX3CR1 (green). (B) Representative images of CX3CR1-macrophage 
migration upon control or CST stimulation of the aortic ring. The graph shows the percentage 
of cells above (yellow) the center of mass (N=8). (C) Representative images of vessels by CD31 
(red) upon control or CST stimulation of the aortic ring. (D) Quantification of angiogenesis. Total 
number of sprouts and branches (left) and their length (right) (N=5-6). (E) Cremaster muscle 
imaging. Phagocyte attachment to vessel wall upon overflowing the muscle with buffer (control, 
gray) and buffer with the chemoattractant MIP-2 (blue), CST (black) or both (red) (N=3, two-
way ANOVA). (F) Gradientech migration assay. Representative x- and y-movement of human 
monocytes exposed to opposite gradients of CST and CCL2 (N=3). (G) Model showing leukocyte 
extravasation in presence of low and high concentrations of CST. Mann-Whitney test *: P<0.05; **: 
P<0.01; ***P<0.001; ****P<0.0001; ns: not significant.
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Sup. 1: Attachment of granulocytes and monocytes to vessel wall. (A) Venules of 
the cremaster muscle were overflown with bicarbonate-buffered saline buffer (buffer 
only control), the chemoattractant MIP-2 or CST as shown in main Fig. 1D-F. Graph 
shows quantification of rolling cells (cells/min). (B) Quantification of cell in tissue. (C) 
Representative brightfield snapshots of in vivo cremaster muscle imaging as in main figure 
1D-F. (C) Quantification of adherent granulocytes (visualized by Ly6G-mAb, main Fig. 1F) 
and monocytes (brightfield, panel C) after 0, 30, 60 and 90 minutes (N=1-2).
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Sup. 2: Quantification of CX3XR1+ cell movement in the aortic ring model. 
(A) Brightfield image of the aortic ring with islets. (B) Description of CX3CR1-cell 
movement quantification by determination of total amount outside the aortic ring 
(endothelium), center of mass (red spot) and the islet side (black arrow). 
92
Chapter 4 - The anti-inflammatory peptide catestatin blocks chemotaxis
Sup. 3: Branches and sprouts in the aortic ring assay. (A) Representative images of 
angiogenesis quantification of main figure 2C-D. The images show the ring endothelium, 
main sprout (red), branch (gray) (B) Quantification of total number of sprouts and branches 




Sup. 4: The combination of CST and MIP-2 reduced chemotaxis. Venules of the 
cremaster muscle were overflown with bicarbonate-buffered saline buffer (buffer only 
control), the chemoattractant MIP-2 or CST, as shown in main Fig. 1D. Graph shows 
quantification of tissue migration (A), rolling cells (cells/min) (B) and velocity (C) upon CST, 
MIP-2 or stimulation with both (N=3, two-way ANOVA) *: P<0.05; **: P<0.01; ***P<0.001; 
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Chapter 5 - Cross-presentation in macrophages
Abstract 
The contribution of dendritic cell (DC) antigen cross-presentation to the activation 
of CD8+ T lymphocytes for immune defense against tumors, viruses and intracellular 
pathogens has been recognized widely. Although originally thought to be an exclusive 
characteristic of DCs, recently also other immune cells, particularly macrophages, 
have been shown capable of cross-presentation. Here we provide an overview of in 
vitro and in vivo evidence on cross-presentation by macrophages. As we discuss, it is 
now firmly established that various types of tissue-resident macrophages are able to 
cross-present via similar cellular pathways as DCs. This is based on a wide range of 
antigens in macrophages from many different tissue origins such as blood, tumors 
and lymphoid tissue. However, the physiological relevance of macrophage cross-
presentation with potential contributions to activation of CD8+ T lymphocytes is still 
mostly unknown. While cross-presentation by various types of pro-inflammatory 
macrophages might be involved in cross-priming of naive CD8+ T lymphocytes, it might 
also be involved in local re-activation of memory and/or effector CD8+ T lymphocytes. 
Moreover, cross-presentation by anti-inflammatory macrophages could be related to 
immune tolerance. Since cross-presentation promotes the initiation and potentiation 
of antigen-specific CD8+ T lymphocyte responses, stimulating macrophages to cross-




Since the first evidence of their antigen cross-presenting capacities for activation 
of naive CD8+ T lymphocytes in 1976, dendritic cells (DC) have been heavily studied 
for the mechanisms and physiological roles of cross-presentation (1). Antigen cross-
presentation is crucial for the initiation of adaptive immune responses against cancer, 
viruses and numerous other intracellular pathogens. During this process, antigen 
presenting cells (APCs) present peptides derived from ingested antigens in their 
major histocompatibility complex class I (MHC-I) protein complex to naive CD8+ T 
lymphocytes. If the DCs also provide sufficient levels of co-stimulatory receptors (e.g., 
CD80, CD86) and cytokines (interleukin-12; IL-12), cross-presentation results in the 
activation of naive CD8+ T lymphocytes to effector cytolytic T cells in a process called 
cross-priming. Effector cytolytic T cells can induce apoptosis in infected or malignant 
cells (2,3). Since DCs were assumed the only (or at least main) cross-presenting cells 
capable of cross-priming naive CD8+ T lymphocytes, by far most research has been 
focused on cross-presentation pathways in DCs. However, recently also macrophages 
have been shown to be capable of antigen cross-presentation and this might have 
large implications for our understanding of CD8+ T lymphocyte responses. Therefore, 
the aim of this review is to provide an overview of the current studies covering the 
roles and mechanisms of antigen cross-presentation by macrophages.
Role of dendritic cells and macrophages in CD8+ T lymphocyte 
activation
During their lifetime, DCs can exist in two discrete stages: immature and mature. 
Immature DCs are overall considered to be better in endocytosis and protein 
processing, and their primary role is to sample antigen in the circulation and peripheral 
tissues. The recognition of antigen by pattern recognition receptors (PRRs), such as 
Toll-like receptors (TLRs), results in the maturation of the DCs. The resulting mature 
DC can migrate to the lymphoid organs, where it can  activate antigen-specific CD8+ 
T lymphocytes by cross-presentation (4). DCs can be categorized into subsets based 
on their cross-priming ability and origin. Many studies are devoted to characterize 
the capacity of various DC subsets to cross-present to CD8+ T lymphocytes in mouse 
and human by for example the use of RNA sequencing and lineage tracing, which has 
been extensively reviewed elsewhere (2,5,6). Briefly, the main subsets in human are: 
plasmacytoid CD123+CD303+CD304+ DCs (pDC) and conventional DCs (cDC) including 
CD1a+CD11chighXCR1-BDCA-1+ (cDC2) and CD1a−CD11clow CLEC9A+XCR1+BDCA-
3+CD141+ (cDC1) (2,5,6). All these subsets have the capacity to cross-present, but due 
to the high expression of MHC-I pathway genes, cDC1s are considered as the most 
efficient cross-presenting cells in human (2,5,6). The same subsets are present in mice, 
but then based on expression of CD11c and MHC class II in combination with CD4, 
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CD8α, CD11b, XCR1, CLEC9a, CD103 and CD205. The mouse classical DCs express 
either CD11b (equivalent to human cDC2) or CD8α, XCR1, CLEC9A (also known as 
DNGR1) and CD103 (equivalent to human cDC1), where the cross-presenting efficiency 
depends on the expression of CD8 (in lymphoid tissue), making the classical CD8+ DC 
the best  mouse subset for activation of cytolytic T lymphocytes (2,5,6).
Tissue macrophages such as liver Kupffer cells, spleen red-pulp and large peritoneal 
macrophages  develop during embryogenesis, where they originate from precursors 
in the yolk sac, fetal liver and bone marrow (extensively reviewed in (7)). These 
embryonically-derived macrophages become tissue-resident macrophages that can 
propagate via self-renewal (7,8). Later in life, the hematopoietic stem cells in the 
bone marrow give rise to LY6C+ monocytes in mice or CD14+CD16+ monocytes in 
human, which  can subsequently be recruited from the blood into the tissues, such 
as sites of infection or tumors, to either promote further inflammation or tissue 
repair (8–10). Upon arrival, these monocytes can differentiate into pro- or anti-
inflammatory monocyte-derived macrophages, depending on the PRR signaling, 
growth factors and cytokines present in the tissue. The pro-inflammatory, also known 
as M1 or classically-activated, macrophages  are activated by signaling from PRRs 
or inflammatory cytokines (e.g., interferon-γ; IFN-γ) and express pro-inflammatory 
cytokines, IL-6, TNF-α, IL-1β, and inducible nitric-oxide synthase (iNOS) (6,11). The anti-
inflammatory, also called M2, pro-resolving or alternatively-activated, macrophages 
are stimulated by interleukin-4 (IL-4) or IL-13 and express arginase 1 (Arg1), the 
mannose receptor CD206 and the IL-4 receptor α-chain (IL-4Rα). The main function 
of the pro-inflammatory macrophages is to eliminate tumors and pathogens by 
production of inflammatory cytokines and phagocytosis, while the main functions of 
the anti-inflammatory macrophages are tissue repair and homeostasis (12–14).When 
there is space in the tissue niche, blood-recruited monocytes might also differentiate 
into tissue macrophages (8). Both embryonically-derived and monocyte-derived 
macrophages are able to sense and phagocytose tumor cells and pathogens (15). 
The precise phenotype and access to antigen of tissue-resident macrophages depends 
on the tissue, but especially spleen, lymph node, liver and peritoneal macrophages 
(Fig. 1) constantly encounter blood- or lymph-borne antigens, which means that they 
are ideally positioned for antigen uptake and they are thus in principle well-positioned 
for cross-presentation to CD8+ T lymphocytes. 
Although antigen cross-presentation by macrophages is less well understood than for 
DCs, it is increasingly clear that especially pro-inflammatory macrophages are capable 
of cross-presentation. The function of this cross-presentation is unclear, but evidence 
suggests it might be important for cross-priming of naive CD8+ T lymphocytes similar 

























Fig. 1 Macrophage types potentially capable of antigen cross-presentation. Populations of 
macrophages in various tissues of the body that can cross-present antigen and their potential 
interactions with CD8+ T lymphocytes. Lymph node: blood vessel (red), cortex and follicle (green) with 
CD8+ T lymphocytes (gray) in the T cell zone and subcapsular macrophages on the edge (blue), medulla 
(brown) including medullary sinus macrophages and medullary cord macrophages (blue), subcapsular 
macrophages and. Liver: blood vessel (red) containing CD8+ T lymphocytes (gray) and Kupffer cells 
(blue) on the edge, which are surrounded by hepatocytes. Tumor environment: tumor-infiltrating 
macrophages (blue) and CD8+ T lymphocytes (gray) in-between tumor cells (brown). Bone marrow: 
hematopoietic stem cells (HSCs), which give rise to monocytes (dark blue) that leave the bone marrow 
by blood vessels (red). Blood: Monocytes in the blood vessels (red) can extravagate through the vessel 
wall into tissues, where monocytes (dark blue) differentiate into macrophages (blue) and there could 
be memory T cells (gray) to re-activate upon infection. Spleen: the spleen consist of red pulp (pink), 
white pulp (soft pink) with follicles (white) containing CD8+ T lymphocytes (gray)  and blood vessels 
(red). The red and white pulp are separated by the marginal zone. All contain macrophages (blue), 
including the marginal zone, which contains marginal metallophilic and marginal zone macrophages. 
Peritoneum: the adipocytes (soft yellow) surround the peritoneal cavity (yellow) which includes large 
and small peritoneal macrophages macrophages (blue) and CD8+ T lymphocytes (gray).
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which are important in case of recurrent infections. Memory CD8+ T lymphocytes   are 
present in tissues such as in the skin (16), where they might encounter macrophages. 
Additionally, inflammatory macrophages may cross-present to re-activate effector 
CD8+ T lymphocytes upon sustained infections in combination with production 
of IL-12 and IL-23, but independent of CD80, CD86, and CD28 co-stimulation (2). 
In contrast, cross-presentation by anti-inflammatory macrophages might have 
functions in immune tolerance against ‘self ’ proteins, commensal microbes and food 
components, similar to the cross-presentation of immature DCs (17). The different 
roles of cross-presentation by macrophages possibly relate to the antigen source, type 
of macrophage and location of the macrophage as will be discussed below. 
Cross-presentation by various macrophage types
Cross-presentation by splenic macrophages 
In the spleen, different subsets of macrophages can be distinguished based on 
their anatomical location and function (Fig. 1). In mice the red pulp macrophages 
(F4/80highCD68+VCAM1+CD11blow) are involved in iron metabolism and clearance of 
senescent erythrocytes. The white pulp macrophages (F4/80lowCD68+) are specialized 
in phagocytosis, for instance for clearance of apoptotic B cells, and for regulating 
immune responses against pathogens. The white and red pulps are separated by the 
marginal zone, and macrophages located in this area can recognize and clear blood-
borne antigens. Marginal zone macrophages can be subdivided in the phenotypically 
and functionally different marginal metallophilic macrophages (F4/80lowCD68+CD169+), 
involved in virus clearance, and marginal zone macrophages (F4/80lowCD68+SIGN-R1+), 
involved in tolerance against apoptotic cells in blood (18). Given that both types of 
marginal zone macrophage encounter blood-borne antigens and the role of CD169+ 
macrophages in CD8+ T lymphocyte activation in the lymph nodes (see below), a role 
for these macrophages in CD8+ T lymphocyte activation in the spleen is likely (19,20). 
Evidence that splenic macrophages are capable of cross-presentation comes from 
the in vitro finding that isolated mouse splenocytes incubated with microspheres 
encapsulated with the model antigen ovalbumin could induce activation of 
ovalbumin-specific B3Z hybridoma cells (LacZ assay) (21). Macrophages might play a 
role in this CD8+ T lymphocyte activation and it was not exclusively due to splenic DCs, 
since ovalbumin-specific T cell activation (in vivo cytotoxicity assays) was still observed 
with splenocytes from mice that were depleted of CD11c+DCs (21). Moreover, 
splenocytes from mice depleted of both CD11c+DCs and CD11b+macrophages showed 
less T cell activation  compared to mice depleted of CD11c+DCs only, suggesting that 
macrophages can cross-present in the absence of DCs (21). However, the ovalbumin-
containing microspheres used in this study were specifically designed for vaccination 
and thereby might enhance cross-presentation also in cell types that normally are 
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not (or less) able of this process. Moreover, the physiological relevance of this finding 
is unclear, because CD11c and CD11b expression alone seems not sufficient to 
distinguish splenic macrophages and DCs (5). For instance, although depletion with 
CD11c will remove both CD11chiCD11b+CD8α−MHCII+ and CD11chiCD11b−CD8α+MHCII+ 
cDC subsets (22), the selection of CD11b is not sufficient to distinguish the various 
spleen macrophage populations since this would require selection on CD169 or 
SIGN-R1+ (5,22). Moreover, this isolation method might result in contamination of the 
CD11c+ DC population with CD11cintF4/80high red pulp macrophages (23).
Recently, these CD11cintF4/80high red pulp macrophages became of interest 
since, similar to DCs, they express CD11c and their location in the spleen allows 
them to acquire blood-borne antigens (23). Indeed, in vitro cross-presentation 
of fluorescently-labelled ovalbumin by murine CD11cintF4/80highCD4-CD8-CD11b-
CD80+CD86+MHCII+Gr1-MARCO- red pulp macrophages resulted in faster OT-I cell 
proliferation and higher expression of the T cell activation markers granzyme-B, TNF-α 
and production of IFN-γ than with the CD11chighCD8α+DEC205+ cDC1 subset (23). 
These OT-1 cells activated by the red pulp macrophages did not express activation 
markers CD127, KLRG1 and CX3CR1, suggesting they were so-called early effector 
cells which do not develop into memory cytolytic T cells (23,24). In contrast to the 
cDC1 cells, uptake of the model antigen ovalbumin by the red pulp macrophages 
relied on the mannose receptor CD206 (23). To address the role of cross-presentation 
by red pulp macrophages in vivo, mouse negative for the transcription factor SpiC 
were studied (23). SpiC mice lack CD11cintF4/80high red pulp macrophages, as SpiC is 
required for their development, while cDC1 DCs are unaltered because they rely on the 
transcription factor Batf3 (23,25). Infection of SpiC knockout OT-1 mice with AdLGO 
adenovirus expressing ovalbumin resulted in a higher initial viral load, while viral 
clearance by ovalbumin-recognizing OT-I cytolytic T cells was achieved after ten days. 
In contrast, cDC1 deficient Batf3 knockout mice showed no changes in the initial viral 
load, but viral clearance was delayed until day 14 (23). In line with the KLRG1-CX3CR1- 
phenotype of the cytolytic T cells induced by red pulp macrophages in vitro, in vivo 
reinfection experiments in SpiC knockout mice showed that red phase macrophages 
are not essential for induction of memory cytolytic T cell responses (23). These findings 
suggest that cross-priming by red pulp macrophages is necessary to contain early viral 
spread by triggering a fast but short antiviral response, whereas the main function 
of cDC1 cells is cross-priming of cytolytic T cells for complete viral clearance and 
development of memory cytolytic T cells.
The cross-presentation capabilities of other splenic macrophages have also been 
investigated in vivo. First, in mice with melanoma that underwent thermal ablation, 
isolated CD11b+CD11c-CD45+ splenic macrophages were shown capable of cross-
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presentation as directly shown with a fluorescently-labelled antibody recognizing 
MHC-I (H-2Kb-) loaded with the ovalbumin-derived epitope SIINFEKL (26). In 
addition, the  CD8+ lymphocytes in the tumor were specific for the antigen as 
shown by MHC-I tetramers carrying this epitope (26). Second, increased numbers 
of CD169+F4/80+CD11b+CD45+ macrophages were observed in the treated tumor 
region and spleen, which might suggest a role for these CD169+ macrophages in 
CD8+ T lymphocyte activation for elimination of the tumor (26). In line with a role 
for macrophages in cross-presentation, depletion of all phagocytosing cells using 
clodronate liposomes showed that after seven days, when the DCs already repopulate 
while the spleen macrophages need two weeks, the CD11c+ DCs were unable to 
activate  OT-I cells (IFN-γ, ovalbumin-specific cytotoxicity) with ovalbumin targeted by 
an antibody to the Siglec-1 receptor (CD169) in vitro (27). In contrast, direct targeting 
to CD8+ DCs via ovalbumin conjugated to an antibody recognizing CD205 resulted 
in efficient  activation of CD8+ T lymphocytes in vitro (27), indicating that directly 
targeted antigen was cross-presented by the DCs.
However, a role for DCs in activation of cytolytic T cells by macrophages cannot be 
excluded, as the antigen might be transferred from the macrophages to the DCs (26). 
Thus, although for instance ovalbumin targeted to the receptor Siglec-1 is ingested 
by marginal metallophilic macrophages, it might be subsequently transferred to CD8+ 
DCs for cross-presentation to CD8+ T lymphocytes (27). CD8+ DCs reside not only in 
the white pulp, but also locate the red pulp and marginal zone (28), and in principle 
they could encounter marginal metallophilic macrophages residing in the latter area. 
Migration of the DCs to the marginal zone might be important for antigen transfer, 
because treatment of mice with pertussis toxin, which blocks chemokine receptor 
mediated migration, no longer resulted in OT-I CD8+ T lymphocyte proliferation using 
ovalbumin targeted to Siglec-1 (27). In contrast, CD8+ T lymphocyte responses after 
direct targeting of ovalbumin to CD8+ DCs via CD205 were unaffected by treatment 
with pertussis toxin (27). The CD169+ macrophages and CD8+ DCs have also been 
visualized in close interaction with each other using immunofluorescence microscopy 
and flow cytometry. In this case, the CD169+ macrophages were suggested to move 
to the CD8+DCs, although  this was not specifically shown (29). Moreover, the specific 
antigen transfer seems to depend on the sialoadhesin CD169, which is involved in 
cell adhesion, since the use of Sn-KI mice, which expresses a mutated form of CD169, 
resulted in a reduced amount of antigen positive CD8+ DCs (fluorescent ovalbumin) 
and a reduced amount of ovalbumin-specific IFN-γ producing CD8+ lymphocytes 
(29). The immune stimulus of CD169+ macrophages is also important, since in vivo 
administration of liposomes targeted to CD169L, present on CD169+ macrophages, 
and containing ovalbumin and a TLR7 agonist induced expression of the activation 
markers CD86 and CD80 in the CD169+ macrophages and induced in vivo OT-I CD8+ 
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T lymphocyte activation  measured by proliferation, whereas only OT-II CD4+ T cell 
responses were observed in absence of the TLR7 agonist (30). Altogether, it seems that 
murine CD169+ macrophages in the spleen contribute to cross-presentation either 
directly or by transferring antigens to CD8+ DCs in the spleen. 
Cross-presentation by lymph node macrophages
According to their anatomical location in the lymph nodes and expression of surface 
markers, lymph node macrophages can be divided into subcapsular sinus macrophages 
(SSM; F4/80-CD169+), medullary sinus macrophages (MSM; F4/80+CD169+) and 
medullary cord macrophages (MCM; F4/80+CD169-) (31) (Fig. 1). Many lymph node 
macrophages are directly exposed to lymph fluid (31), which in principle enables them 
to efficiently take up lymph-borne antigens to present to T cells (31). 
In vivo evidence that F4/80+CD169+ MSMs and F4/80+CD169- MCMs are capable of 
cross-presentation, comes from the finding that only these cells can induce anti-tumor 
effects through stimulation of tumor-specific CD8+ T lymphocytes when targeted by 
a nanogel packed with tumor-specific synthetic long peptide antigen (LPA) and a 
TLR9 agonist (32). In this study, isolated F4/80+CD169+ MSMs, 18 hours after injection 
of the nanogel, were most efficient at inducing LPA-recognizing DUC18 CD8+ T cell 
responses in vitro measured by IFN-γ production and proliferation, which is possibly 
caused by a higher expression of CD80 and CD86 when compared to MCMs (32). 
Moreover, DCs and F4/80-CD169+ SSMs did not induce T cell responses and thereby 
it was concluded that were not essential for cytolytic T cell activation, probably 
because they did not have access to the nanogel. Injection of clodronate containing 
liposomes, which deplete macrophages but less DCs because they regenerate faster, 
blocked these antigen-specific CD8+ T lymphocyte response in the lymph node (32). 
However, the physiological relevance of this finding is unclear, given that a highly 
artificial antigen was used, and it was not confirmed whether in vivo the macrophages 
actually processed the peptide for cross-presentation, presented it directly on MHC-I, 
or transferred it to DCs as described for splenic CD169+ macrophages (27,29).
Other in vivo evidence that cross-presentation by CD169+ macrophages might be 
important in vivo, is the finding that mice specifically depleted of CD169+ SSM and 
MSM macrophages by induced expression of diphtheria toxin receptor (DTR) showed 
no  OT-I CD8+ T lymphocyte responses upon injection with ovalbumin expressing 
apoptotic cells or tumors (33). Additionally, CD169+CD11c+ macrophages were better 
cross-presenters compared to CD169+CD11c- macrophages and CD169-CD11c+CD8+ 
DCs, as shown by footpath stimulation with ovalbumin-expressing dead cells, followed 
by flow sorting of the DC and macrophage subsets and in vitro culturing with OT-I cells 
(proliferation, IFN-γ). Moreover, injection of CD8α+ DCs in CD169-depleted mice did 
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not increase OT-I CD8+ T lymphocyte responses (proliferation, IFN-γ) (33). Although 
this result at first glance seems strange given the essential role of CD8α+ cDCs in 
CD8+ T lymphocyte activation (2), DCs are mostly located in the T cell zone upon 
arrival in the lymph node, where the antigens might possibly not be well accessible 
to the DCs, whereas the sinus location of the macrophages is beneficial for the 
antigen sampling (12). Additionally, microscopy revealed that CD169+ macrophages 
and ovalbumin-specific OT-I CD8+ T lymphocytes are in close contact already at four 
hours after antigen challenging, suggesting that the CD8+ T lymphocytes re-localize 
to the sinus to be activated by antigen cross-presentation and then return to the T 
cell zone for proliferation (33,34). Thus, CD169+ sinus macrophages might well activate 
CD8+ T lymphocytes in the sinus, which would suggest that they are able of cross-
presentation. This might explain the physiological relevance of these macrophages 
and their location in the sinus and not in the T cell zone (Fig. 1). Another option is that 
the CD169+ SSM and MSM might transfer the antigen to DCs by CD169 to contribute 
to CD8+ T lymphocyte activation, similar to CD169+ macrophages in the spleen (see 
above) (27,29).
A role for CD169+ macrophages in cross-priming is in line with in vivo mouse 
experiments with subcutaneous injection of antibodies targeting different receptor 
complexes where the model antigen ovalbumin is fused to IgG-binding domains of 
protein G (35). In this study, it was found that targeting to CD11c, CD40 and TLR2 (all 
present in dendritic cells) resulted in the most efficient in vivo cross-priming of OT-I 
T cells, while targeting to CD207 (expressed strongly by Langerhans cells) or CD169 
(expressed by subcapsular sinus macrophages) still resulted in stronger cytolytic T 
cell responses than ovalbumin alone (i.e., without antibody targeting). In addition, 
microscopy showed that the protein complexes were ingested not only by CD35+ 
follicular dendritic cells, but also by CD169+ cells located in the marginal zone  (35).
The cross-presentation capabilities have also been studied for macrophages from the 
tonsils. Although CD11c+HLA-DR+CD14+ macrophages isolated from human tonsils 
efficiently ingested fluorescently-labelled necrotic cells, in vitro activation (IFN-γ) of 
the MelanA-recognizing LT12 CD8+ T cell clone pulsed with a long peptide fragment of 
MelanA was much less efficient for macrophages than for HLA-DR+CD14-BDCA1+ cDC2, 
CD11c+HLA-DR+CD14-BDCA3+ cDC1 and CD11c-HLA-DR+ pDC tonsil DCs (36). Also, the 
in vitro cross-presentation of NS3 protein from hepatitis C to NS3 antigen specific CD8+ 
T cell clones (IFN-γ) was less efficient for CD11c+HLA-DR+CD14+ tonsil macrophages 
than for these DC subsets (36). These findings show that although tonsil macrophages 




Cross-presentation by liver macrophages 
The macrophages in the liver are called Kupffer cells. This very heterogenous cell 
population (37) plays a major role in the clearance of gut-derived antigens and 
pathogens from the blood, making them in principle ideally positioned for cross-
presentation to blood CD8+ T lymphocytes. However, studying the Kupffer cells is 
challenging due to loss of cells during isolation and lack of consistent cell-membrane 
markers for sorting (37). 
Murine hepatic cells cultured in vitro with the model antigen ovalbumin could induce 
proliferation of ovalbumin-recognizing Th1 HTL clone cells but not Th2 HTL cells 
(38,39). Although this cell mixture included Kupffer cells, the contribution of other 
hepatic cells, such as liver resident DCs, liver endothelial cells and hepatocytes, 
cannot be excluded. Indeed, a recent side-by-side comparison of ovalbumin-pulsed 
hepatocytes, Tie-2+CD11blow liver endothelial cells, and CD11b+F4/80+ Kupffer cells 
showed that all these cell types can induce OT-I CD8+ T lymphocyte proliferation in 
vitro with similar efficiency as splenic CD11c+DCs (40). However the physiological role 
in the initiation of cytolytic T cell responses by liver cells is unclear, because the levels 
of cytolytic T cell  activation markers (CD44, CD25) and IFN-γ production were lower in 
the proliferated OT-I CD8+ T lymphocytes upon stimulation by the liver cells than upon 
stimulation with CD11c+ DCs (40). 
Interestingly, Kupffer cells seem to suppress immune responses for immune 
tolerance as seen in murine transplantation studies by rejection of allogeneic liver 
transplants (41). Injection of CFSE labelled OT-I CD8+ lymphocytes in the portal vein 
and intraperitoneal injection of ovalbumin peptide, resulted in retention of activated 
OT-I CD8+ cells (proliferation and CD45 expression) in the liver, followed by their 
deletion, probably by apoptosis as shown by DNA fragmentation (42). This apoptosis 
seems to be dependent on interactions with the Kupffer cells since CSF-1 deficient 
mice, which have no mature developed tissue macrophages since CFS-1 is essential 
for their differentiation, resulted in an increased presence of activated OT-I CD8+ 
lymphocytes(proliferation and CD45 expression) (42). Thus, it seems that Kupffer cells 
are able of cross-presentation and although the physiological relevance of this is still 
unclear, this might play a role in immune tolerance. 
Cross-presentation by tumor-infiltrating macrophages
The immune system can either combat cancer by immunosurveillance where the 
cancer is recognized and cross-presented by antigen presenting cells (43) or promote 
tumor progression via (in)direct suppression of CD8+ T lymphocytes and other immune 
cells (43,44). When directly comparing cross-presenting capacities of DCs and primary 
macrophages isolated from human peritoneal tumor ascites in vitro, it was found 
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that HLA-DR+CD11c+CD1c−CD16+ tumor macrophages even more effective than HLA-
DR+CD11c+CD1c+CD16− DCs at cross-presentation to the LT12 CD8+ T cell lines (IFN-γ) 
recognizing the tumor-specific antigen MelanA, which does not require co-stimulation 
for activation (45). Moreover, thermal ablation of ovalbumin-expressing melanoma 
in mice resulted in increased cross-presentation of ovalbumin-derived epitopes by 
intratumoral CD11b+CD11c- macrophages as directly measured by an antibody that 
recognizes MHC-I loaded with SINFEKL (26). Additionally, this cross-presentation was 
concomitant with an increased presence of ovalbumin-specific CD8+ T lymphocytes 
(26). Although these findings support a role for macrophages in ovalbumin-specific 
CD8+ T cell responses, evidence shows that DCs are essential in the initial activation of 
the naive CD8+ T lymphocytes. 
Although human ascites monocyte-derived CD1a+CD16+ macrophages efficiently 
presented an MelanA epitope to the LT12 CD8+ T cell clone in vitro, cross-priming of 
allogeneic naive cytotoxic CD8+ T cells (proliferation and expression of granzyme 
A, perforin, IFN-γ)  was only observed by ascites monocyte-derived DCs and not 
ascites-monocyte-derived macrophages (45). The reason for this is that the ascites 
monocyte-derived macrophages lacked expression of co-stimulatory signals such 
as CD80 and CD86 and produced almost no IL-12, whereas these were expressed by 
the ascites monocyte-derived DCs (45). These findings indicate that although tumor-
infiltrating macrophages are capable of cross-presentation, they do not provide the 
co-stimulatory signals required for cross-priming of cytolytic T cells.
More indirect evidence on cross-presentation by tumor infiltrating macrophages 
was obtained in a microscopy study in mice showing that migrating OT-I CD8+ T 
lymphocytes in ovalbumin-expressing tumors can have long interactions with F4/80+ 
macrophages, which might suggest activation by cross-presentation (46). Furthermore, 
CD8+ T lymphocytes might be activated for virus peptide by macrophages, because 
tumors in mice caused by injected fibrosarcoma cells transfected with lymphocytic 
choriomeningitis virus (MCA102(gp33)) were infiltrated by CD8+ T lymphocytes, a 
few CD11c+ DCs and a high number of CD11b+ macrophages (44). However, these 
tumor-infiltrating CD8+ T lymphocytes exhibited a highly activated phenotype 
(up-regulated CD25, CD44 and CD69 and down-regulated CD62L expression) but 
lacked effector cell function, measured by a killing assay, suggesting modulation of 
the CD8+ T lymphocytes by the tumor environment. The tumor-infiltrating CD11b+ 
macrophages were also able to efficiently cross-present to tumor infiltrating CD8+ T 
lymphocytes  (proliferation, IFN-γ, cytolytic activity) for gp33 in vitro (44). However, 
the co-stimulatory molecules CD80, CD86 and ICAM-1 were not expressed in these 




Cellular pathways of cross-presentation by macrophages
In DCs, antigen cross-presentation can be the result of two distinct cellular pathways: 
the cytosolic and vacuolar pathway (2,47). In the cytosolic pathway, proteins are 
first transported from the lumen of the endosomal compartment to the cytosol for 
degradation by the proteasome. Subsequently, the derived peptides can be processed 
via the MHC-I presentation pathway. The peptides are relocated via the transporter 
associated with antigen presentation (TAP) into the ER, where they are processed by 
ER aminopeptidases (ERAP), or brought back into the antigen containing endosomes 
to be processed by insulin-regulated aminopeptidase (IRAP). The loading of peptides 
on MHC-I occurs within these compartments (2,17). The other main cross-presentation 
pathway is the vacuolar pathway, where proteins are processed by endo/lysosomal 
proteases, such as cathepsin S, and loaded on MHC-I within the endo/lysosomal 
compartments (2,17). As we will discuss below, evidence suggests that the vacuolar 
pathway seems to be predominantly used by macrophages, although they might be 
able to also cross-present via the cytosolic pathway.
Bone marrow and blood monocyte-derived macrophages cross-
present via the vacuolar pathway
Monocytes derived from haematological precursors in the bone marrow (BM) can 
migrate via the blood stream to other tissues where they can differentiate into 
macrophages to perform tissue specific functions, eliminate pathogens or restore 
tissue homeostasis (48). Therefore, for research on mouse macrophages, stem cells 
are frequently isolated from the BM and differentiated into macrophages in vitro. 
For research on human macrophages, CD14+monocytes are often isolated from 
the blood. Both are then differentiated into macrophages in vitro, either by the use 
of macrophage colony stimulating factor (M-CSF), which results in a homogenous 
macrophage population, or by the use of granulocyte-macrophage (GM)-CSF, which 
results in a cell population reflecting resident macrophages (6). However, GM-CSF 
is also used to differentiate DCs from monocytes, therefore the macrophage culture 
might contain DCs (5,6). Thereby, it should be kept in mind that in vitro cultured 
monocyte-derived macrophages and monocyte-derived DCs have similarities (5,6) 
and that both in vitro BM-derived and monocyte-derived macrophages and DCs are 
artificial cell populations that might not be identical to their in vivo murine and human 
counterparts (Fig. 1).
The cross-presenting capacities of BM-macrophages seem to be higher than BM-
DCs when tested side-by-side using liposomes encapsulating a mixture of the model 
antigen ovalbumin and the pore-forming protein sticholysin II. M-CSF differentiated 
BM-macrophages were better in activating the ovalbumin-recognizing B3Z CD8+ 
T cell line (which does not require co-stimulation) than GM-CSF differentiated BM-
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derived DCs in vitro (49). This could be explained by the lower ability of the DCs to 
internalize the antigen-containing liposomes (49). Furthermore, inhibitors of the 
lysosomal proteases cathepsins and leupeptin resulted in a reduced efficiency of B3Z T 
cell activation by the BM-macrophages, whereas a proteasome inhibitor (epoxomicin) 
had no effect (49). This suggests that ovalbumin is processed for cross-presentation in 
lysosomes instead of the cytosol and therefore that cross-presentation occurs via the 
vacuolar pathway in BM-derived macrophages. 
In line with the conclusion that BM-derived macrophages cross-present via the 
vacuolar pathway, the proteasome inhibitor lactacystin did not inhibit cross-
presentation of FITC-labelled ovalbumin peptide complexed with heat shock protein 
to CD8OVA1.3 T hybridoma cells (colorimetric bioassay for IL-2) in M-CSF differentiated 
BM-macrophages, activated 48h with IFN-γ, whereas there was only a slight reduction 
in activation when TAP-deficient macrophages were used (50). In contrast to BM-
macrophages, proteasome inhibition resulted in a marked reduction of CD8OVA1.3 T 
hybridoma cell activation by GM-CSF differentiated BM-DCs (50), suggesting that these 
macrophages and DCs use different pathways for cross-presentation. Final evidence 
that BM-macrophages employ the vacuolar pathway for cross-presentation comes 
from the finding that cross-presentation of ovalbumin to B3Z T cells by MAC-1+ BM-
macrophages was reduced by a peptide aldehyde inhibitor that also inhibits lysosomal 
proteases (LLnL), whereas a proteasome inhibitor (LLM) had no effect and resulted in 
normal B3Z T cell activation (51). Thus, whereas BM-DCs can use the cytosolic route 
of cross-presentation, antigens seem to be predominantly cross-presented by BM-
macrophages via the vacuolar pathway. This would explain why BM macrophages have 
lower expression and activity of the NADPH oxidase NOX2, which is essential for cross-
presentation via the cytosolic pathway (52,53).
Less data is available on cross-presentation mechanisms in human monocyte-derived 
macrophages. They can also cross-present via the vacuolar pathway similar to murine 
BM-macrophages, because an in vitro study showed that the proteasome inhibitor 
lactacystin did not impair cross-presentation by human blood monocyte-derived 
CD1a+CD16+ macrophages of MelanA antigen to CD8+T cell LT12 clones (IFN-γ), 
whereas lysosomal cysteine protease inhibition (with a pan-cathepsin inhibitor) 
impaired activation of this T cell line (45). These results support that monocyte-
derived macrophages can cross-present via the vacuolar pathway, which might 
explain why lysosomal proteases are expressed in higher levels in human monocyte-
derived CD1a+CD16+ macrophages compared to monocyte-derived CD1a+CD14+ 
DCs (45). However, for various HIV-1 epitopes, evidence suggests that monocyte-
derived macrophages can cross-present via both the cytosolic and vacuolar pathways. 
Proteasome inhibition by MG132 or epoxomicin did not completely block activation 
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(IFN-γ) of epitope-specific CD8+ T lymphocyte clones by LPS and R848 matured 
monocyte-derived macrophages, suggesting both proteasome-dependent and 
-independent processing, although inhibition of lysosomal cysteine proteases by E64 
did not affect cross-presentation (54). In line with this notion that human monocyte-
derived macrophages might cross-present via both the cytosolic and vacuolar 
pathways, similar to DCs,  is that the difference in expression levels of NOX2, required 
for the cytosolic route of cross-presentation, is less clear for human monocyte-derived 
macrophages and DCs (55) than for murine BM-macrophages and BM-DCs (52).
Besides the macrophage types described so far, a new murine F4/80+ subset of  antigen 
presenting cells was described containing characteristics of both macrophages 
(CD64+MERTK+) and cDC2s (CD11chiMHCIIhiCD11b+CD24+CD64+CD169+), while being 
from mouse monocyte origin (56). These hybrid DC-macrophages have been found 
in multiple tissues including lymph node and spleen, and they seem increased in the 
tumor microenvironment. Supporting a functional role in the tumor environment, 
these cells are efficient at B16 tumor cell uptake (GFP-labelled)_and in vivo blocking of 
CSF1R-positive cells (blocking most macrophages, including the new DC-macrophage 
hybrid subset) significantly decreased antigen cross-presentation to ovalbumin-
specific OT-I CD8+ T lymphocytes (proliferation) (56). Moreover, when isolating these 
DC-macrophage hybrid cells from lymph nodes of mice inoculated with ovalbumin-
expressing cancer cells and in vitro culturing them with OT-I CD8+ T lymphocytes, 
efficient T cell proliferation was observed (56). 
Splenic red pulp macrophages cross-present via the cytosolic 
pathway
As discussed above, both in vitro and in vivo evidence indicate that murine 
CD11cintF4/80high red pulp macrophages from spleen are capable of cross-presentation 
(23). At least for the model antigen ovalbumin, evidence shows that they process this 
antigen via the cytosolic pathway. Following its uptake via the mannose receptor 
CD206, microscopy showed that fluorescently-labelled ovalbumin colocalizes with the 
mannose receptor to early endosomes but not to late endosomes in CD11cintF4/80high 
red pulp macrophages (23). In vitro cross-presentation to OT-I T cells was almost 
completely blocked by the TAP-inhibitor UL49 and the proteasome inhibitor 
epoxomicin (23), indicating that red pulp macrophages cross-present via the cytosolic 
pathway(23).
Peritoneal macrophages cross-present via both cellular pathways
There are two subsets of peritoneal macrophages: large peritoneal macrophages 
(F4/80high, MHC-IIlow) which play a role in maintaining homeostatic conditions in the 
peritoneal cavity and represent an anti-inflammatory type, and small peritoneal 
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macrophages (F4/80low, MHCIIhigh) which are important during inflammation (57) 
(Fig. 1). The large peritoneal macrophages express higher levels of TLR-4 and co-
stimulatory molecules (CD80/CD86/CD40). Likely, both peritoneal macrophage types 
can cross-present (58–61), but there is contrasting evidence whether peritoneal 
macrophages use the vacuolar or cytosolic pathway. The yield of macrophages from 
the peritoneum is low, therefore mice are often pre-stimulated with thioglycolate, 
which recruits immature macrophages into the peritoneum. Thioglycolate isolated 
peritoneal macrophages resemble mostly small peritoneal macrophages, but have an 
atypical morphology and function that is not consistent with the phenotype of tissue 
macrophages, but more with monocyte-derived macrophages (62). Moreover, during 
the isolation they can come in contact with LPS from the used broth, which is ingested 
by the macrophages, and as a result they are able to respond to INF-γ priming without 
any other stimulation (63). A better option for isolation of peritoneal macrophages for 
cross-presentation and phagocytosis studies is called Bio-Gel-elicted macrophages 
isolation, which makes use of Bio-Gel beads that cannot be phagocytosed (63). 
The angiotensin-converting enzyme (ACE) 10/10 mice overexpress the peptidase ACE, 
which is a peptidase normally located within the endoplasmic reticulum (ER) and 
involved in generation of MHC-I epitopes. ACE is also involved in cross-presentation 
probably following its transfer antigen-containing phagosomes or endosomes (2,61). 
The injection of ovalbumin-pulsed peritoneal macrophages isolated from ACE 10/10 
mice (using thioglycolate) and ovalbumin-specific OT-1 CD8+ T lymphocytes into a 
wildtype mouse resulted in proliferation of the CD8+ T lymphocytes (61). Moreover, 
upregulation of the CD8+ T lymphocyte activation marker CD69 occurred faster with 
peritoneal macrophages isolated from the ACE 10/10 mice, than with macrophages 
isolated from wildtype mice (61). Although these studies rely on overexpression of 
ACE, these findings indicate that peritoneal macrophages in principle can cross-
present antigen (61). Moreover, as ACE is potentially transferred from the ER to the 
lumen of antigen-containing endosomes (61), these findings suggest that peritoneal 
macrophages can cross-present via the vacuolar pathway.
More direct evidence that peritoneal macrophages can cross-present comes from 
the finding that a murine peritoneal macrophages cell line that recombinantly 
expresses interferon regulatory factor 7 (IRF7) was able to induce activation  of 
ovalbumin-specific OT-I CD8+ T lymphocytes in vitro (IL-2 production and CD40, 
CD80 and CD86 expression) (58). This activation could be inhibited by a proteasome 
inhibitor (lactacystin) (58), suggesting that the cytosolic pathway was used for cross-
presentation of the antigen. Also the uptake by peritoneal macrophages of Escherichia 
coli in which ovalbumin was expressed could trigger activation (IL-2 production) of 
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the ovalbumin-recognizing B3Z CD8+ T cell line (60). These ingested E. coli bacteria 
remained in phagosomes that fused with lysosomes (60), suggesting processing of the 
bacteria for cross-presentation via the vacuolar pathway in this case.
Murine peritoneal macrophages also cross-presented virus-like particles containing 
the immunodominant epitope (p33) of lymphocytic choriomeningitis virus in vitro 
as observed by increased antigen-specific transgenic CD8+ T cell proliferation, but 
with a reduced efficiency compared to peritoneal isolated DCs (59). The DCs used 
both the TAP-dependent and independent pathway for cross-presentation (59), but 
there was no difference in activation of CD8+ T lymphocytes between TAP1-deficient 
peritoneal macrophages (thioglycolate stimulated) and wild-type controls, suggesting 
the use of the TAP-independent vacuolar pathway (59). Finally, murine peritoneal 
macrophages (thioglycolate stimulated) showed efficient cross-presentation of 
ovalbumin encapsulated in polylactic-co-glycolic acid particles to the B3Z CD8+ T cell 
line in vitro, and these particles resided in LAMP1-positive lysosomes even 48 hours 
after phagocytosis (64). Based on this observation, it was suggested that the antigenic 
proteins might be translocated from the endo/lysosomal compartments to the cytosol. 
However, it might also be possible that the antigen is processed by endo/lysosomal 
proteases and cross-presentation occurs via the vacuolar pathway. 
To target cross-presentation by peritoneal macrophages, the effect of downregulation 
of various signaling pathways has been investigated. Compared to macrophages 
isolated from wildtype mice, CD11b+F4/80+ peritoneal macrophages (thioglycolate 
stimulated) from signal transducer and activator of transcription (STAT) 3 knockout 
mice were able to stimulate more potent OT-1 CD8+ T lymphocyte proliferation and 
IFN-γ production in vitro with irradiated tumor cells expressing ovalbumin (65). Similar 
observations were made with a different antigen derived from the influenza protein 
hemagglutinin in combination with hemagglutinin-recognizing CD8+ T lymphocytes 
isolated from CLN4 transgenic mice (65). Since STAT3 is activated by inflammatory 
cytokines, such as IL-6, this finding indicates that cross-presentation by peritoneal 
macrophages is influenced by the tissue environment. The increase in ovalbumin-
recognizing CD8+ T lymphocyte activation was not seen for STAT4 or 6 knockout mice 
(65). Additionally, the antigen VSV8 in a complex with heat shock protein gp96 was 
more efficiently cross-presented (cytotoxicity by 51Cr release) to VSV-specific cytotoxic 
T cells in vitro by mice peritoneal macrophages compared to the antigen alone 
(66), again indicating that the form of the antigen plays an important role for cross-
presentation by peritoneal macrophages. 
112
Chapter 5 - Cross-presentation in macrophages
So, although these results clearly show that peritoneal macrophages are able of cross-
presentation in vitro, the in vivo relevance remains unclear because of the highly 
artificial nature of the antigen and the lacking definition of the used peritoneal 
macrophage subset.
Concluding remarks
As discussed in this review, many macrophage types seem capable of antigen cross-
presentation with similar, or even better, efficiency as DCs. Moreover, macrophages 
seem to employ mostly the vacuolar pathway of cross-presentation while DCs use 
both the vacuolar and cytosolic pathway. Especially the cross-presenting abilities of 
macrophages in the spleen, liver and lymph nodes might be physiologically relevant, 
because they have easy access to blood-borne antigens, whereas for the DC this 
access might be restricted. However, the role of macrophages in CD8+ T lymphocyte 
activation should be further investigated, since CD169+ macrophages might not 
activate the CD8+ T lymphocytes themselves but could transfer antigen to DCs by 
CD169 (20). The role of CD169+ macrophages should therefore be further investigated, 
and it should be investigated if they directly cross-present to CD8+ T lymphocytes in 
vivo or transfer the antigen to DCs (27,29).
As apparent from this review, the in vivo roles and cellular pathways of macrophage 
cross-presentation are mostly unknown. One important reason for this is that the 
isolation of the specific macrophage types is technically challenging because (i) 
surface markers overlap resulting in contamination with other cell types and (ii) low 
numbers of primary macrophages can be isolated (63). Moreover, the available in 
vivo research on cross-presentation by macrophages is almost exclusively focused 
on the effect of vaccination strategies, such as liposomes encapsulating antigen, 
where  CD8+ T lymphocyte activation markers and/or proliferation are used as the 
sole measures of cross-presentation. Although CD8+ T lymphocyte activation and 
proliferation depend on cross-presentation, they also depend on other factors such as 
co-stimulation by cytokines (e.g. IL-12) and co-stimulatory receptors (e.g. CD80, CD86) 
(2). This co-stimulation is generally stronger present in DCs than macrophages, and 
it is particularly absent in the alternatively-activated anti-inflammatory macrophages. 
Using T cell activation as the sole readout might thereby result in overlooking cross-
presentation capabilities in macrophage types that do not provide co-stimulation, 
whereas this might have important roles for instance in maintenance and/or 
restoration of immune tolerance. Cross-presentation by immature/inactivated DCs 
has been suggested to allow maintenance of tolerance (67), and it might well be 
that cross-presentation by Kupffer cells and/or anti-inflammatory macrophages plays 
a similar role (41,42). Therefore, the macrophage cross presenting capabilities and 
pathways should be further elucidated, for instance in vitro by exposing the cells to 
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antigens and measuring cross-presentation directly using antibodies (26,27) followed 
by measuring their ability to activate CD8+ T cell lines that do not need co-stimulation. 
However, since environmental factors might be needed, these in vitro experiments 
should be performed in parallel with in vivo experiments. To determine if a particular 
macrophage type is needed for efficient CD8+ T lymphocyte activation in vivo, this 
macrophage type could be depleted using DTR-mice as previously explained (68,69). 
However, this relies on surface marker expression and is not effective if the targeted 
macrophage type does not express an unique surface marker. 
It is increasingly clear that not only DCs and macrophages can cross-present 
antigens, but many other endocytic cell types are capable of cross-presentation as 
well, including monocytes (70,71), B cells (72), neutrophils (73) and endothelial cells 
(74). The physiological roles of cross-presentation by these diverse cell types are still 
unclear, but it seems likely that this also allows the potentiation of CD8+ T lymphocyte 
responses or the maintenance or restoration of immune tolerance. 
Lastly, studies on cross-presentation have focused on direct CD8+ T lymphocyte 
activation, but the potential role of tissue macrophages in development and 
reactivation of memory CD8+ T lymphocytes has hardly been investigated. Although 
CD11cintF4/80high splenic red pulp macrophages are not essential for development of 
memory CD8+ T lymphocytes (23), it might well be that other macrophage types are 
involved in this process or that macrophages are capable of reactivation of memory 
CD8+ T lymphocytes upon recurrent immune challenges (75,76). Recently, there is a 
growing interest in the activation of memory T cells in the tissues and lymphatic 
system, which can confer rapid host protection upon cognate antigen-mediated 
activation and results in direct killing of infected cells (75,76). Especially tissue-
resident macrophages might be important in the development and reactivation of 
tissue-resident memory CD8+ T lymphocytes by rapid and local cytokine secretion 
during re-infection (74). It is increasingly clear that macrophages can provide factors 
such as chemokines and cytokines that regulate the localization, differentiation and 
survival of tissue-resident memory T cells (73). Moreover, monocyte-derived antigen 
presenting cells provide TNF superfamily costimulatory signals, which substantially 
increase the formation of tissue-resident memory T cells during viral infection (73).
Since macrophages can cross-present and thereby might aid in CD8+ T lymphocyte 
responses, stimulating macrophages to cross-present might be a promising strategy 
for anti-tumor or anti-viral therapies. 
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Abstract 
Major histocompatibility complex (MHC) molecules are well-known for their role in 
antigen (cross-) presentation, thereby functioning as key players in the communication 
between immune cells, for example dendritic cells (DCs) and T cells, or immune cells 
and their targets, such as T cells and virus-infected or tumor cells. However, much 
less appreciated is the fact that MHC molecules can also act as signaling receptors. In 
this process, here referred to as reverse MHC class I (MHC-I) signaling, ligation of MHC 
molecules can lead to signal-transduction and cell regulatory effects in the antigen 
presenting cell. In the case of MHC-I, reverse signaling can have several outcomes, 
including apoptosis, migration, induced or reduced proliferation and cytotoxicity 
towards target cells. Here, we provide an overview of studies showing the signaling 
pathways and cell outcomes upon MHC-I stimulation in various immune and non-
immune cells. Signaling molecules like RAC-alpha serine/threonine-protein kinase 
(Akt1), extracellular signal-regulated kinases 1/2 (ERK1/2) and nuclear factor-κB (NF-
κB) were common singaling molecules activated upon MHC-I ligation in multiple 
cell types. For endothelial and smooth muscle cells, the in vivo relevance of reverse 
MHC-I signaling has been established, namely in the context of adverse effects after 
tissue transplantation. For other cell types, the role of  reverse MHC-I signaling is less 
clear, since aspects like the in vivo relevance, natural MHC-I ligands and the extended 
downstream pathways are not fully known. The existing evidence, however, suggests 
that reverse MHC-I signaling is involved in the regulation of the defense against 
bacterial and viral infections and against malignancies. Thereby, making reverse MHC-I 
signaling a potential target for therapies against viral and bacterial infections, cancer 




Major histocompatibility complex class I (MHC-I) molecules are present on all 
nucleated cells and are classically known for presenting peptides derived from 
endogenous antigens to cytotoxic CD8+ T lymphocytes (CTL). Additionally, in the case 
of professional antigen presenting cells (APCs) (i.e. dendritic cells (DCs), macrophages 
and B cells), MHC-I can also present exogenous antigens through a process called 
antigen cross-presentation. Moreover, MHC-I molecules are important immune 
regulators, since their expression levels regulate activation of natural killer (NK) cells 
(1,2). 
An underappreciated function of MHC-I molecules is their ability to act as signaling 
receptors. In this process, here referred to as reverse MHC-I signaling, ligation of MHC 
molecules can lead to signal-transduction and cell regulatory effects in the APC (3,4). 
Multiple studies have shown that reverse MHC-I signaling can influence processes 
like cell activation, proliferation, maturation, cytotoxicity and migration, or even 
lead to cell anergy and apoptosis (3,5,6). MHC-I reverse signaling has been observed 
in multiple cell types, ranging from immune cells, such as macrophages, NK cells, T 
cells and B cells, to non-immune cells like endothelial and smooth muscle cells (7,8). 
Furthermore, reverse MHC-I signaling has been investigated in the context of viral and 
bacterial infections (6,9), transplantation immunity (10), malignancies (11) and brain 
development (12). Here, we review the evidence for the alternative role of MHC-I as 
reverse signaling molecules across immune and non-immune cells. 
MHC-I function in T cell activation and NK cell regulation 
MHC molecules (referred to as human leukocyte antigen (HLA) in humans and 
histocompatibility system 2 (H-2) in mice) play an important role in the communication 
between the innate and adaptive immune system. There are two classes of MHC 
molecules that are involved in antigen presentation: MHC class I and MHC class 
II. MHC-I molecules are present on all nucleated cells and classically function to 
activate CTLs with endogenous antigens, whereas MHC-II molecules are present on 
professional antigen-presenting cells, and are involved in the activation of CD4+ T cells 
with exogenous antigens (1). Exogenous antigens can also be presented by MHC-I to 
CD8+ T cells, in a process called antigen cross-presentation, which is important for the 
defense against tumors and intracellular pathogens (13). 
The interface formed between an APC and an antigen-recognizing T cell is called 
an immunological synapse. T cell activation requires the delivery of three molecular 
signals by the APC: First, the complex formed by MHC and the antigenic peptide is 
recognized by the T cell receptor (TCR) along with the co-receptor CD4 on helper T 
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cells (for MHC-II) or CD8 on CTLs (for MHC-I). Second, a costimulatory signal provided 
by CD80/86 is recognized by CD28 on the T cell. Third, the APC releases stimulatory 
cytokines that are recognized by their receptors on the T cell. Additionally, the 
immunological synapse is stabilized by adhesion molecules such as lymphocyte 
function-associated antigen (LFA)-1 and intercellular adhesion molecule 1 (ICAM-1). The 
combination of costimulatory signals and cytokines secreted by the APC determines 
the functional outcome of the interaction, such as the activation or inhibition of the 
T cell (14) (Figure 1A). The immunological synapse can be seen as a radially symmetric 
structure consisting of several supramolecular activation clusters (SMACs) (15). The 
classical synapse contains a central SMAC (cSMAC), where the MHC-TCR interactions, 
co-receptors (CD3 and CD4 or CD8) and costimulatory molecules are located. The 
surrounding peripheral SMAC (pSMAC) includes adhesion molecules LFA-1 and ICAM-
1 and the distal SMAC (dSMAC) contains the transmembrane tyrosine phosphatase 
CD45, which activates signaling molecules promoting the T cell response (14,16,17). 
There are exceptions to this structure, for instance when T cells interact with DCs, 
where a multifocal synapse is formed (16,18). 
In addition to their role in CD8+ T cell activation, MHC-I molecules provide signals that 
are crucial for the regulation of different immune cells. For instance, NK cells carry 
inhibitory receptors that bind to MHC-I on the surface of other cells, independent 
of the antigen presented, thereby suppressing NK cell activation. This is particularly 
important as viruses and malignancies often downregulate MHC-I expression to 
circumvent T cell detection, requiring the action of NK cytotoxic function (2). In mice, 
one type of inhibitory receptors is the Ly49 family, which have a C-type lectin-like 
structure, with two transmembrane domains. Their functional homologs in human are 
the killer Ig-like receptors (KIR), which belong to the Ig-superfamily. These two families 
have similar inhibitory functions despite their differences in structure and evolutionary 
origin. Additionally, in both species the C-type lectin-like molecules CD94 and NKG2 
(CD94/NKG2) form heterodimers with inhibitory properties (2). Another important 
group of MHC-I receptors are the Leukocyte Immunoglobulin-Like Receptors (LILRs), 
also known as CD85. They can have both activating and inhibitory roles, and have 
been found in immune (e.g. lymphocytes, neutrophils, eosinophils, macrophage, DCs) 
and non-immune cells (e.g. endothelial cells) (19).
The alternative role of MHC-I as signaling molecules and their 
structure
Besides their role in antigen presentation for T cell activation, both MHC-I and MHC-
II molecules are involved in reverse signaling, meaning that ligation of the MHC 
molecule leads to signal-transduction and cell regulatory effects in the APC (3). In this 
review we will focus on reverse MHC-I signaling, given the ample literature available 
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across different cell types, its importance for medical outcomes in transplantation 
patients, and its potential role regulating immune responses against infection and 
malignancies.
Figure 1. The antigen presenting role of MHC class I molecules and their structure. (A) 
The immunological synapse is a communication platform between a (professional) antigen-
presenting cell and a T or NK cell. In the example presented here, MHC-I molecules on the 
surface of a dendritic cell (purple) present antigens (orange) for their recognition by the TCR of a 
CD8+ T cell (blue). CD8 acts as co-receptor of the TCR for the recognition of the MHC-I molecule. 
At the immunological synapse (red box), other molecules required for the engagement and 
modulation of the interaction are also recruited, such as adhesion molecules (LFA-1 and ICAM-I) 
and costimulatory molecules (CD80/86 and CD28). (B) MHC-I molecules are heterodimers 
composed of a heavy α chain (blue) and a light chain (β2-microglobulin) (grey). Most α chains 
are made up of two peptide binding domains (α1 and α2), and an Ig-like α3 domain recognized 
by CD8 molecules on T cells. Additionally, the α chain has a transmembrane and a short 
cytoplasmic tail (cyan). (C) The cytoplasmic regions of several classical and non-classical MHC-I 
α chains contain a tyrosine residue that can be phosphorylated. This phospho-tyrosine residue 
has been proposed to interact with signaling proteins and thus lead to reverse signaling. Here 
we present the cytoplasmic regions of human classical (MHC-Ia) and non-classical (MHC-Ib) α 
chains, and the classical mouse α chains. However, some of the multiple non-classical mouse α 
chains also contain this tyrosine residue. 
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So far, there is no consensus on the molecular mechanism underlying reverse MHC-I 
signaling, as the existing hypotheses rely on different domains of the complex for 
signal transduction or different MHC-I subclasses. MHC-I molecules are heterodimers 
composed of a heavy α-chain, and a light chain called beta-2 microglobulin (β2m). 
Typically, the α-chain contains domains α1 and α2, both involved in peptide binding, 
and the immunoglobulin-like α3 domain, proximal to the membrane, which is 
recognized  by CD8 co-receptors on the T cell  (1). β2m expression is important for 
the stable expression of the α-chain at the cell surface, the proper binding of the 
complex to the antigenic peptide for presentation and for TCR recognition (20,21). The 
transmembrane helix of the α-chain anchors the MHC-I complex to the membrane. 
The α-chain also has a short cytoplasmic tail of around 30 to 40 amino acids (Fig. 1B). 
Multiple genes, grouped into MHC gene clusters, encode for heavy α-chains in mouse 
and human, and are divided in classical and non-classical MHC molecules. The classical 
MHC-I molecules (MHC-Ia) are responsible for activating CD8+ T cells and correspond 
to α-chains that are expressed at high levels and are highly polymorphic to allow for 
increased variability of peptide binding sites. In humans, these correspond to the 
HLA-A, HLA-B and HLA-C genes and in mice, these genes are H-2K, H-2D and H-2L. 
The non-classical MHC-I molecules (MHC-Ib) are expressed at lower levels and are less 
polymorphic. They participate in activation or regulation of NK cells, among other 
less understood functions. In humans MHC-Ib molecules include genes HLA-E, HLA-F, 
HLA-G and the pseudogene HLA-H, whereas in mice it includes several genes under 
the H2-Q, H2-T, and H2-M regions (22–25). Interestingly, the cytoplasmic domains of 
some classical and non-classical α-chains in different species have a conserved tyrosine 
residue (9,26) (Figure 1C). As discussed in the following sections, part of the evidence 
for reverse MHC-I signaling is supported by the notion that this tyrosine residue can be 
phosphorylated and that tyrosine phosphorylation is a posttranslational modification 
frequently involved in signal transduction (27). Besides this, based on their structure, 
MHC-I molecules belong to the Immunoglobulin (Ig) superfamily, which is widely 
involved in cellular recognition and intercellular signaling (6,28). Moreover, the 
existence of open conformers, cell surface MHC molecules that are not associated with 
peptide and/or β2-microglobulin (β2m), and their ability to associate with themselves 
or other receptors, suggest that MHC-I molecules have more functions than only 
antigen presentation to T and NK cells (29). The formation of open conformers is also 
associated with tyrosine phosphorylation, further supporting the idea of reverse 
signaling by MHC-I (30). 
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Reverse MHC-I signal transduction in myeloid immune cells
Macrophage activity regulation by reverse MHC-I signaling
Early evidence of MHC-I reverse signaling in macrophages was already reported in 
1987 (Table 1). Immunoglobulin G2 (IgG2) antibodies that targeted MHC-I, but not 
the corresponding F(Ab’)2 fragments, induced guinea pig alveolar macrophages to 
release reactive oxygen species (ROS) in the oxidative burst (31). This increase was not 
observed for IgG1 antibodies, which even reduced ROS release, whereas their F(Ab’)2 
did not have an effect (31). This finding was explained as a consequence of bipolar 
bridging, an event in which an antibody binds simultaneously to an Fc-receptor via 
its Fc-tail and to MHC-I with its antigen-binding Fab motif on the same membrane 
(cis bridging). Therefore, this finding cannot be considered as solely MHC-I reverse 
signaling, but as an effect of collaboration between MHC-I and the Fc receptors for 
IgG2 or IgG1. Notably, although the antibody Fc-tail could also bind to an Fc receptor 
on a different cell (trans bridging), different authors claim that bipolar bridging is a 
monocellular event (32,33). The main evidence for this comes from experiments 
with mast cell mixtures where only those cells expressing both the right H-2 antigen 
and Fc-receptor degranulate upon antibody binding (34), and with antibody-
induced degranulation of single cells isolated with a micromanipulator (35) (see also 
section 2.3 on mast cells). Furthermore, the bipolar bridging hypothesis relies on 
physicochemical models proposing that the high local concentration of proteins at the 
plasma membrane makes it easier for an antibody to bind to MHC-I and Fc-receptors 
on the same cell, rather than on two different cells (36,37). The physiological relevance 
of simultaneous signaling during bipolar bridging is unclear, because it is unknown 
when for instance a CD8+ T cell or an NK cell would display ligands for both MHC-I and 
Fc-receptors. 
Table 1 Summary MHC-I signaling in macrophages. 
Cell type MHC-I stimulation Signaling Cell outcome Ref 
Guinea pig alveolar 
macrophages 
Guinea pig IgG1 and -2 
antibodies 
- In combination with Fc-
receptor stimulation, ↑ or ↓ 




TLR ligands, bacteria, 
monoclonal antibodies 
(anti-H-2Kb; AF6-88.5) 
↑ Fps, SHP-2 
↓TRAF6, NF-kB
↓ TLR response (9)
Mouse bone marrow-
derived macrophages 
VSV infection, IFN-β ↑ SHP2
↓STAT1, ISG  





Synapse with CD8+ T 
cells or beads coated 
with mouse anti 
HLA-A2 antibodies
- Remodelling of recycling 







- Increased production of  
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A few decades later, a modulatory effect by MHC-I reverse signaling on the toll-like 
receptor (TLR) signaling cascade was described. When compared to β2m knockout 
mice, it was established that normal expression of MHC-I suppresses the TLR 
response, including the production of tumor necrosis factor (TNF), interleukin (IL)-
6 and interferon-beta (IFN-β). This TLR suppression is suggested to restrict innate 
inflammatory responses upon bacterial infection, to prevent excessive damage as 
seen during septic shock (9). However, this data should be interpreted with caution 
since β2m also dimerizes with the heavy chains of other MHC-I-like surface molecules 
such as CD1 and the neonatal Fc-receptor (FcRn), and therefore its deletion might 
have effects beyond MHC-I function (20). In mouse peritoneal macrophages, this 
MHC-I-induced inhibition of TLR-mediated inflammatory responses was shown to be 
induced by interaction with naïve CD8+ T cells (9). Based on experiments using MHC 
class I ligation with antibodies, this study proposed a mechanism in which the Src 
homology 2 (SH2) domain of the tyrosine kinase Fps interacts with a phosphorylated 
tyrosine site in the cytoplasmic domain of MHC-I, leading to Fps activation (Fig. 2) (9). 
TLR stimulation activates the kinase Src, which was suggested to phosphorylate the 
tyrosine in the cytoplasmic domain of MHC-I, thus facilitating its association with Fps 
(9). In turn, activated Fps associates with the phosphatase SHP-2, which then interacts 
with TNF receptor associated factor (TRAF) 6 thereby downregulating its ubiquitination 
and activity. In this way, MHC-I stimulation suppresses the MyD88-TRAF6-mediated 
activation of NF-κB and thus inhibits TLR downstream responses (9). 
In addition to the role of MHC-I reverse signaling in dampening TLR signaling, its 
roles in type I interferon (IFN) signaling and antiviral infections has been investigated. 
Using bone marrow-derived macrophages from MHC-I-deficient mice, it was shown 
that MHC-I promotes replication of vesicular stomatitis virus (VSV) in macrophages 
independent of T cells (6). Additionally, MHC-I plays a regulatory role in type I IFN 
signaling, which was shown by increased phosphorylation of signal transducer and 
activator of transcription 1 (STAT1) and elevated interferon-stimulated gene (ISG) 
expression in MHC-I-deficient macrophages (6). To fulfil this function, MHC-I depends 
on phosphorylation of its intracellular tyrosine site, as shown by immunoprecipitation. 
Moreover, SHP-2 was necessary for suppression of IFN signaling by MHC-I engagement, 
via interaction of  SHP-2 with STAT1 after VSV infection (6). 
In conclusion, MHC-I seems to be involved in reverse signaling in macrophages, 
either alone or in collaboration with Fc-receptors, thereby affecting ROS release, 
TLR responses and type I IFN responses. Therefore, reverse MHC-I signaling may 
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(9). This effect could be induced after interaction with the TCR on CD8+ T cells (9), 
but potentially also receptors on NK-cells, such as KIR receptors or C-type lectin-like 
receptors like Ly49 (38).
Reverse MHC-I signaling modulates membrane trafficking and 
cytokine production in dendritic cells
In comparison to the other cell types discussed in this review, reverse MHC-I signaling 
has been understudied in DCs (Table 1). In human monocyte-derived DCs (moDCs) 
it was demonstrated that establishment of antigen-specific immunological synapses 
with CD8+ T cells induces the remodelling of endosomal recycling compartments 
(ERC), going from a vesicular to a tubular morphology (39). To dissect the molecular 
mechanisms of ERC remodelling, moDCs were stimulated with antibody-coated beads. 
These experiments revealed that ERC remodelling could be triggered by beads coated 
with antibodies against MHC-I (HLA-A2) and/or antibodies against ICAM-I molecules. 
Furthermore, remodelling was more extensive in moDCs previously activated with LPS 
than in immature moDCs. The tubules were suggested to facilitate the transport of 
antigen-loaded MHC-I molecules to the immunological synapse. However, this study 
did not explore the signaling pathway(s) triggered by MHC-I stimulation that lead to 
endosomal remodelling (39). 
In the same study reporting the modulation of TLR downstream signaling by reverse 
MHC-I signaling in macrophages (9) (see section 2.1), it was shown that bone marrow-
derived DCs (BMDCs) derived from mice lacking β2-microglobulin release higher 
amounts of TNF, IL-6 and IFN- β than their wild-type counterparts upon TLR stimulation. 
These results suggest that, similar to macrophages, MHC-I might have a regulatory role 
on TLR signaling in DCs (9). However, this study only studied the mechanism of reverse 
MHC-I signaling in macrophages.
Reverse MHC-I signaling in peritoneal cells induces mast cell 
degranulation  
In an early study, alloantibodies against MHC molecules were generated by 
immunizing mice of the CBA strain with spleen cells from mice of the A/JAX strain, 
which has a different alloantigen profile. When serum from the CBA immunized 
mice was applied to BALB/c mast cells, increase degranulation from 3% in non-
treated cells to 61% in treated cells was observed (40) (Table 2). This physiological 
degranulation was attributed to alloantibodies against H-2 molecules, mainly from 
the IgG1 type (41). However, it cannot be concluded that this was solely the result of 
MHC-I reverse signaling, because this serum may have contained antibodies against 
other biomolecules, such as MHC-II, and thus these experiments should be repeated 
with purified monoclonal anti-MHC-I antibodies. Additional experiments showed 
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that degranulation was caused by antibody bipolar bridging (see section 2.1 on 
macrophages), which is the simultaneous binding of  the antibody paratopes to H-2 
molecules and of the Fc tails to Fc-receptors on the same mast cell (34,40,42). This 
induced degranulation of mast cells was later confirmed with monoclonal IgG2a 
antibodies directed against H-2 antigens (43) and polyclonal antibodies against H-2 
K and H-2 D (42). However, to be able to draw conclusions about the specific role of 
MHC-I reverse signaling in mast cells, anti-MHC-I antibodies need to be compared with 
their F(ab’)2 fragments and irrelevant antibodies, since degranulation is known to be 
caused by Fc-receptor signaling (44). If reverse MHC-I signaling contributes to mast 
cell degranulation in vivo, it might be involved in the inflammatory process induced by 
antibodies or other inflammatory cells such as CD8+ T cells.
Neutrophil activity and cell death might be affected by reverse 
MHC-I signaling  
As shown for guinea pig macrophages, bipolar bridging of MHC and Fc-receptors 
on peripheral and peritoneal guinea pig neutrophils by IgG2 induced superoxide 
anion (O2
●-) release (32) (Table 2). Moreover, in human peripheral blood neutrophils, 
ligation of MHC-I with F(ab’)2 fragments of the antibody W6/32 also induced signal 
transduction, reflected in reduced apoptosis rate (45). Furthermore, it was shown that 
as neutrophils start aging in culture, their apoptotic activity increases along with a 
reduction of MHC-I surface expression, suggesting a reciprocal relation between both 
phenomena. In line with this hypothesis, the in vitro treatment of neutrophil cultures 
with granulocyte-macrophage colony-stimulating factor (GM-CSF) or cyclic adenosine 
monophosphate (cAMP), two molecules that delay age-related apoptosis, also blocked 
the downregulation of MHC-I (45). Similar to mast cell degranulation, O2
●- release and 
decreased apoptosis in neutrophils by reverse MHC-I signaling might contribute to 
inflammation upon encountering an activated inflammatory cell or infected cell.
Table 2 Summary MHC-I signaling in peritoneal cells and neutrophils.
Cell type MHC-I stimulation Signaling Cell outcome Ref 
Mouse peritoneal 
cells 
Serum of CBA mice 
immunized with A/JAX 
spleen cells














Anti-B and anti-Ia 
antibodies 






- ↓ cell death (45)
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Reverse MHC-I signal transduction in lymphocytes
Reverse MHC-I signaling affects cytotoxicity and cell death of NK cells
Early studies on the role of β2m and reverse MHC-I signaling in NK cell activity led to 
contradictory findings, probably because some studies used the full fraction of human 
peripheral blood lymphocytes or spleen leukocytes (46–49), while another study used 
enriched NK cells (50). While the former studies proposed that reverse MHC-I signaling 
in NK cells reduces their cytotoxic activity when compared to unstimulated NK cells, the 
latter study found the opposite (Table 3). An alternative reason for these differences 
could be the use of different antibodies to stimulate MHC-I. Evidence that this indeed 
might be the case, comes from another early study (51). Using  NK cell lines, such as 
NK3.3, and primary NK cells, it was shown that different anti-MHC-I antibodies have 
either an stimulating, inhibiting or no effect on their lytic activity against cancer cell 
lines (e.g. leukemic K562 and lymphoblastic MOLT-4), when compared to unstimulated 
or irrelevant antibody (Cenox 3.53)-stimulated cells as a control (51). This variability in 
effects of anti-MHC-I antibodies was also observed for the induction of the oxidative 
burst in macrophages (31).
More recent studies found that stimulation with anti-MHC-I antibodies inhibits 
cytotoxic activity of human peripheral blood NK cells and NK cell lines (52–54). 
Reverse MHC-I signaling was studied in the context of treatment with either anti-CD16 
antibodies, which inhibited NK cell cytotoxicity, or IL-2 activation, which augmented 
cytotoxicity. MHC-I antibodies in combination with anti-CD16 antibodies or IL-2 
treatment, further inhibited cytotoxicity of human blood NK cells against several 
tumor cell lines when compared to an isotype antibody control (IgG1), unstimulated 
cells or cells stimulated only with IL-2 or CD16 (54). Since anti-MHC-I antibodies alone 
did not have any effect, an interaction between MHC-I and CD16 or IL-2 receptor 
signaling could be needed for blocking cytotoxicity. Blocking of NF-κB with a cell 
permeable inhibitory peptide in CD16 antibody-treated human blood NK cells reduced 
cytotoxicity, suggesting a role of NF-κB in the downstream signaling pathway (55). 
When using the NKL cell line, derived from a human leukemia patient, cytotoxic activity 
against K562 cells was not affected by MHC-I ligation with the mouse monoclonal 
W6/32 antibody (53). However, cross-linking of MHC-I molecules by further addition 
of sheep-anti-mouse IgG inhibited cytotoxic activity, which was confirmed for human 
blood NK cells (53).  Compared to ligation with only a primary monoclonal antibody, 
efficient cross-linking requires a secondary antibody and induces clustering and 
interaction between the target molecules (56), potentially leading to increased reverse 
MHC-I signaling. The inhibition of cytotoxicity after cross-linking was not caused by an 
induction of NK cell apoptosis, masking of MHC-I on the target cells, or reciprocal NK 
cell-NK cell killing, as indicated by similar cell viability and lysis under all conditions 
(53). Similarly, NKL cell cytotoxicity against the P815 mastocytoma cell line triggered 
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by anti-CD16, anti-NKp46 and anti-2B4 (but not anti-NKG2D) was inhibited as well by 
anti-MHC-I antibodies when compared to an isotype antibody control (IgG2a) (52). 
Human blood NK cell cytotoxicity was also inhibited by anti-MHC-I antibodies when 
triggered by CD16, NKG2D, NKp46 and 2B4, while isotype antibody control (IgG2a) had 
no effect (52). Additionally, the IFN-γ secretion by NKL cells and primary NK cells was 
inhibited with anti-MHC-I antibodies, in contrast to incubation with isotype antibody 
controls (IgG2a or IgG2b) (52). Thus, most studies suggest a role for reverse MHC-I 
signaling in the inhibition of NK cell cytotoxicity. 
Besides NK cell cytotoxicity, cell death after MHC-I triggering has been investigated. 
Stimulation of NK cells isolated from healthy human blood mononuclear cells with 
anti-CD16 antibodies led to increased cell apoptosis in comparison to unstimulated 
cells, which was further augmented by anti-MHC-I antibodies (54). The combined 
stimulation of CD16 and MHC-I in NK cells also induced TNF-α secretion in positive 
correlation with cell death, while no effect was seen on IFN-γ secretion. These results 
suggest that reverse MHC-I signaling plays a role in upregulating TNF-α secretion in 
anti-CD16-treated NK cells (54). This was further confirmed by blocking TNF-α with 
antibodies, which inhibited the increase in cell death induced by CD16 and MHC-I 
triggering, suggesting a role for TNF-α in regulating NK cell apoptosis (54). Since 
the functional inhibition was observed prior to the increased cell death, they were 
Table 3 Summary MHC-I signaling in natural killer cells.
Cell type MHC-I stimulation Signaling Cell outcome Ref 
NK cell line clones and 
NK cell bulk populations
Anti-MHC-I antibodies 
(131, 164, W6/32, 404, 
4E, 46)




blood NK cells 
Anti- β2m antibodies  
(Table 1 in article)
- ↑ lytic activity (50)
Human peripheral 
blood NK cells 
Anti-MHC-I antibodies 
(PA.2.6 HB118 IgG1) 
- In combination with CD16 
stimulation, ↓ NK cell 
cytotoxicity ↑ cell death 
(54)
Human peripheral 




↑ IkB,  JNK
↓ NF-κB  
In combination with CD16 
stimulation, ↑ NK cell death 
(55)
Human peripheral 
blood NK cells and NKL 
cell line 
Anti-MHC-I antibodies 
(W6/32 IgG2a) and 
secondary antibodies 
(sheep anti-mouse IgG 
F(ab’)2)
- ↓ conjugation with target 
and ↓ cytolytic activity 
(53)
Human peripheral 
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suggested to be successive. Since, in principle, adding antibodies against MHC-I 
molecules on NK cells could interfere with the inhibitory signals to other NK cells, 
resulting in reciprocal NK-to-NK cell killing, a coculture was made with two groups of 
NK cells treated separately with MHC-I antibodies or CD16 antibodies. This coculture 
had similar cell death levels to cells treated only with anti-CD16 antibodies, and 
decreased cell death compared to cells treated with both antibodies simultaneously. 
This experiment confirmed that there is an additive signaling effect when stimulating 
CD-16 and MHC-I on the same cell. (55). Moreover, addition of anti-LFA-1 antibodies 
also did not change NK cell death, suggesting that LFA-1 mediated cell adhesion was 
not involved in the reverse MHC-I signaling process (55). 
In an attempt to describe the signaling cascade downstream of MHC-I, focus was 
placed on NF-κB. Here treatment with anti-CD16 antibodies led to induction of NF-
κB activity in the nucleus, while blocking of NF-κB in CD16 antibody-treated human 
blood NK cells induced cell death. This protective effect through CD16 stimulation was 
inhibited by addition of anti-MHC-I antibodies (55). Moreover, an increased expression 
of the NF-κB inhibitor IkB and upregulation of the proapoptotic c-Jun N-terminal 
kinase (JNK) was observed when both antibodies against CD16 and MHC-I were used 
(55). Hence, it was proposed that reduction of CD16-mediated NF-κB activity and 
increased JNK underlie the increased NK cell death after anti-MHC-I ligation. 
Interestingly, in resting conditions MHC-I molecules were uniformly distributed on the 
surface of cells from the NKL cell line, similar to the control protein CD59 (also known 
as protectin), and co-localized with glycolipid-enriched membrane microdomains 
called lipid rafts. However, MHC-I cross-linking with primary and secondary antibodies 
before fixation excluded these molecules from lipid rafts in a similar way to the cell-
surface transferrin receptors (CD45 and CD71), which locate outside the lipid rafts 
and were included as controls (53). Moreover, while MHC-I molecules were present in 
the immunological synapse between untreated NKL cells and the leukemia cell line 
K562, cross-linking with primary and secondary antibodies displaced MHC-I molecules 
to the opposite site of the NKL cell, away from the synapse (53). MHC-I cross-linking 
on NKL cells was also observed to induce intracellular tyrosine phosphorylation when 
compared to untreated NKL cells, although the progression of the MHC signaling 
pathway and immediate interaction partners are topics for further investigation (53). 
An important aspect of NK cell biology is that they express a wide variety of receptors 
that recognize MHC-I. This raises the question whether these receptors could 
recognize MHC-I on the same cell (cis binding), and how this affects the interpretation 
of the literature cited in this section. A few studies have shown that cis binding 
indeed occurs (57,58).  In mouse NK cells, the inhibitory receptors Ly49A and Ly49C, 
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which typically binds to H2-Db,d,k molecules on other cells, can also associate with the 
allele H-2Dd on the same NK cell (57,58). Although MHC-I signaling was not studied 
in this type of cis binding, it is important to highlight that Ly49A inhibitory signaling 
does not seem to be elicited by MHC-I molecules in cis (59). On the contrary, cis binding 
promotes NK cell activation as Ly49A receptors bound to MHC-I in cis are prevented from 
binding MHC-I molecules on other cells (trans binding) (57–60). In the case of human 
NK cells, cis binding has not been confirmed, but it has been hypothesizes to occur (61). 
Considering that cis binding is not completely well understood, it is difficult to establish 
to what extent the use of monoclonal antibodies against MHC-I will affect cis binding to 
NK cell receptors and its equilibrium with trans binding. This is mostly important in the 
cytotoxicity assays reviewed in this section. Furthermore, it is difficult to say how well the 
experimental control conditions chosen by the studies presented here (e.g. unstimulated 
cells, or stimulation with isotype controls) account for potential background cis binding 
between MHC-I and its receptors on the NK cell surface.
In conclusion, MHC molecules might be involved in reverse MHC-I signaling in 
triggered NK cells, mostly leading to decreased cytotoxicity and increased cell 
death. Possibly, this inhibition could be a way for cancer or infected cells to escape 
from NK cell killing in vivo. Furthermore, it might be a mechanism of other (healthy) 
immune cells to protect themselves from being attacked by NK cells. However, which 
specific natural ligands of MHC-I would establish such inhibitory interactions remains 
unknown. Potential candidates would be members of the Ly49 family in mouse, or the 
LILR family in human, which are expressed by different myeloid and lymphoid cells 
(Reviewed by (59)). Moreover, lymphoid cells could use KIR or CD94-NKG2 receptors 
to communicate and regulate NK cells. In the future, consideration should be given to 
MHC-I itself or its downstream signaling molecules as therapeutic targets for treatment 
of pathologies with involvement of NK cells, such as cancer and viral infections.
The role of reverse MHC-I signaling in B cell proliferation and cell death 
Cross-linking of MHC-I on human acute lymphoblastic leukemia (ALL) B cell lines and 
myeloid precursor cell lines by several mouse anti-MHC-I antibodies combined with a 
secondary rabbit-anti-mouse Ig antibody, reduced proliferation and induced apoptotic 
cell death, measured as DNA fragmentation. Those primary antibodies recognized 
epitopes in HLA-A,-B and -C or β2m and cross-linking with the secondary antibody 
was strictly required for apoptosis induction (62). Interestingly, MHC-I signaling also 
induced apoptosis in the context of mature peripheral blood B cells activated in 
vitro with an antibody against CD40, which is considered a cell rescue signal (62). In 
contrast, MHC-I did not have an effect in proliferation in B cells previously activated 
with the mitogenic bacteria Staphylococcus aureus or staphylococcal enterotoxin A 
(62). The authors suggest that MHC-I stimulation might lead to initial B cell activation, 
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as seen previously in T cells, followed by cell death, based on the observation of an 
initial increase in metabolic activity in the ALL KM-3 cell line and a slow start of DNA 
fragmentation following MHC-I stimulation (12 hours) (62) (Table 4). A different result 
was obtained by another study in which anti-MHC-I antibodies used on purified human 
tonsillar B cells prevented the onset of proliferation typically induced by S. aureus, 
indicating a role of MHC-I in inhibiting B cell activation (63). On the contrary, MHC-I 
stimulation had no effect on B cell proliferation induced by treatment with phorbol-
12-myristate-13-acetate (PMA), a diacylglycerol analog that activates protein kinase C 
(PKC), suggesting that the inhibitory role of MHC-I targets signaling events preceding 
upregulation of PKC activity (63). The fact that inhibition of proliferation was not 
observed with F(ab)2 fragments of one of the antibodies used (W6/32) suggests that 
Fc-receptors are involved or that the Fc region inhibits interaction with another cell 
surface protein (63). 
Besides proliferation, short-term intracellular changes and signaling were observed 
upon MHC-I stimulation of B cells. Antibody-mediated cross-linking of MHC-I on human 
B lymphoma cells increased intracellular calcium levels, first derived from intracellular 
stores and later due to calcium influx (64). This increased intracellular calcium was 
positively correlated with the levels of MHC-I expressed by the cells (64). The early 
activation marker CD69 was upregulated upon cross-linking and MHC-I did not have 
a costimulatory effect on the anti-IgM-mediated activity of the cells (64). Finally, it 
Table 4 Summary MHC-I signaling in B cells.
Cell type MHC-I stimulation Signaling Cell outcome Ref 
Cell lines KM-3, 
HL-60 and CD40-
activated B cells 
Anti-MHC-I antibodies 
(PA2.6,  W6/32, BB7.5, 
BB7.7 and L368) and 
secondary rabbit anti-
mouse Ig






(131, 4E and W6/32)







Anti-human β2m antibody 
from rabbit serum 




Rabbit anti-human β2m 
antibody
↑ protein tyrosine 
phosphorylation





lines Solubo and 
Loukes 
Rabbit anti-human β2m 
antibody and mouse anti-
human HLA-ABC
↑ protein tyrosine 
kinases and PI-3 
kinase





was suggested that MHC-I can activate intracellular second messengers itself. For 
instance, upon MHC-I cross-linking, the protein tyrosine kinases p53/56lyn and p72syk 
are phosphorylated in human B lymphoma cells (65). Besides protein tyrosine kinases, 
serine/threonine kinases might be involved in reverse MHC-I signaling, since their 
inhibition with the molecule H7 reduced B cell apoptosis after MHC-I cross-linking (66).
As is the case for most of the cell types presented in this review, the physiological 
scenario in which reverse MHC-I signaling in B cells would be relevant remains unclear. 
Wallén-Öhman et al. suggested that the observed induction of apoptosis and reduction 
of proliferation seen upon reverse MHC-I signaling might be important for negative 
selection of autoreactive B cells (62). They hypothesized that, if an autoreactive B 
cell would target a cell bearing an MHC-I binding receptor, such as T or NK cells, the 
simultaneous binding of BCR-antigen and MHC-I-ligand would lead to apoptosis (62). 
This hypothesis was inspired by another study in which T cell precursors recognizing 
CTLs underwent apoptosis (67). Here, the simultaneous binding of the precursor’s TCR 
to an endogenous antigen on the CTL and of MHC-I to CD8 on the CTL induced the 
precursor’s death. This effect was not seen after T cell maturation (67). However, this 
hypothesis has not been tested yet for B cells. 
The effect of reverse MHC-I signaling on proliferation, activity and 
apoptosis of T cells
Early studies found anti-MHC-I antibodies to either induce or inhibit T cell proliferation 
(68–72)(reviewed in (8)). In these studies, the outcome of MHC-I stimulation depended 
on whether the anti-MHC-I antibody was used alone or in combination with other 
stimuli, and on the concentration of antibody used. On one hand, studies indicating an 
induction in proliferation only used anti-MHC-I antibodies (CR11-351, Q6/64, W6/32) 
or in combination with exogenous IL-2, PMA or antibodies against CD2. On the other 
hand, anti-MHC-I antibodies had an inhibitory effect when combined with stimuli 
that promote proliferation, such as the T cell activating lectin phytohemagglutinin 
(PHA)-P or antibodies against CD8 and CD3 (e.g. OKT3) (8,69,73–75). An antibody 
clone designated as 4-10 had a mitogenic effect and led to TCR downregulation 
in resting peripheral blood isolated T cells, when immobilized on a plate or on the 
surface of macrophages. However, when combined with immobilized anti-CD8 
antibody it reduced CD8-elicited proliferation (68). Furthermore, 72 hour incubation 
of peripheral blood T cells with the anti-MHC-I antibody W6/32 immobilized on culture 
plates at concentrations of 0.1 μg/ml and 1 μg/ml induced T cell proliferation, tyrosine 
phosphorylation and increased expression of TCR/CD3 and CD28. In contrast, very low 
amounts of immobilized W6/32 antibody (picograms/well) inhibited TCR/CD3-elicited 
proliferation. Importantly, incubation of the cells with W6/32 in solution had no effect 
on proliferation, even at a concentration of 40 μg/ml (69). 
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Induction of proliferation by Qa-2 (H2-Q7), a non-classical mouse MHC-I molecule, 
was compared to its human homolog HLA-G within a murine background (76). 
For this, resting splenic T cells were isolated from wild type mice and transgenic 
mice recombinantly expressing HLA-G. Stimulation of both protein complexes 
with monoclonal antibodies led to an induction of proliferation, but only when 
combined with a secondary antibody for cross-linking and stimulation with PMA 
(76).  Both Qa-2 and HLA-G localized to lipid rafts. However, whilst Qa-2 localizes via 
a lipid glycosylphosphatidylinositol (GPI) tail, HLA-G localizes via its transmembrane 
domain. The mechanism for signaling was attributed to interactions with other lipid 
raft-located proteins as Qa-2 has no cytoplasmic domain and HLA-G has only a short 
6-amino acid cytoplasmic tail (76,77) (Table 5). 
MHC-I is also proposed to play a role in the induction of apoptosis in T cells, because 
anti-MHC-I antibodies induced apoptosis in resting T cells (67), activated T cells (78), 
and the leukemic Jurkat T cell line (64,79–82) (reviewed in (8)). Studies focused on 
Jurkat cells provided a detailed description of the early signaling cascade following 
stimulation with biotinylated anti-β2m antibodies crosslinked with avidin. It was shown 
that shortly after cross-linking, MHC-I signaling induced tyrosine phosphorylation of 
several proteins, including the ζ-chain of the TCR/CD3 complex, ZAP-70, p56lck  and 
PLC-γ1, followed by an increase of intracellular Ca2+ (80). Although similar to TCR/CD3 
signaling, MHC-I stimulation led to inferior association of ZAP-70 with other molecules, 
a phosphorylated version of the TCR ζ-chain with a higher molecular weight, and 
weaker phosphorylation of p56lck (80). Furthermore, reverse MHC-I signaling was 
dependent on the expression of TCR/CD3 complex on the cell surface. Overall, these 
results suggest that MHC-I uses the TCR/CD3 complex for signaling but creates a 
different pattern of protein phosphorylation compared to the pattern seen after direct 
stimulation of TCR/CD3. The main outcome was strong inhibition of proliferation and 
Table 5 Summary MHC-I signaling in T cells.
Cell type MHC-I stimulation Signaling Cell outcome Ref 
Jurkat T cell line Anti-MHC-I (W6/32) 
cross-linked by 
supernatant from W6/32-
hybridoma cell cultures 
↑ Src, Bcl-2 In the stationary growth phase  
↑ apoptosis.
(84)
Cytotoxic T cell 
clone K14B06 
Anti-MHC-I antibodies 
(W6/32, HP-1F7, ME-1, 
anti-H2Dd) 
- ↓ anti-CD94 redirected target lysis (86)
Mouse splenic 
T cells 
Anti-HLA-G clone 87G 
and secondary rabbit 
anti-mouse IgG 





apoptosis induction (Figure 2D) (80,83). In a similar study, crosslinking of β2m in Jurkat 
cells led to activation of Tyk2, but not of the other members of the JAK family Jak1, 
Jak 2 or Jak3. STAT3, a substrate of Tyk2, was also phosphorylated and migrated to 
the nucleus where it could bind to the promoter of c-fos. Expression of a dominant 
negative version of STAT3 interfered with apoptotic processes associated to MHC-I 
stimulation (79). Another study on Jurkat cells proposed that apoptosis upon MHC-I 
stimulation did not follow the conventional Fas/Caspase signaling pathway but rather 
one that includes activation of phosphoinositide 3 kinase (PI3K) followed by JNK 
activation (81).
Another factor determining the outcome of reverse MHC-I singaling is the cell cycle. A 
study reported that the effect of MHC-I ligation on apoptosis depends on the growth 
phase of Jurkat cells, since in exponentially growing Jurkat cells Fas- or anisomycin 
(SAPK/JNK activator)-induced apoptosis is prevented by MHC-I ligation. This involves 
Src signaling, the upregulation of anti-apoptotic protein Bcl-2 and stabilization of the 
mitochondrial membrane potential (84). 
A potential explanation as of why MHC-I reverse signaling can have opposite effects 
could be the nuclear recruitment of different homo- or heterodimers from members of 
the NF-κB/Rel family. Stimulation with antibodies against HLA-A,-B or -C leads to nuclear 
location of NF-κB1 (p105/p50) homodimers, and formation of heterodimers by either 
NF-κB1+RelA (p65) or NF-κB1+RelB. Since NF-κB1 homodimers lack transcriptional 
activation domains, they are considered to have an inhibitory function (85).
MHC-I reverse signaling also affects the T cell effector function. This was demonstrated 
in an in vitro experiment based on antibody-dependent cell-mediated cytotoxicity 
(ADCC) (86). To achieve ADCC cancer cells were coated with antibodies against 
the CD94/NKG2 receptor. Because the antibodies’ Fc tails bind to the Fc-receptors 
on the cancer cell, the paratopes of the antibody were outwardly displayed. The 
antibody-coated cancer cells were then mixed with CD8+ cytotoxic T cells, leading 
to CD94-mediated T cell activation and increased CD25 expression. As a result of 
this interaction, the T cells were prompted to kill the cancer cells (86). This ADCC 
triggered by CD94 ligation was shown to be independent of TCR stimulation and 
could be reduced by co-ligation of MHC-I molecules on the T cell. MHC-I stimulation, 
however, had no effect on the elevated CD25 expression, indicating that reverse MHC-I 
signaling affects only one branch of the CD94-elicited signaling cascade (86). Another 
hallmark of CD94-mediated ADCC is the reorientation of the microtubule organizing 
center (MTOC) of the T cell towards the synapse with the cancer cell, the same way 
it happens upon CD3 stimulation. MHC-I co-ligation significantly reduced CD94-
mediated MTOC reorientation, explaining its inhibitory effect on target lysis (86). 
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MHC-I stimulation did not affect cytotoxicity after CD3-mediated activation, and 
only had a partial effect after exposure to the T cell activating lectin phytohemagglutinin 
(PHA), confirming the existence of several signaling cascades underlying T cell activation 
and therefore different degrees of crosstalk with reverse MHC-I signaling (86). 
MHC molecules can also interact with cytokine receptors at the plasma membrane. 
For instance, MHC-I can cluster with IL-9 receptor α (IL-9Rα) and IL-2 receptor (IL-2R) 
in lipid rafts on human T lymphoma cells (87). Although the exact effect of MHC-I on 
the clustering remains unknown, several anti-MHC-I antibodies (CR11-351, Q6/64 
and W6/32) block the expression of the IL-2R, as well as inhibit IL-2 secretion of T cells 
(74,75,88). Interactions within the receptor clusters may affect the signaling capability of 
these receptors, and although this has not yet been proven, a similar mechanism might 
also explain the increased insulin receptor signaling observed when MHC-I interacted 
with the insulin receptor on a B-lymphoblast cell line (87,89). 
Interestingly, it was observed that upon human peripheral blood lymphocyte 
stimulation with the T cell activating lectin PHA, the fraction of MHC-I misfolded proteins 
increased, as shown by immunoprecipitation with antibodies against misfolded MHC-I. 
The levels of misfolded MHC-I molecules peaked at the same time as T cell proliferation 
(30). The fact that misfolded molecules were fully glycosylated suggested that they 
derived from fully mature MHC-I molecules that reach the plasma membrane but lost 
the peptide antigen and/or the β2m subunit. It was also found that misfolded MHC-I 
molecules were more likely to dimerize and presented phosphorylation of the tyrosine 
in their cytoplasmic tail, associated with activity of the Src-kinase Lck (30). However, it is 
unclear whether phosphorylation is a cause or a result of the misfolding. The study also 
suggested that misfolded MHC-I molecules can associate with other proteins on the cell 
surface, such as CD8αβ and calreticulin, potentially regulating events related to T cell 
activation and its intensity. The reason for these interactions might be that misfolding 
and the lack of peptide unmasks amino acid motifs that are hidden in the folded form, 
especially in the α1 and α2 domains (29,30). 
Overall, reverse MHC-I signaling has been shown to be involved in modulation of the 
immune response by regulating proliferation, activity and apoptosis of T cells. These 
contradictory outcomes might be caused by the use of different T cells and varying 
stimuli across the different studies. Interestingly, there is even contradictory evidence 
on which MHC-I domain ensures reverse signal transduction, as some studies state that 
the cytoplasmic and transmembrane domains are not needed for reverse MHC-I signal 
transduction (90,91), while others propose that the transmembrane region is required, 
as it might facilitate interaction with other surface receptors (92). The significance of 
the modulation of T cell function by reverse MHC-I signaling in vivo is not yet clear. 
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It is thought that reduced cytotoxicity might play a role in the protection of target 
cells, which could be beneficial to prevent microbial dissemination from dying cells 
(86), but also disadvantageous if tumor cells are spared by this reduced cytotoxicity. 
Furthermore, it might prevent non-specific lysis of healthy cells. It is yet unknown 
which natural membrane-bound ligands of MHC-I are able to exert the proposed 
effects and if these effects are also present in vivo. Possibly, T cells can mutually 
activate each other via reverse MHC-I signaling, since a common ligand for MHC-I is 
the TCR. 
Non-immune cells contribute to inflammation by reverse MHC-I 
signal transduction 
Epithelial cell proliferation and activity upon reverse MHC-I signaling
Multiple studies have shown that the development of anti-HLA antibodies by recipients 
of lung transplantation plays an important role in the pathogenesis of bronchiolitis 
obliterans syndrome (BOS). This seems to be caused by activation of airway epithelial 
cells by such HLA-A antibodies (93). As shown by an in vitro experiment modelling 
the transplantation environment, binding of anti-MHC-I antibody W6/32 to the KCC-
266 airway epithelial cell line induced cell proliferation within 24 hours, followed by 
apoptosis. The observed proliferation was accompanied by production of the growth 
factors platelet-derived growth factor (PDGF), heparin-binding EGF-like growth factor 
(HB-EGF), insulin-like growth factor 1 (IGF-1), and basic fibroblast growth factor 
(bFGF). These factors led to proliferation of the fibroblast cell line MRC-5, explaining 
the processes of tissue remodelling and formation of fibrous tissue observed in BOS 
(93). In a similar study, cells from the A549 lung epithelial carcinoma cell were treated 
with anti-HLA serum from transplantation patients who developed BOS or with the 
antibody W6/32. Both treatments led to induced proliferation as well as tyrosine 
phosphorylation of intracellular proteins. These results could be attributed to reverse 
signaling by MHC-I but also to signaling by MHC-II, since anti-MHC-II antibodies could 
be present in the serum (94) (Table 6).
Similar to macrophages, MHC-I was proposed to modulate TLR signaling in epithelial 
cells. In vitro experiments showed that miRNA or siRNA knock down of MHC-I in 
primary bovine endometrial epithelial cells (bEECs) and a bovine endometrial cell 
line (BEND), led to increased secretion of the pro-inflammatory cytokines IL-1β and 
TNF-α after LPS stimulation (95). In accordance, MHC-I cross-linking by antibodies on 
bEECs decreased production of the same cytokines. Additionally, MHC-I heavy chain-
silenced bEECs and BEND cells showed increased TLR4 expression, as well as increased 
activation of TLR4 downstream molecules, such as myeloid differentiation primary 
response 88 (MyD88), TRAF6 and NF-κB. This was even confirmed by reduced NF-κB 
activity after MHC-I cross-linking (95). Interestingly, MHC-I cross-linking enhanced the 
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interaction between MHC-I and the tyrosine kinase Fps, while Fps knock down resulted 
in reduced levels of SHP-2 and increased cytokine production (95). This indicates that 
MHC-I on endometrial cells negatively regulates the TLR4-induced inflammatory 
response through enhancement of the Fps-SHP-2 pathway, which might be relevant 
in the maternal-fetal interface (Figure 2E). This signaling mechanism closely resembles 
the one described in macrophages in section 2.1 (9)
Altogether, MHC-I stimulation was suggested to cause proliferation and inhibit TLR-
4 signaling in lung and endometrium epithelial cells, which could have different 
implications. In the lung, reverse MHC-I signaling might play a role in the development 
of bronchiolitis obliterans syndrome after lung transplantation. While in the 
endometrium, reverse MHC-I signaling might be involved in interactions between 
mother and fetus or even control congenital inflammatory reactions (95,96).
Table 6 Summary MHC-I signaling in epithelial and endothelial cells.
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Reverse MHC-I signaling in endothelial cells contributes to adverse effects 
after transplantation
The endothelium is a specialized form of epithelium and will therefore be separately 
discussed here. The role of reverse MHC-I signaling in endothelial cells has been 
reviewed extensively in the context of transplant vasculopathy and concomitant tissue 
rejection. Specifically, alloantibodies generated by the transplant recipient against 
MHC-I and MHC-II alloantigens present in the transplanted tissue have been linked 
to endothelial cell proliferation, survival and migration that can be accompanied by 
recruitment of inflammatory cells into the transplanted tissue (5,7,10,97,98). The organ 
recipient develops antibodies not only against MHC-I, but also against different types 
of alloantigens. However, endothelial cell lines stimulated with allosera from a rat 
cardiac allograft model characterized by vasculopathy and rejection in vitro, showed 
that anti-MHC-I and II antibodies were more toxic for endothelial cells, than antibodies 
against non-MHC antigens. This toxicity was due to complement activation upon MHC 
stimulation (99,100). 
In contrast to most other cell types in this review, reverse MHC-I signaling in 
endothelial cells has been studied in more detail and is therefore better understood. 
Phosphorylation of multiple signaling proteins has been observed after antibody-
induced MHC-I cross-linking on endothelial cells. One of the earliest events is Ras 
homolog (Rho) activation immediately followed by Src, focal adhesion kinase (FAK) 
and paxillin activation, which together contribute to cytoskeletal remodelling and 
formation of focal adhesions and stress fibers (101–104). Furthermore, activation of 
PI3K leads to the formation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which 
promotes Akt activation and its interaction with the mTOR pathway, which overall 
supports protein synthesis, cell survival and migration (102,103,105–109). Akt and 
mTOR activation can also promote cell survival by favouring the expression of the 
antiapoptotic molecules Bcl-xL and Bcl-2 (108,110), as well as by the inhibition of 
the proapoptotic protein Bad (109)(Reviewed in (5,7,10,106)). Notably, the effects of 
anti-MHC antibodies on endothelial cell signaling are independent of their Fc regions 
(108). Additionally, MHC-I stimulation can increase the sensitivity of the cell to growth 
factors by mobilizing their receptors to the plasma membrane. This is the case for 
the fibroblast growth factor receptor (FGFR), which promotes proliferation via the 
extracellular signal-regulated kinase (ERK) pathway (111), in a signaling cascade that is 
independent from one in which ERK is directly activated by MHC-I (112). 
Interestingly, it was found that integrin β4 is an important interaction partner of 
MHC-I, as they coimmunoprecipitate when MHC-I is crosslinked. This interaction is 
likely mediated by the cytoplasmic domain of the MHC-I α chain, as shown by the lack 
of reverse signaling upon heterologous expression of α chains lacking the cytoplasmic 
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domain. Knocking down integrin β4 led to reduced phosphorylation of FAK, Src, Akt 
and ERK after MHC-I stimulation. As a consequence, endothelial cell proliferation 
was less when MHC-I was stimulated in the absence of integrin β4. Similarly, MHC-I α 
chain knock-down affected the ability of integrin β4 to induce migration (113,114). A 
recent study found that Src signaling under MHC-I/integrin β4 leads to translocation 
of the transcriptional coactivator yes associated protein (YAP) from the cytoplasm to 
the nucleus. Once in the nucleus, YAP enhances the expression of connective tissue 
growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (Cyr61), which promote 
endothelial cell proliferation and migration (115).
Recent studies support reverse MHC-I signaling in endothelial cells, with special focus 
on how it affects the recruitment and adhesion of the recipient’s monocytes. This is 
important because intragraft macrophages correlate with worse transplant outcomes 
(116–118) (Table 6). An in vitro study showed that ligation of MHC-I by antibodies 
for 15 minutes on primary human aortic endothelial cells was sufficient to stimulate 
the exocytosis of the cell adhesion molecule P-selectin. The display of P-selectin 
on endothelial cell monolayers facilitated the adhesion of two monocyte cell lines 
(U937 and MM6) via the P-selectin glycoprotein ligand-1 (PSGL-1) on their surface. 
Additionally, it was found that MHC-I antibodies bound to endothelial cells further 
favoured cell-cell adhesion by binding to Fc-receptors on the monocytes with their Fc-
region (117,119). Adhesion of monocytes to anti-MHC-I antibody-treated endothelial 
cells was enhanced by intact complement present in the culture media compared 
to heat-inactivated complement. In addition, complement further promoted MHC-I-
induced P-selectin expression, which was important for adhesion (118). Human IgG1 
appeared to be more effective in stimulating adhesion when compared to human 
IgG2, in accordance with its higher affinity for Fc-receptors (117). The integrin Mac-
1 (CD11b) contributed to the increase in monocyte adhesion, since neutralizing 
antibodies reduced adhesion (118). Importantly, there was variation between 
endothelial cells and monocytes from different donors, which should be considered 
when designing a treatment strategy for patients with transplant rejection. The in vivo 
relevance was demonstrated by an increased macrophage burden in mice with murine 
cardiac allografts treated with MHC-I antibodies, whereas P-selectin blockers reduced 
this macrophage burden (120).
Inhibition of mTOR by drugs or siRNA in endothelial cells reduced MHC-I-induced 
adherence of MM6 macrophage-like cells or peripheral blood mononuclear cell 
(PBMC)-derived monocytes (116). This reduced firm adhesion of monocytes to 
endothelial cells by mTOR inhibition was comparable to ICAM-1 neutralizing 
antibodies, suggesting that mTOR plays a role in regulating firm adhesion of monocytes 
to ICAM-1 on endothelial cells stimulated with MHC-I antibodies (116). Indeed, MHC-I 
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ligation triggers ICAM-1 clustering via mTOR and ERM signaling (116). Moreover, mTOR 
activation after reverse MHC-I signaling was proposed to lead to activation of RhoA, 
ROCK and ezrin/radixin/moesin (ERM), as investigated with the help of small molecule 
inhibitors (116). Mice with a heart transplant and anti-MHC-I antibody treatment 
showed endothelial cell swelling and intravascular activated immune cells, which was 
reduced by mTOR blockade (116). Using these mice, it was also observed that anti-
MHC-I antibodies increased endothelial phosphorylation of ERM, which was abolished 
by mTOR inhibitors (116). 
In summary, reverse MHC-I signaling in endothelial cells has been linked to several cell 
outcomes that underlie tissue rejection, such as proliferation, migration and adhesion of 
immune cells like monocytes. Also, multiple mediators, such as Akt, mTOR and ERK1/2, 
have been associated with this signaling. Understanding these signaling pathways could 
facilitate the development of pharmacological interventions to treat chronic antibody-
dependent tissue rejection (121). Moreover, this knowledge is not only interesting in 
the field of transplantation outcomes, but might also be relevant for other immune 
responses that require trans-endothelial migration, or diseases such as atherosclerosis in 
which endothelial activation and immune infiltration are involved (122).
Proliferation and migration of smooth muscle cells after reverse MHC-I 
signaling
Reverse MHC-I signaling in smooth muscle cells has been studied in the same context 
of transplantation as endothelial cells (Table 7). Cross-linking with anti-MHC-I and a 
secondary antibody, but also with F(ab’)2 fragments, induced proliferation of human 
aortic smooth muscle cells (SMC) (123,124). The same was observed with human 
mesenteric SMC and a human aortic SMC cell line triggered by MHC-I ligation with 
the monoclonal antibodies W6/32 and MEM-147 (125,126). Moreover, proliferation 
was inhibited by anti-bFGF antibodies, suggesting that MHC-I stimulation triggers 
bFGF synthesis or uptake (123). Additionally, anti-MHC-I antibodies lead to a rapid 
release of stored fibroblast growth factor receptor (FGFR) to the plasma membrane 
and thereafter increased synthesis of FGFR (123,127). The combination of anti-MHC-I 
antibody W6/32 and either TNF-α or IFN-γ, increased the FGFR expression even more 
(127). This could be explained by the finding that both inflammatory cytokines 
increased the expression of MHC-I (127). Besides smooth muscle cell proliferation, 
migration upon MHC-I ligation has also been investigated, since both cells are involved 
in intimal thickening of vessels during chronic rejection of a transplant. Antibody 
cross-linking of MHC-I on human aortic smooth muscle cells induced wound healing. 
This wound healing involved proliferation and migration, but also migration alone 
when proliferation was inhibited by mitomycin C (124). MHC-I knockdown inhibited 
anti-MHC-I-mediated SMC proliferation and migration (124).
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At the signaling level, MHC-I ligation increased the tyrosine phosphorylation of several 
proteins (123,124), such as those involved in cell survival and proliferation like FAK, 
Akt and ERK1/2, while downregulation of MHC-I with siRNA abrogated MHC-I-induced 
phosphorylation (124). Additionally, decreased FAK and p-FAK after siRNA knockdown 
of FAK reduced the MHC-I-mediated phosphorylation of Akt and ERK1/2, indicating 
that their phosphorylation depends on FAK. In accordance, integrity of the actin 
cytoskeleton, in which FAK is involved, is important for the MHC-I-induced activation 
of SMC, since the phosphorylation of cellular proteins was attenuated by disruption of 
the cytoskeleton upon stimulation with cytochalasin D or latrunculin A (124). Overall, 
FAK was found to play a role in the MHC-I-mediated proliferation and migration of 
SMC (124). 
Another major signaling pathway linked to reverse MHC-I signaling is the sphingolipid 
signaling pathway, related to transduction of stress signals. Early players of this 
pathway, such as the matrix metalloproteinase 2 (MMP2) and its target neutral 
sphingomyelinase-2 (nSMase2), which catalyses the hydrolysis of  sphingomyelin into 
Table 7 Summary MHC-I signaling in smooth muscle cells and myeloma cells.
Cell type MHC-I stimulation Signaling Cell outcome Ref 
Human aortic smooth 
muscle cells
Anti-MHC-I antibodies 





Human aortic smooth 
muscle cells
Anti-HLA-A1 IgG and 
W6/32
- ↑ FGFR 
expression 
(127)
Human aortic smooth 
muscle cells 
Anti-MHC-I (W6/32, 
human anti-HLA- A24/ 
A32 and murine anti-
HLA-A2)






artery smooth muscle 
cells, human aortic 
SMC CRL-1999 cell 









artery smooth muscle 
cells (primary and 
immortalized) and 




↑ SK1, S1P, and 
S1PR1/R3 signaling
↑ proliferation (126)
Myeloma cells Mouse anti-human β2m 
(clone B2, IgG1)
↑ Lyn, PLCγ2, JNK




ceramide, were shown to be involved in the induction of proliferation and migration 
by MHC-I stimulation, indicating that anti-MHC-I antibodies behave like stress-
inducing agents (125). A later player of the pathway, sphingosine kinase 1 (SK1), which 
phosphorylates sphingosine to sphingosine-1-phosphate (S1P), and the SP1 receptors 
S1PR1/R3 were also required for the induction of proliferation and migration by MHC-I 
stimulation, as observed when using several antibodies, inhibitors and silencing by 
siRNA (126). Altogether, it can be proposed that after MHC-I stimulation, MMP2 is 
activated and acts on nSMase2 to stimulate ceramide generation (97). Ceramide can 
then be converted to S1P, which activates Akt and MAPK/ERK pathways and thereby 
promotes proliferation (97,126). However, the signaling cascades are probably more 
complex than this proposed model, as for instance S1P was suggested to have a role as 
extracellular mediator (126).
Immunodeficient SCID/beige mice grafted with human mesenteric segments 
and injected with W6/32 anti-MHC-I antibody showed vascular abnormalities 
(vasculopathy) in the transplant, which was characterized by intimal hyperplasia. 
These vascular abnormalities were not observed in untreated mice or mice treated 
with irrelevant antibody (125,126). This suggests that also in vivo reverse MHC-I 
signaling plays a role in smooth muscle cell proliferation and migration, of which 
the former was confirmed by an increase in proliferating cell nuclear antigen (PCNA) 
(125,126). Moreover, increased intimal MMP2 expression was observed, while MMP 
and nSMase2 inhibitors (partly) prevented the increased PCNA expression and intimal 
thickening (125). Besides, PCNA labelling and intimal thickening were reduced by anti-
S1P antibodies, supporting the notion that W6/32 stimulates SMC proliferation via S1P. 
However, it is uncertain if these outcomes are caused by direct reverse MHC-I signaling 
or are the result of inflammatory cytokine production (126).
In conclusion, MHC-I signaling can induce SMC proliferation and migration, but the 
complete molecular pathway remains to be elucidated. The induction of proliferation 
and migration of smooth muscle cells by MHC-I-stimulation might contribute to 
transplant vasculopathy, a hallmark of chronic rejection after transplantation (123,124). 
Several reviews have addressed the role of MHC-I antibodies in SMC activation, also in 
relation to transplant outcomes (7,97,98,128). However, anti-MHC-I antibody-specific 
effects need to be validated in human cardiac transplants showing vasculopathy.
Reverse MHC-I signal transduction results in cancer cell apoptosis 
The potential of β2m stimulation in inducing myeloma cell death    
To study the potential of monoclonal antibodies in cancer treatment, the effect of anti-
β2m antibodies on myeloma cells was first investigated in vitro. Anti-β2m antibodies, 
but surprisingly not the antibody W6/32 which targets a conformational epitope in the 
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MHC-I α-chain, induced apoptosis of human myeloma cell lines and human primary 
myeloma cells. This apoptotic effect was not counteracted by myeloma pro-survival 
cytokines such as IL-6 and insulin-like growth factor-I (129). In contrast, non-cancer 
cells such as PBMCs, were not killed, which could be due to the higher expression of 
β2m and HLA-ABC on myeloma cells (129). Knockdown of β2m expression on myeloma 
cells by siRNA induced resistance to the apoptosis (129). Upon anti-β2m treatment, 
MHC-I was internalized and caspase-9, -3, -7 and poly (ADP-ribose) polymerase (PARP) 
were activated in myeloma cells (129). At the same time, the proapoptotic proteins 
Bad and Bax were upregulated while expression levels of antiapoptotic Bcl-2 and Bcl-
xL did not change (129). In combination with an increase in cytosolic cytochrome 
c, this indicates increased permeability of mitochondria (129). Moreover, levels of 
phosphorylated JNK increased, phosphorylated Akt and ERK decreased and partial 
JNK inhibition almost completely abrogated myeloma cell apoptosis (129). After 
anti-β2m treatment, MHC-I molecules were recruited to lipid rafts and disruption of 
lipid raft structure by methyl-β-cyclodextrin treatment abrogated apoptosis (129). 
Immunoprecipitation showed that Lyn and PLCγ2 associated with MHC-I, which 
were both phosphorylated after antibody treatment (129). Altogether, this suggests 
that due to anti-β2m antibodies, MHC-I locates to lipid rafts, activates Lyn and PLCγ2, 
which activate JNK and inhibit Akt and ERK pathways and finally induce myeloma 
cell apoptosis. In mice, anti-β2m injections reduced tumor volumes and improved 
survival, whereas no other tissues were damaged, and pJNK, cleavage of caspase-9 
and caspase-3 and myeloma apoptosis were induced (129). Further evidence on the 
potential of anti-β2m antibodies as therapeutic agent for multiple myeloma has been 
reviewed extensively elsewhere (11,130). 
Altogether, it is likely that β2m is involved in the regulation of cell death in myeloma 
cells and it might be interesting to study the role of MHC-I (components) in other 
tumor cell types. Drug targeting β2m might be a potential treatment for myeloma 
patients, but it should be confirmed that there are no effects on other cells than 
myeloma cells as suggested by Yang et al. (2006) (129). However, the ability of tumor 
cells to reduce their surface MHC-I expression should be taken into account (131). It 
could also be useful to study if and to which extent cell death of tumor cells by ligation 
of MHC-I or β2m occurs in cancer patients. Finally, as also mentioned in section 2.1, the 
effects triggered by anti-β2m antibodies might not be exclusively related to reverse 
MHC-I signaling, since other heterodimers such as CD1 and the neonatal Fc-receptor 




Here we summarized available evidence of reverse MHC-I signaling. Reverse MHC-I 
signaling has been observed in multiple immune and non-immune cells in vitro as 
well as in vivo. MHC-I signaling has been shown to affect cell apoptosis, activation 
(e.g. growth factor production), proliferation, cytotoxicity and migration in many cell 
types, including immune cells, epithelial cells and tumor cells (3,5,6). Because of these 
broad actions, reverse MHC-I signaling is relevant to several fields, including research 
into viral and bacterial infections (6,9), transplantation outcomes (9) and malignancies 
(11). One difficulty in the study of reverse MHC-I signaling has been separating it 
from the canonical roles of MHC-I in antigen presentation for T cell activation and 
NK cell suppression. This is technically difficult because deletion of MHC-I would 
interfere with both these functions and would therefore also impair the formation of 
the immunological synapse. As a consequence, most studies have used monoclonal 
antibodies to stimulate cell surface MHC-I, leaving the physiological relevance in vivo 
to be elucidated. Similarly, the in vivo ligands that induce reverse MHC-I signaling are 
often unknown. One exception is observed in transplantation biology, where anti-
MHC-I antibodies are produced by the tissue recipient.
Identifying the MHC-I domain important for reverse signaling has been controversial. 
Wagner et al. (1994) concluded that the cytoplasmic domain of MHC-I is not needed for 
signal transduction, whereas the transmembrane part is (92). In contrast, others found 
that neither the cytoplasmic nor the transmembrane region of MHC-I are needed for 
reverse MHC-I signaling, and suggested that the extracellular domain interacts with 
other cell surface molecules to ensure signal transduction (90,91). More recently, 
cytoplasmic tyrosine phosphorylation of MHC-I was observed and phosphorylated 
MHC-I was co-immunoprecipitated with Fps, suggesting a role of the cytoplasmic 
domain in reverse signaling (9). Similarly, others suggest that the first event following 
MHC-I ligation is an interaction of MHC-I with intracellular Lyn and PLCy2 in tumor 
cells (129) or association with other surface receptors on T cells (90). Additionally, 
the presence of putative PDZ (PSD95/disc large/zonula occludens-1) ligand motifs in 
the cytoplasmic region of MHC-I suggests potential interactions with PDZ domain-
containing proteins in vivo (26). This is further supported by the fact that these PDZ 
ligand-like regions are conserved across species and seem to be under positive 
selective pressure. Moreover, in vitro experiments showing that MHC-I cytoplasmic 
domains can bind to immobilized PDZ domain peptides, are the starting point to 
study MHC-I downstream signaling via its cytoplasmic domain (26). Nevertheless, it is 
possible that the cytoplasmic, transmembrane and extracellular domains of MHC-I are 
all important for signal transduction, depending on the cell type and stimulus.  
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Although the exact pathways following MHC-I ligation are not yet completely known 
for all cell types, several mechanisms have been suggested (Figure 2). The emerging 
picture shows commonalities between different cell types, where signaling molecules/
pathways triggered by reverse MHC-I signaling are shared: Fps and SHP-2 as early 
events in macrophages and epithelial cells (9,95); the involvement of STAT proteins in 
macrophages and T-cells (6,79); JNK in NK cells and tumor cells (55,129); Akt and ERK1/2 
signaling in endothelial cells  (103,105,107–110,112), smooth muscle cells (124,126), 
and myeloma cells (129); and an inhibition or activation of NF-κB in macrophages, NK 
cells, T cells and epithelial cells (9,55,85,95) (Table 1-8). However, as not all of these 
signaling pathways are studied in all cell types, it might well be that the reverse MHC-I 
signaling mechanism is actually quite similar in different cell types. Also, the signaling 
pathway and outcome might depend on the cell subtype (e.g. resting blood T cells vs. 
Jurkat T cells), differentiation state, type of MHC-I stimulus, and co-stimulation (45,62). 
A recurrent pattern among different cell types is the crosstalk between reverse MHC-I 
signaling and signaling pathways initiated by for instance TLR, Fc receptors, integrins 
and growth factor receptors (9,31,95,112–114). Such a cross-talk with other signaling 
pathways would position MHC-I molecules as major modulators of immunological 
physiology and homeostasis.  
Interestingly, similar outcomes and signaling pathways to MHC-I stimulation have 
been described after  stimulation of MHC-II molecules in professional antigen-
presenting cells, such as B cells and DCs (reviewed in (132), as well as in other immune 
cells, like T cells and monocytes (133–135). In B cells, reverse MHC-II signaling was 
suggested to play a role in B cell activation, proliferation, differentiation or apoptosis 
after B cell-T cell interaction (reviewed in (136–138)), and also killing of malignant B 
cells (136,139). Similar to MHC-I, both cytoplasmic tail-dependent and –independent 
mechanisms have been proposed for reversed MHC-II signaling (136,137). Another 
similarity to reverse MHC-I signaling is the location of MHC-II signaling molecules 
in lipid rafts. While stimulated MHC-II molecules present in lipid rafts of antigen-
presenting cells can signal via tyrosine kinases to ensure activation, maturation or 
proliferation, the MHC-II molecules that are relocated to non-raft regions can signal 
via protein kinase C to induce cell death (132). Likewise, in murine B cells the way 
in which the α- and β- chains of MHC-II interact with each other creates different 
conformers, 10% of which locate preferentially in lipid rafts where they interact with 
the B cell receptor (BCR) partner CD79 to induce tyrosine kinase activity (140). Other 
intracellular reverse MHC-II signaling events similar to reverse MHC-I signaling are for 
example tyrosine phosphorylation and activation of Src, AKT, ERK and JNK (136). Also, 
the transmembrane adaptor protein SCIMP was shown to be tyrosine phosphorylated 
after MHC-II stimulation serving as scaffold for downstream signaling pathways (141). 
A potential role of SCIMP or a similar scaffold protein in MHC-I signaling could explain 
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the connection observed to tyrosine kinases. T cell studies showed that similar to 
MHC-I, MHC-II ligation also inhibits the activation cascades elicited by CD3 stimulation 
with OKT3. This inhibition was evidenced by reduced proliferation and reduced 
expression of the cytokines IL-1β, IL-6 and IL-2, and of the IL-2 receptor when compared 
to T cells treated with only OKT3 (133–135). While reverse MHC-I signaling has been 
poorly studied in DCs, studies on MHC-II in these cells showed induced maturation and 
apoptosis. Monocyte-derived DCs underwent maturation when stimulated with a pan-
HLA-DR epitope (PADRE) when bound to particles, in a process involving MAP kinase, 
p72syk and NF-κB (142). Moreover, stimulation of HLA-DR molecules in plasmacytoid 
DCs lead to apoptosis but only when already mature (143). These commonalities 
strengthen the idea of a general regulatory role for MHC molecules on immune and 
non-immune cells, beyond their antigen presenting function. 
Looking forward, the field of reverse MHC-I signaling has great potential for basic and 
applied research. Despite that it is increasingly clear that reverse MHC-I singaling has 
major effects on many cell types, our knowledge of this process is still in its infancy. 
The main limitation in the field is our poor knowledge of the ligands that bind MHC-I 
in vivo. Potential candidates include the members of the human KIR family and their 
murine functional homologs in the Ly49 family, members of the LILR and PIR family, as 
well as members of the CD94-NKG2 family. The fact that the expression of some of these 
receptors is not limited to NK and T cells, but extends to myeloid cells (reviewed in 
(59)), opens the possibility that multiple types of cell-cell interactions could be shaped 
by reverse MHC-I signaling. Moreover, the search for MHC-I ligands could be broaden 
to other non-immune receptors, as shown by a study on the role of MHC-I in neuronal 
development. This study proposes that MHC-I and the insulin receptor are expressed 
in different sets of neurons and can bind to each other in trans. This interaction allows 
MHC-I to downregulate the synapse-promoting role of the insulin receptor, leading to 
a reduced density of synapses during brain development. However, this study did not 
look at potential signaling downstream of MHC-I (144). Another important challenge 
in the field is to establish what the first signaling event after MHC-I stimulation is, as 
this is required for a complete understanding of reverse MHC-I signaling. In many of 
the studies cited in this review, this first molecular interaction was elusive and only the 
downstream signaling pathways were confirmed. Confirming functional relevance of 
the putative PDZ domains of MHC-I (26) and identifying their interaction partners (e.g. 
by mass spectrometry) could help to identify these early signaling events. Moreover, 
the reported recruitment of MHC-I molecules to lipid rafts raises the question whether 
reverse MHC-I signaling is regulated by the clustering and segregation of MHC-I with 
other receptors (53,76,77,87,129).  It would also be important to study whether the 
signaling processes reported previously via the different MHC-I domains (cytoplasmic, 
transmembrane, extracellular or β2m) can actually coexist, expanding the modulatory 
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capacity of MHC-I. In order to address these questions, approaches used in the past 
for the study of TCR and BCR signaling could come in handy, using for example 
purified ligand candidates (as mentioned above) tethered to supported lipid bilayers 
(145,146). Furthermore, it would be important to assess the contribution of reverse 
MHC-I signaling cellular outcomes, such as proliferation and apoptosis, to in vivo 
physiological and pathological processes. Finally, future efforts could focus on the 
identification of potential therapeutic approaches to target reverse MHC-I singaling 
for managing tissue transplantation (see for example (121)), and treatment of viral and 
bacterial infections, as well as malignancies. If successful, this new knowledge would 
establish that MHC molecules are not only passive displays of antigenic peptides, but 
are also genuine immune receptors that modulate the intracellular signaling within 
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Abstract
In response to infection, dendritic cells (DCs) have a pivotal role in the activation of 
both helper and cytotoxic T cells. The tight contact that facilitates the communication 
between these two immune cells is called the immunological synapse. To define the 
immune response, this contact is followed by the polarization of the microtubule 
organizing centers (MTOC) and secretory machineries of both cells towards the site 
of contact. This polarization allows the local delivery of activation signals by the DC 
including antigen peptides, co-stimulatory molecules and cytokines, to an antigen-
specific T cell, while preventing activation of nearby non-specific T cells. While MTOC 
polarization is well-understood in T cells, the signals that drive polarization in DCs are 
unclear. Here, we used beads coated with T cell orchestrators to identify the molecules 
that initiate polarization of the MTOC in the DC. Our data show that MTOC and Golgi 
polarization are triggered via reverse signaling by major histocompatibility complex 
class I (MHC-I). The encountering of an antigen-recognizing T cell by MHC-I prompts 
signaling of Src and Syk kinases and the phospholipase C/protein kinase C signaling 
axis. This study shows that MHC-I is the key orchestrator of MTOC polarization which 





Dendritic cells (DCs) are key players in many immunological processes, ranging from 
destroying pathogen infected cells or cancer cells to autoimmunity. The DC is an 
innate immune cell that functions as the connection between innate and adaptive 
immunity by phagocytosis of malignant cells and pathogens which are then presented 
on the DC’s membrane to activate T lymphocytes (1).
The activation of naive CD8+ cytotoxic T lymphocytes (CTLs) requires the formation of a 
tight cellular interface between a dendritic cell (DC) and a T cell, called immunological 
synapse. Peptide fragments derived from ingested or expressed proteins are presented 
in major histocompatibility complex class I (MHC-I) on the surface of the DC to naive 
T cells in the lymphatics (2–5). This occurs via a process called repertoire scanning, 
where the DCs sequentially present peptides to a large number of T cells to identify 
T cell clones with cognate antigen-specific T cell receptors (TCRs) (6). In the absence 
of cognate antigen, migrating T cells only briefly interact with DCs in lymph nodes (< 
3 min contact) (7). Here, only naive T cells are activated that express a cognate T cell 
receptor (TCR) that recognizes the peptide fragment presented in MHC-I at sufficiently 
high levels (7–9). Once such an antigen-specific T cell is encountered, DCs form an 
immunological synapse which can be stable for hours (10). The activation of naive T 
cells requires not only the engagement of the TCR with the MHC-peptide complex, but 
also co-stimulation by membrane bound receptors and soluble cytokines (2–5).
The engagement of a DC with a cognate T cell triggers a reorganization of the 
microtubular cytoskeleton within the cytoplasm of the DC resulting in the migration 
of the MTOC to the immunological synapse. This MTOC reorientation is paired with 
the translocation of the Golgi apparatus and the secretory machinery towards the 
immunological synapse in a process that depends on the Rho GTPase Cdc42 (11,12). 
This leads to secretion of the T cell activating cytokine Interleukin (IL)-12 at the 
immunological synapse that occurs from vesicles of late endosomal nature by the 
action of the SNARE protein VAMP7 (13). Such a reorientation of the MTOC is a common 
feature of immune cells engaged in synapse formation, and is also present in T cells, B 
cells and natural killer (NK) cells (1,14). For most of these immune cell types, the signals 
that trigger MTOC polarization are known (15–17). For example, MTOC polarization in 
B cells is triggered by the B cell receptor (18) while it is triggered in NK cells by CD28, 
NKG2D, NKp30 and CD94 signaling (19). In T cells, microtubule reorganization at the 
immunological synapse depends on TCR downstream signaling effectors, including 
protein tyrosine kinases Lck and Fyn (16,20,21) and ZAP70 (f-associated protein of 70 
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kDa) (22) and on a protein kinase C (PKC) dependent signaling cascade that induces 
cytoskeletal reorganization by dynein-dependent trafficking of the MTOC towards the 
APC (3,4,23). 
However, the signals that trigger relocation of the MTOC at the immunological synapse 
in DCs are largely unknown. In this study, we use human and mouse synapse models 
between DCs and CD8+ T cells to further describe the signaling mechanisms leading 
to T cell activation and cytokine release at the immunological synapse. Using beads 
coated with antibodies recognizing MHC class I, we show that polarization of the 
MTOC is mediated by ligation of MHC-I. This process, where MHC-I acts as a signaling 
receptor is called reverse MHC-I signaling (24). Our data shows that in DCs, MHC-I 
reverse signaling triggers tyrosine phosphorylation within the DC. Moreover, MTOC 
polarization could be blocked by small molecule inhibitors of Scr and Syk kinases and 
of PLC and PKC. Altogether, our data shows that MHC-I is the key triggering molecule at 
the DC synapse interface that initiates MTOC polarization, which is crucial information 
to understand the dynamics between T cells and DCs, leading to elimination of 
pathogens and malignant cells. 
Results
Polarization of the Golgi network in murine DC-T cell synapses
We first wanted to confirm the polarization of the MTOC in DCs towards the interface 
with naive CTLs and determine whether the Golgi network translocates to the DC 
side of the immunological synapse (12). To induce synapse formation, murine Flt3L 
differentiated bone-marrow derived DCs (BMDCs) were activated with ligands for Toll-
like receptors (lipopolysaccharide (LPS), TLR4 agonist; CpG, TLR 9 agonist) for 4h and 
loaded with the model antigens ovalbumin (OVA), OVA-Immunocomplexes (OVA-IC), 
which consist of OVA complexed with antibodies raised against OVA, or the MHC class I 
epitope SIINFEKL. The BMDCs were then co-cultured for one hour with OT-I CD8+ T cells 
that express a T cell receptor recognizing peptide SIINFEKL derived from ovalbumin 
(OVA) in the context of MHC-I (H-2Kb) (Fig. 1A). The cells were subsequently fixed with 
paraformaldehyde (PFA) and immunostained for α-tubulin and γ-tubulin, to identify 
the tubulin network and the MTOC respectively (Fig. 1B). Co-staining for the Golgi 
marker GM130 showed that the Golgi apparatus was surrounding the MTOC regardless 
of the activation state of the DC, the antigen or the presence of T cells.
To quantify the polarization to the immunological synapse in the DCs, the polarization 
index of the MTOC was calculated by measuring the distance between the MTOC 
and the DC-T cell interface divided by the diameter of the DC (Fig. 1C), as reported 
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previously (17,25). DCs with a polarization index below 0.3 were considered polarized 
and displayed as percentage of polarized cells as shown before (25) (Fig. 1D-E). In line 
with previous research (12,13), MTOC and Golgi polarization was observable in DCs 
that were both activated with TLR ligands and loaded with antigen. TLR activated DCs 
that were not loaded with antigen did not show polarization, while quantification 
showed that DCs loaded with OVA, OVA-IC or SIINFEKL all displayed MTOC polarisation 
to the synapse. Transmission electron microscopy also revealed the localization of the 
MTOC at the synapse in both the BMDC and the T cells for the majority of cells (Fig. 
1F). In these experiments, we observed that the plasma membranes of each cell were 
pressed flat against each other. We did not observe membrane ruffles of pseudopodia-
like protrusive structures as observed previously between CTLs and target cells (5,15). 
Instead, despite the short co-culturing time of the BMDCs and the CTLs (30 min), we 
observed a smooth membrane interface that seems more reminiscent of the late stage 
(>4 h) synapses observed between helper T cells and B cells and DCs (17). Thus, the 
Golgi apparatus is transported together with the MTOC to the immunological synapse 
with CTLs.
MHC-I induces MTOC polarization in DCs 
The exact signals in the DC leading to the MTOC polarization are unknown. Based on 
the receptors triggering MTOC polarization in B, T and NK cells (18,19,23), we selected 
the following candidates on the DC membrane that might potentially trigger MTOC 
polarization: antigen presentation receptors (MHCI and MHC-II) (26,27), costimulatory 
molecules (CD80/86) (28) and adhesion molecules (LFA-I and ICAM-I) (12). To identify 
the molecule leading to MTOC polarization we developed a model where mouse 
Flt3L-differentiated BMDCs were stimulated with antibody or protein domain-coated 
beads (Fig. 2A). Non-activated BMDCs and BMDCs stimulated with naked beads or 
isotype control antibody were included as negative control conditions. To visualize 
the polarization of the MTOC and the Golgi network in our bead synapse formation 
model, cells were again immunostained for the α- and γ-tubulin network and GM130 
(Fig. 2B). Quantification of the polarization index revealed that BMDCs only polarized 
when conjugated to beads coated with antibody against MHC-I and not with 
antibodies recognizing MHC-II, ICAM-1 or protein domains CD28 (ligand of CD80) and 
LFA-I (Fig. 2C-D). Also for human blood monocyte-derived DCs (moDCs), we observed 
polarization of the MTOC and the Golgi when stimulated with beads conjugated to 
MHC-I antibody and not when stimulated with naked beads or beads that were 
conjugated to an irrelevant antibody (isotype control) (Fig. 2E-G). Thus, MTOC and 
Golgi polarization during synapse formation in mouse and human DCs is induced by 
reverse MHC-I signaling. 
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Chapter 7 - MHC-I reverse signaling triggers MTOC polarization
Involvement of Src, Syk kinase and PKC signaling pathways in 
MTOC polarisation in DCs 
In the next set of experiments, we addressed the signaling cascades downstream of 
MHC-I. In T cells, microtubule reorganization at the immunological synapse depends 
on TCR downstream signaling effectors, like the protein tyrosine kinases, including Src 
family of protein tyrosine kinases Lck and Fyn (16,20,21), and the Syk-family tyrosine 
kinase ZAP70 (f-associated protein of 70 kDa) (22). We therefore determined whether 
reverse MHC class I signaling triggered by antibody ligation would result in tyrosine 
phosphorylation. Coating of plates with a monoclonal antibody against MHC-I 
(Fig. 3A), showed that MHC-I stimulation leads to tyrosine phosphorylation in mouse 
Flt3L-differentiated BMDCs and human moDCs (Fig. 3B-C). In contrast, stimulation 
with only BSA or with plates coated with an isotype control antibody did not result in 
altered phosphorylation. 
Since these experiments were in line with the involvement of tyrosine kinases in 
reverse MHC-I signaling, we determined MTOC polarization with MHC-I antibody 
coated beads in the presence of small molecule inhibitors of Src (Src-I and PP1) and 
Syk (P505) family kinases. Because MTOC polarization in T cells depends on signaling 
by PLC (phospholipase C) and several PKC (protein kinase C) isoforms (29), we also 
used small molecule inhibitors of PKC (Gö6983) and PLC (U73122) in our assay. As a 
positive control, we included Nocodazole that disrupt microtubules. After two hours of 
incubation with these inhibitors, the beads coated with antibody against MHC-I were 
added and MTOC polarization was assessed using immunofluorescence microscopy. 
Quantitative analysis of the polarisation index showed that all these small molecule 
inhibitors could block MTOC polarisation in DCs, whereas the negative control 
compound (U73343) resulted in normal MTOC polarization (Fig. 3D-E). In BMDCs and 
macrophages, reverse MHC-I signaling has also been shown to suppress cytokine 
production (TNF-α, IL-6) via inhibition of NF-κB signaling. However, we did not observe 
significantly altered production of IL-12 upon conjugation to beads coated with MHC-I 
antibodies compared to naked beads and antibody isotype control (Fig. 3F). 
Discussion
In this study, we showed that MTOC polarization in DCs at the interface with T cells 
is triggered by reverse MHC-I signaling. MHC-I reverse signaling has been observed 
in different immune cell types, such as macrophages, NK cells, T cells, and B cells, 
and non-immune cell types such as endothelial and smooth muscle cells (24,30). 
MHC-I reverse signaling can affect a wide range of cellular processes including cell 
activation, proliferation, maturation, cytotoxicity, migration and apoptosis (24,30–
177
7
32). The intracellular signaling mechanism of MHC-I is not well understood, because 
both human and murine MHC-I forms have only a very short cytosolic motif (~30 
residues) that contains no known signaling region. However, most MHC-I forms 
contain a conserved tyrosine that can become phosphorylated and has therefore 
been suggested to be involved in signaling (24). Despite this, MHC-I ligation has been 
shown to trigger a wide range of signaling pathways, including Fps and SHP-2 in 
macrophages and epithelial cells (33,34), STAT signaling in macrophages and T-cells 
(32,35), JNK in NK cells and tumor cells (36,37), Akt and ERK1/2 signaling in endothelial 
cells (38,39), smooth muscle cells (40,41), and myeloma cells (42), and inhibition of NF-
κB signaling in macrophages, NK cells, T cells and epithelial cells (33,36,43). Our study 
now shows that, in DCs, MHC-I ligation triggers tyrosine phosphorylation. Moreover, 
we show that inhibition of the Src and Syk family of tyrosine kinases and of the PKC and 
PLC signaling axis blocks MTOC polarization downstream of MHC-I reverse signaling. 
Interestingly, these signaling pathways are also involved in the MTOC polarisation in 
T cells (16,20–22,29), where reorientation of the MTOC to the immunological synapse 
also facilitates membrane trafficking over microtubules to the synapse (44,45). We 
therefore conclude that reverse MHC-I signaling results in translocation of the MTOC 
to the immunological synapse in a manner dependent on Src and Syk kinases and PKC 
and PLC signaling.
Reverse MHC signaling likely underlies the polarized trafficking events to the 
immunological synapse in DCs. Such polarized trafficking has not only been described 
for IL-12 (11–13,46), but also for other cargo molecules including CD40 (47) and both 
MHC-I and MHC-II (48–51). Although trafficking of MHC-I and MHC-II do not seem to 
involve the translocation of the MTOC and the Golgi network, but rather the extension 
of tubular compartments from recycling endosomes (for MHC-I) and the MHC-II 
containing compartment (MIIC; for MHC-II) (48–51), evidence suggests that this DC 
polarization is also mediated by reverse MHC signaling. For MHC-I, tubulation of MHC-
I-containing early recycling compartments in human DCs requires antigen-specific T 
cell interaction and involves interactions of both MHC-I and ICAM-1 by T cell-expressed 
TCR and LFA-1, respectively (51). For MHC class II, the MIIC tubules can orientate 
selectively towards the immunological synapse in mouse DCs and depends on TCR and 
ICAMs (48–50). Finally, the F-actin cytoskeleton of the DCs is also polarized towards 
the immunological synapse in an antigen-specific manner, and this polarization is 
required for complete T cell activation (52,53). Thus, it is increasingly clear that reverse 
MHC-I and MHC-II signaling trigger several polarized trafficking cascades: extension of 
endosomal networks (recycling endosomes and MHC-II), rearrangements of the F-actin 
cytoskeleton, and recruitment of the MTOC and the accompanying Golgi network. 
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Altogether the MTOC and Golgi polarization leads to T cell activation. During this 
interaction the combination of cytokines sensed by the T cell define its differentiation 
into various types of effector or repressor T cells (54). For instance, IL-12 mediates 
the differentiation of CD4+ helper T cells to Th1 cells for clearance of (mainly) viruses 
and other intracellular pathogens, whereas TNF-α and IL-6 promote a differentiation 
to Th2 and Th17 phenotypes, which are more important for extracellular pathogens 
and humoral responses (54). Additionally, many other cytokines, including IL-4, IL-10 
and TGF-β, are involved in differential T cell activation (54). However, lymph nodes are 
very crowded organs that contain millions of T cells and only a very small fraction, as 
low as one in a million, of these T cells carries a TCR recognizing a particular epitope 
(55). Although the DC usually interacts with several T cells at the same time in the 
so called rosette structure (7,56), only one at the time gets activated. This arises the 
question how does the DC prevent bystander activation? Our hypothesis is that the 
DC delivers a variety of signals directly to one antigen-specific T cell at the time via the 
MTOC and Golgi trafficking, which might prevent bystander activation of the other T 
cells in the rosette. Thus, our mechanism explains how most cytokines can be locally 
released at the immunological synapse, explaining how DCs can direct specific T cell 
differentiation in crowded cellular environments.
Materials and methods 
Animals
C57BL/6 wild-type (WT) and OT-I mice were purchased from Charles River and hosted 
at the Central Animal Laboratory (CDL) of the Radboud University Medical Center. 
The mice were kept in top-filter cages and received a standard diet. At the time of an 
experiment, the mice were sacrificed by cervical dislocation at an age of 8-12 weeks 
old. All experiments in this project were approved by an animal ethical committee 
[2015-0019TIL-067] with regard to the care and use of animals.
Murine cell culture
For the generation of BMDCs, murine femurs and tibias were taken from female WT 
mice. From the femurs and tibias, bone marrow derived stem cells were obtained and 
cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS, 758093, Greiner bio-
one), 1% antibiotic-antimycotic (15240-062, Gibco), 1% ultraglutamine (BE17-605E/
U1, Lonza Bioscience), 50 μM β-mercaptoethanol (60-24-2, Sigma-Aldrich) and 200 ng/
ml human Flt3L (130-096-479, Miltenyi Biotec) for eight days at 37ºC in an incubator 
with 10% CO2. After eight days, floating cells were collected and a CD45R (B220) 
depletion (microbead isolation kit (130-049-501), Miltenyi Biotec) was performed to 
remove plasmacytoid DCs from the cell population. For the isolation of naive CD8+ 
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T lymphocytes, spleen and lymph nodes were isolated from female OT-I mice. The 
organs were homogenized and digested for 30 minutes at 37ºC by using a mixture 
of collagenase and DNAse, at 1 mg/ml and 130 μg/ml, respectively. CD8+ T cells were 
obtained after LD column magnetic antibody cell sorting (MACS, 130-042-901, Miltenyi 
Biotec) with anti-CD8 antibody beads from Miltenyi Biotec (130-104-075). The beads 
were used according to the company’s protocol. 
Human cell culture
Human cells were obtained from a buffy coat from healthy individuals received 
as anonymous coded specimens from Sanquin Bloodbank Nijmegen and were 
handled according to practice and legal guidelines. The research with human blood 
samples at the Department of Tumor Immunology complies with all institutional 
and national ethics regulations and has been approved by the ethics committee of 
Sanquin. All blood donors were informed of the research and have granted their 
consent. Density grading media Ficoll facilitated the isolation of leukocytes. After a 
series of centrifugation and washing steps with cold PBS with 1 mM EDTA (6381-92-
6, Sigma-Aldrich) and 1% human serum (47-196, Sigma-Aldrich), the peripheral blood 
mononuclear cells (PBMCs) were obtained. To generate moDCs, the PBMCs were 
plated and left to attach for 1 hour at 37 ºC, whereafter the floating cells (lymphocytes) 
were removed. The moDCs were cultured for six days in complete medium with 300 
U/ml interleukin 4 (IL-4, 130-093-924, Miltenyi Biotec) and 450 U/ml granulocyte-
macrophage colony-stimulating factor (GM-CSF, 130-093-867, Miltenyi Biotec) at 37 ºC. 
After three days, new complete medium with 900 U/ml IL-4 and 1350 U/ml GM-CSF 
was added.
BMDC-T cell synapse formation
Fresh day 8 Flt3L BMDCs (B220-) were activated in a non-adherent well plate (7007, 
Corning) for four hours at 37ºC and 5% CO2 with LPS (L4391-1MG, Sigma-Aldrich) and 
CpG ODN1826 (tlrl-1826-1, InvivoGen) both at a concentration of 1 μg/ml. The cells 
either received no addition of protein/peptide, OVA albumin (0.5 mg/ml, 321001, 
Lionex GmbH), OVA in combination with IgG against OVA (20 μg/ml OVA + 500 μg/ml 
Goat polyclonal IgG against chicken ovalbumin, 0855303, MP Biomedicals) or SIINFEKL 
(500 ng/ml, OVA257-264, AS-60193-5, Tebu-Bio). OVA and OVA-immunocomplexes were 
added for the full activation time, while SIINFEKL was added for the last 30 minutes of 
activation. After activation, OT-I T cells obtained from mouse spleen and lymph nodes 
and labelled with CFSE (C34554, Invitrogen) were added 2:1 to the BMDCs and placed 
on PLL-coated coverslips. The DCs and T cells were incubated for 1 hour at 37°C and 
5% CO2. After this time the cells were fixed for 20 minutes with 4% PFA.
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BMDC-bead synapse formation
Fresh day 8 Flt3L BMDCs (B220-) were activated in a non-adherent well plate for four 
hours at 37ºC and 5% CO2 with TLR4 agonist LPS and TLR9 agonist CpG-B ODN1826 
both at a concentration of 1 μg/ml. During activation, 6 μm streptavidine beads were 
coated with different biotinylated antibodies (3.75 μg of antibody per 6 million beads, 
see table 1.) and incubated for 30 minutes in PBA (PBS + 1% BSA and 0.05% sodium 
azide) at room temperature (RT). After activation, the BMDCs were mixed with beads 
on poly-L-lysine (PLL, 25988-63-0, Sigma-Aldrich) coated coverslips in a 1:1 ratio and 
were incubated for 30 minutes at 37ºC and 5% CO2. After this time the cells were fixed 
for 20 minutes with 4% paraformaldehyde (PFA). Bead coating was tested with flow 
cytometry (Appendix 1). 
Table 1 The antibodies and protein domains used in the BMDC-bead experiments.
Target Antibody Catalog number Company
MHC-I Rat anti-mouse H-2 monoclonal antibody 
(biotinylated)
MBS2533680 MyBioSource
Isotype MHC-I Biotin Rat IgG2a, kappa isotype control 
clone R35-95
553928 BD Biosciences
MHC-II Biotin rat-anti mouse I-A/I-E clone 2G9 553622 Sigma Aldrich
ICAM-I ICAM-I/CD54 antibody (1A29) biotinylated NBP2-22541B Novus Biologicals
LFA-I Monoclonal anti-human IgG1-biotin 
antibody + recombinant mouse ICAM-I-Fc 
chimera (carrier free)
B6775+553006 Biolegend
CD80/86 Monoclonal anti-human IgG1-biotin 




Day 6 moDCs were activated in a non-adherent well plate for four hours at 37ºC and 
5% CO2 with LPS and TLR7/8 agonist R848 at a concentration of 1 μg/ml and 2.5 mg/ml 
respectively. After activation, the moDCs were mixed with beads coated with either an 
antibody against MHC-I (13-9983-82, ThermoFisher) or its corresponding isotype control 
(13-4724-85, ThermoFisher) on PLL-coated coverslips in a 1:1 ratio and were incubated 
for 30 minutes at 37ºC and 5% CO2. After this time the cells were fixed for 20 minutes 
with 4% PFA. The coating of the beads was analyzed with flow cytometry (Appendix 1).
Immunofluorescence staining of MTOC
After fixation with PFA for 20 minutes at RT, excess PFA was quenched with a solution 
containing 100 mM glycine and 100 mM NH4Cl in PBS for 20 minutes at RT. Human 
DCs were blocked-permeabilized with 2.5% BSA + 1% donkey serum (017-000-121-, 
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Jackson) + 0.15% Triton X-100 in PBS, mouse DCs were blocked-permeabilized with 
2.5% BSA + 1% donkey serum + 0.1% Triton X-100 in PBS. Synapses from murine 
BMDCs were stained with antibodies against α-tubulin (1:500, rat IgG, NB100-1639, 
Novus Biological),γ-tubulin (1:500, rabbit IgG, T5192, Sigma-Aldrich) and the cis-Golgi 
marker GM-130 (1:100, mouse IgG, 610822, BD Pharmigen) for one hour at RT. After 
washing, the synapses were stained with fluorescently labelled secondary antibodies: 
donkey-anti-rat alexa488 (1:400, A21208, Thermo-Fisher Scientific) donkey-anti-rabbit 
alexa568 (1:400, A11036, Thermo-Fisher Scientific) and donkey-anti-mouse alexa647 
(1:400, A10037, Thermo-Fisher Scientific). After incubation with the secondary 
antibody, the cells were washed with PBS and mounted with a glycerol-containing 
mounting medium (68 g glycerol, 100 mM NaPi pH 7.4 + trollox + DAPI).
Human cells were stained for α-tubulin (1:500, rat IgG, NB100-1639, Novus Biological), 
γ-tubulin (1:500, rabbit IgG, T5192, Sigma-Aldrich) and the trans-Golgi marker 
TGN46 (1:1000, sheep IgG, AHP500GT, BioRad) for one hour at RT. After washing, the 
synapses were stained with fluorescently labelled secondary antibodies purchased 
from Thermo-Fisher Scientific: donkey-anti-rat alexa488 (A21208), donkey-anti-rabbit 
alexa568 (A11036) and donkey-anti-sheep alexa647 (1:400, A21448). Lastly, the cells 
were washed with PBS and mounted with a glycerol-containing mounting medium (68 
g glycerol, 100 mM NaPi pH 7.4 + trollox + DAPI).
Electron Microscopy
Synapses of mouse BMDCs and T cells were seeded and cryo-fixed on aluminum discs 
by plunging rapidly in liquid propane.  Cells were dehydrated and fixed using the rapid 
freeze substitution method (K.L.  McDonald,  R.I. Webb  Freeze substitution in 3 hours 
or less) in the presence of 1% OsO4 and 0.5% Uranyl acetate in acetone containing 
5% water. Samples were embedded in epon and 100 nm sections  were collected on 
formvar coated and carbon evaporated grids. Sections were post contrasted  with 
uranyl cetate and lead citrate and examined in a CM12 transmission electron 
microscope (Philips) operating at 100kV. Synapses were imaged on an SP8 confocal 
microscope with a 63x 1.2 NA water immersion objective (Leica).
In-plate MHC-I activation for Western Blot
A six well plate was coated with 15 μg/μl BSA (10735108001, Roche), 15 μg/μl of 
MHC-I antibody (BE0077, BioXCell) and 15 μg/μl of isotype control antibody (400202, 
BioLegend) in PBS overnight at 4ºC. On the day of the experiment, fresh day 8 mouse 
Flt3L BMDCs (B220-) were activated in a non-adherent 6 well plate (3471, Corning) 
coated with 10% BSA for four hours at 37ºC and 5% CO2 with LPS and CpG-B ODN1826 
at a concentration of 1 μg/ml. 45 minutes before the end of activation, the wells were 
blocked with blocking buffer (2% BSA in PBS) at 37ºC and 5% CO2. After activation, the 
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BMDCs were added to the wells and the plate was centrifuged to ensure synchronized 
contact between the antibody and the cells. The plate was incubated for 30 minutes 
at 37 ºC and 5% CO2. The cells were collected and lysed with lysis buffer (1% Nonident 
P-40, 100 mM Tris pH 7.5, 150 mM NaCl supplemented with phosphatase (04-906837-
001, Roche) and protease inhibitors (05-892-791-001, Roche)) and incubated for 20 
minutes on ice. The lysates were collected and wells were washed 3 times with lysis 
buffer. Sample buffer without β-mercaptoethanol was added to each well and the 
plate was incubated for 10 minutes in a water bath at 60ºC. 
The lysates and complex fractions were run on a 10% (for p-Tyr) and 15%-SDS gel. The 
samples were transferred to polyvinylidene difluoride (PVDF) membranes. After the 
transfer, the membranes were washed with demineralized water and were blocked 
with Odyssey blocking buffer (927-40000, LI-COR: Tris-buffered saline (TBS) 10mM 
Tris, pH 8.0, 150 mM NaCl, 5% BSA with 0.2% Tween-20) for 1h at RT. After blocking, 
the membranes were incubated with antibodies against phospho-tyrosine (SC-508, 
Santa Cruz), GAPDH (2118, Cell Signaling) or MHC-I (HLA-A, ABIN3023100, Antibodies 
Online) overnight at 4ºC. Additionally, the membranes were washed with TBS-Tween 
[*concentration) and incubated with fluorescently labelled secondary antibodies goat-
anti-mouse IRdye800 (926-32210, LI-COR), donkey-anti-rabbit IRdye 680 (925-68073, 
LI-COR) and goat-anti-rabbit IRdye 800 (925-32211, LI-COR) for one hour at RT. The 
membranes were washed with TBS-Tween and scanned using the Odyssey CLx, a LiCor 
infrared blot imager. Analysis of the blot was done with ImageJ.
Statistical analysis
The plots for polarization index show the average ± standard error of the mean 
(SEM). For the statistical analysis of the polarization index; D’Agostino & Pearson 
omnibus normality test was performed followed by one-way analysis of variance 
(ANOVA) with Bonferroni’s Multiple Comparison Test or Kruskal-Wallis followed by 
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Chapter 8 - General discussion
Abstract
Catestatin (CST: hCgA352-372), a bioactive cleavage product of the neuroendocrine 
pro-hormone Chromogranin A (CgA), is associated with pathological conditions 
hallmarked by chronic inflammation, including autoimmune diseases, cardiac diseases 
and metabolic disorders. CST is an anti-inflammatory and anti-adrenergic peptide, 
and the concept is emerging that CST primarily acts by suppressing the inflammatory 
actions of macrophages. However, recent findings show that CST not only acts on 
macrophages, but that macrophages themselves are main producers of CST, possibly 
producing even more CST than neuroendocrine cells. In this opinion article, we discuss 
new data supporting the exciting possibility that macrophages are the main source of 





Chromogranin A (CgA) is produced and secreted by neuroendocrine and enteroendocrine 
cells, such as chromaffin cells and pancreatic beta-cells (1–5). Proteolytic conversion of 
CgA, either before or after its release, gives rise to six known bioactive cleavage products: 
pancreastatin (PST: hCgA250-301),  WE-14 (hCgA324-337), vasostatin (hCgA1-76), catestatin 
(CST: hCgA352-372), chromofungin (hCgA47-66) and serpinin (hCgA411-436) (5,6). The exact 
regulation of CgA cleavage is not clear, but various proteases have been shown to be 
capable of producing CST, including cathepsin-L (7), thrombin (8), furin (9), pro-hormone 
convertases 1 and 2 (9), kallikrein (10) and plasmin (11,12). Although the receptor and 
downstream signaling pathway for CST remain unknown, the physiological effects of 
the 21-amino acid peptide CST are well established. CST is pleiotropic and functions 
as a neuroregulatory, anti-bacterial as well as chemotactic peptide, regulates insulin 
sensitivity and has anti-inflammatory effects in various inflammatory models, including 
diabetes, inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and cardiac 
disease (13–26). It is believed that by producing CST, neuroendocrine cells regulate 
their own activation by negative-feedback inhibition, and suppress inflammation in a 
paracrine fashion (6,27).
However, in this opinion article, we argue that CST mainly signals in the reverse 
direction: from macrophages to neuroendocrine cells. First, we will discuss the role 
of CST in suppressing catecholamine release and macrophage inflammation. Second, 
we will discuss new evidence suggesting that macrophages are major producers of 
CST. Third, we will discuss the contribution of this macrophage-produced CST to the 
regulation of the neuroendocrine and immune systems. Finally, we touch upon the 
potential clinical implications of CST in chronic inflammatory diseases.
The role of CST in suppression of neurotransmitter release 
CST was first described as a neuropeptide (27,28) present in for example the retina 
and nerves of the eye (29). Additionally, it was found that neuroendocrine cells and 
adrenergic neurons, which both release catecholamines, co-released these together 
with CST (27,28,30). Supporting this co-release, plasma CST levels are accepted as 
a biomarker for sympathetic nervous system activity (31), where high CST levels 
correlate with increased neurohumoral burden (31,32). Neurons and neuroendocrine 
cells do not only produce CST, but CST also affects their activity. For example, 
CST stimulation decreased sympathetic nerve activity, heart rate, sympathetic 
barosensitivity and neuronal response to hypoxia in rats stimulated in the pressor area 
of the medulla (33) as well as improved baroreflex sensitivity and heart variability in 
mice (34,35). Moreover, mice with selective deletion of the region of the Chga gene 
coding for CST, so called CST-KO mice, are hypertensive and have elevated levels of 
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norepinephrine and epinephrine in plasma and the adrenal gland, which are fully 
reversible by intraperitoneal injection of CST (25). This suppression of catecolamine 
release by CST might well be a direct effect on the neurons and/or neuroendocrine 
cells, because CST was found to suppress catecholamine release in the in vitro cultured 
neuronendocrine cell line PC12 (30) as well as in vivo in mice (36). Based on these 
findings, CST is considered to be an autocrine neuromodulatory factor that enables 
neuroendocrine cells to self-suppress their catecholamine release in an activity-based 
fashion (6,27,30).
The role of CST in suppression of inflammation 
CST also suppresses inflammation and is thereby involved in different diseases and 
disorders hallmarked by chronic inflammation (Fig. 1). For instance, plasma CST levels 
are elevated in patients suffering from type 2 diabetes (37), hypertension (38), heart 
failure (31,39–41), sleep apnea (42) and acute lung infection (32). Elevated levels of 
CST have also been measured in blood and stool of IBD patients (13,18,22), and these 
levels seem to correlate with disease severity (14). In animals, high CST levels in the 
saliva correlate with cortisol, indicating physiological stress (43–45). CST-KO mice 
display elevated levels of pro-inflammatory cytokines in the circulation, adrenal 
gland, colon and heart, which could all be reversed upon intraperitoneal injection 
of CST (23,25). Experiments with fluorescently-labelled dextran showed that CST-KO 
mice also have an impaired gut barrier function, a hallmark of intestinal inflammation, 
which was reversed by CST administration (13). Finally, in vitro cultured murine bone 
marrow-derived macrophages were more skewed to an anti-inflammatory phenotype 
in the presence of CST (25). Based on these findings, it is believed that the co-release 
of CST together with catecholamines acts to dampen inflammation upon elevated 
neurohumoral activity (6,27,30–32).
CST controls inflammation via macrophages
The anti-inflammatory effects of CST primarily occur by suppression of monocyte 
infiltration and macrophage-driven inflammation. CST-KO mice have increased 
macrophage infiltration in the adrenal gland, heart, and colon (13,23,25) (Fig. 1). 
Depletion of the macrophages in CST-KO mice, using chlodronate liposomes, reversed 
the hypertensive phenotype and normalized the blood pressure (25). Intraperitoneal 
injection of CST leads to a reduction of monocyte and macrophage infiltration in 
the colon (colitis model), liver (diet-induced obesity model), heart (hypertension 
model) and atheromatous plaques (atherosclerosis model) (13,14,20,21,23–25) (Fig. 
1). Intravital imaging and in vitro assays revealed that CST directly affects monocyte 
chemotaxis (15–17,23). Key evidence showing that macrophages are the main cells 
regulated by CST, comes from bone-marrow transfer experiments from CST-KO 
mice to irradiated wild-type mice. Despite the wild-type mice having completely 
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Fig. 1 The effects of catestatin on several tissues. Tissues that are affected upon CST knockout 
(red) and CST treatment (green). Heart: Macrophage (MΦ) infiltration in absence of CST (red). Colon: 
Affected microvilli and (MV) mucus production, microbiome composition and epithelial barrier 
function and increased macrophage infiltration upon absence of CST (red). Liver: Hepatocytes (HC) 
with more macrophage and monocyte (MoC) infiltration in absence of CST (red). Adrenal medulla: 
Macrophage infiltration upon CST knockout (red).
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autologous CST production from the neuroendocrine cells, this transfer resulted in 
elevated levels of proinflammatory cytokines in the heart (the only organ assessed) 
and induced a hypertensive phenotype (22,25). In contrast, bone marrow transfer in 
the reverse direction (i.e., from wild-type to CST-KO mice) resulted in the opposite 
phenotypes (22,25), proving that the metabolic and inflammatory effects of CST are 
largely due to its suppression of macrophage-driven inflammation. 
Macrophages could be the main source of CST
The bone-marrow transfer experiments (22,25) also revealed another important fact: 
macrophages (and/or other bone-marrow derived cells) are major producers of CST 
themselves. This was shown by the following two observations: 1) the inflammatory and 
hypertensive phenotypes were fully reversible upon bone marrow transfer from WT to 
CST-KO mice, showing that CST produced by bone marrow-derived cells is sufficient for 
these phenotypes, and 2) the levels of CST in cirulation almost normalized following 
transfer (25). Moreover, since bone-marrow transfer from CST-KO mice to WT mice could 
induce the inflammatory and hypertensive phenotypes, this suggests that CST produced 
by the macrophages is essential for the physiological function of CST (25). The production 
of CST by murine peritoneal macrophages was confirmed by Western blot (25).
Thus, it seems that macrophages are both main cells affected by and major producers 
of CST, supporting the conclusion that CST might be a new autocrine signaling 
factor supressing macrophage activation. This extends the current idea that CST is 
mainly produced by neurons and neuroendocrine cells when it is secreted together 
with catecholamines, and this suppresses macrophage-driven inflammation in an 
autocrine/ paracrine fashion (28,30). 
Macrophage-produced CST suppresses neurotransmitter release
If macrophages are the main source of CST for dampening inflammation, this raises 
the questions what the contribution of CST produced by neuroendocrine cells is. Does 
the CST produced by neuroendocrine cells result in self-suppression of catecholamine 
release and dampen macrophage inflammation, as previously envisioned for 
catecholamine secretion induced by nicotine or PACAP (pituitary adenylate-
cyclase-activating polypeptide) (6,27,30,36)? Or alternatively, does CST produced 
by macrophages regulate the activity of neurons and neuroendocrine cells? Recent 
evidence also supports the latter possibility, since bone-marrow transfer from WT mice 
to CST-KO mice resulted in normalization of norepinephrine and epinephrine levels in 
the plasma and adrenal gland, whereas bone marrow transfer in the reverse direction 
resulted in elevated levels of these catecholamines (25). Macrophages are well known 
to communicate with neuroendocrine cells using cytokines (46–48), and CST thus 
seems to be a new factor mediating this communication (Fig.2).
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Especially for the intestine, it seems likely that macrophage-produced CST regulates 
both the enteric nervous system and enteroendocrine system (49–52). In the gut, CST 
affects the bacteria population, intestinal barrier function, macrophage infiltration 
and inflammation (13,14,19–22) and possibly intestinal mobility (unpublished data). 
Many of these processes are regulated by the enteric neuroendocrine system, such 
as intestinal motility, blood flow, mucosal growth and the immune system (46,47). 
Thereby, it seems likely that CST produced by macrophages could signal to this system 
resulting in both reduced inflammation and gastrointestinal activity (Fig.2).
Concluding remarks 
Based on the above discussion, we propose that macrophages are one of the main 
source of CST which controls inflammation in an autocrine fashion and neuronal/
neuroendocrine activity in a paracrine fashion (Fig.2). However, a limitation of the 
current studies in mice is that complete knockout mice for CST were used. This model 
does not allow to discern between CST produced by neurons, neuroendocrine cells 
and macrophages. A conditional CST knockout in these different cell types using a 
Cre/loxp model (53) could help to discern their contribution in CST production.
Moreover, conditional knockout of CST would help to distinguish between 
contributions of locally vs. systemically produced CST and delineate the roles of CST 
in different organs. Since levels of CST in plasma, feces and saliva might be used as 
biomarkers in several inflammatory diseases (13,14,18,31,32,37–41,43–45), it will be 
important to understand these contributions. The specific roles of CST in different 
organs might also be assessed by reducing the local levels of CST in WT mice with 
injections of neutralizing antibodies. Alternatively, local CST concentrations could be 
raised by injection of (coated) vesicles containing CST or RNA coding for CST targeted 
with antibodies to distinct organs (54). 
Direct administration of CST could help patients with over activated macrophages 
in various inflammatory diseases. However, peptides are rapidly degraded in the 
circulation and in general have a low half-life. The use of so called retro-inverso-CST (RI-
CST) might overcome this limitation (55). This peptide contains D-amino acids instead 
of L and has a reversed sequence, but could still rescue hypertension in CgA-KO mice 
similarly as seen for normal CST (55). In contrast to normal CST, RI-CST is not efficiently 
broken down by proteases in the digestive tract and thereby likely has an extended 
half-life and might even be administered orally. Additionally, a pharmacophore-based 
screen identified TKO-10-18 as a potential drug that can mimic CST actions (56). Thus, 
the administration of RI-CST or TKO-10-18 might be promising therapies for diseases 
with inflammatory and neuroendocrine dysfunctions, including metabolic disorders 
and autoimmune diseases such as diabetes and RA.
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Fig. 2 CST mediates communication between macrophages and the enteric neuroendocrine 
system. CST mediates the communication between macrophages and neuroendocrine cells 
resulting in reduced gastrointestinal activity and reduced inflammation. These reactions can 
occur via 1) autocrine signaling, where CST is produced by the macrophages and affects the 
macrophages directly, and 2) paracrine signaling from macrophages to neuroendocrine cells, 





1.  Mahata SK, Mahata M, Marksteiner J, Sperk G, Fischer-Colbrie R, Winkler H. Distribution of mRNAs 
for Chromogranins A and B and Secretogranin II in Rat Brain. Eur J Neurosci (1991) 3:895–904. 
doi:10.1111/j.1460-9568.1991.tb00101.x
2.  Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y. Chromogranins A and B and 
secretogranin II: evolutionary and functional aspects. Acta Physiol (2007) 192:309–324. doi:10.1111/j.1748-
1716.2007.01806.x
3.  Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SRJ. The Extended Granin Family: 
Structure, Function, and Biomedical Implications. Endocr Rev (2011) 32:755–797. doi:10.1210/er.2010-0027
4.  Cohn D V, Elting JJ, Frick M, Elde R. Selective Localization of the Parathyroid Secretory Protein-I/Adrenal Medulla 
Chromogranin A Protein Family in a Wide Variety of Endocrine Cells of the Rat. Endocrinology (1984) 114:1963–
1974. doi:10.1210/endo-114-6-1963
5.  Muntjewerff EM, Dunkel G, Nicolasen MJT, Mahata SK, Van Den Bogaart G. Catestatin as a Target for Treatment 
of Inflammatory Diseases. Front Immunol (2018) 9:2199. doi:10.3389/fimmu.2018.02199
6.  Mahata SK, Corti A. Chromogranin a and its fragments in cardiovascular, immunometabolic, and cancer 
regulation. Ann N Y Acad Sci (2019) 1455:34–58. doi:10.1111/nyas.14249
7.  Biswas N, Rodriguez-Flores JL, Courel M, Gayen JR, Vaingankar SM, Mahata M, Torpey JW, Taupenot L, O’Connor 
DT, Mahata SK. Cathepsin L Colocalizes with Chromogranin A in Chromaffin Vesicles to Generate Active 
Peptides. Endocrinology (2009) 150:3547–3557. doi:10.1210/en.2008-1613
8.  Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A. A new chromogranin 
A-dependent angiogenic switch activated by thrombin. Blood (2012) 121:392–402. doi:10.1182/
blood-2012-05-430314
9.  Eskeland NL, Zhou A, Dinh TQ, Wu H, Parmer RJ, Mains RE, O’Connor DT. Chromogranin A processing and 
secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory 
pathway. J Clin Invest (1996) 98:148–156. doi:10.1172/jci118760
10.  Benyamin B, Maihofer AX, Schork AJ, Hamilton BA, Rao F, Schmid-Schönbein GW, Zhang K, Mahata M, Stridsberg 
M, Schork NJ, et al. Identification of novel loci affecting circulating chromogranins and related peptides. Hum 
Mol Genet (2016) 26:233–242. doi:10.1093/hmg/ddw380
11.  Jiang Q, Taupenot L, Mahata SK, Mahata M, O’Connor DT, Miles LA, Parmer RJ. Proteolytic cleavage of 
chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates 
catecholamine release. J Biol Chem (2001) 276:25022–9. doi:10.1074/jbc.M101545200
12.  Biswas N, Vaingankar SM, Mahata M, Das M, Gayen JR, Taupenot L, Torpey JW, O’Connor DT, Mahata SK. 
Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential 
Processing at Catestatin Region by Plasmin. Endocrinology (2008) 149:749–757. doi:10.1210/en.2007-0838
13.  Muntjewerff EM, Tang K, Lutter L, Christoffersson G, Nicolasen MJT, Gao H, Katkar GD, Das S, Beest M ter, Ying W, 
et al. Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides. Acta 
Physiol (2021) doi:10.1111/apha.13655
198
Chapter 8 - General discussion
14.  Eissa N, Hussein H, Mesgna R, Bonin S, Hendy GN, Metz-Boutigue MH, Bernstein CN, Ghia JE. Catestatin 
regulates epithelial cell dynamics to improve intestinal inflammation. Vaccines (2018) 6:1–18. doi:10.3390/
vaccines6040067
15.  Egger M, Beer AGE, Theurl M, Schgoer W, Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J, Patsch JR, 
et al. Monocyte migration: A novel effect and signaling pathways of catestatin. Eur J Pharmacol (2008) 598:104–
111. doi:10.1016/j.ejphar.2008.09.016
16.  Aung G, Niyonsaba F, Ushio H, Kajiwara N, Saito H, Ikeda S, Ogawa H, Okumura K. Catestatin, a neuroendocrine 
antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and 
chemokines. Immunology (2011) 132:527–539. doi:10.1111/j.1365-2567.2010.03395.x
17.  Muntjewerff EM, Parv K, Mahata SK, Phillipson M, Christoffersson G, van den Bogaart G. The anti-inflammatory 
peptide catestatin blocks chemotaxis. bioRxiv (2020) 2: doi:10.1101/2020.11.23.393934
18.  Zivkovic PM, Matetic A, Tadin Hadjina I, Rusic D, Vilovic M, Supe-Domic D, Borovac JA, Mudnic I, Tonkic A, Bozic 
J. Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel 
Disease. J Clin Med (2020) 9:628. doi:10.3390/jcm9030628
19.  Rabbi MF, Munyaka PM, Eissa N, Metz-Boutigue M-H, Khafipour E, Ghia JE. Human Catestatin Alters Gut 
Microbiota Composition in Mice. Front Microbiol (2016) 7:2151. doi:10.3389/fmicb.2016.02151
20.  Rabbi MF, Eissa N, Munyaka PM, Kermarrec L, Elgazzar O, Khafipour E, Bernstein CN, Ghia JE, Laëtitia Kermarrec, 
Elgazzar O, et al. Reactivation of intestinal inflammation is suppressed by catestatin in a murine model of colitis 
via M1 macrophages and not the gut microbiota. Front Immunol (2017) 8:1–17. doi:10.3389/fimmu.2017.00985
21.  Rabbi MF, Labis B, Metz-Boutigue MH, Bernstein CN, Ghia J-E. Catestatin decreases macrophage function in two 
mouse models of experimental colitis. Biochem Pharmacol (2014) 89:386–398. doi:10.1016/j.bcp.2014.03.003
22.  Muntjewerff EM, Lutter L, Tang K, Lindert MK, Fransen J, Oldenburg B, Mahata SK, van den Bogaart 
G. Title : Catestatin regulates the colonic mucus layer in inflammatory bowel disease. (2021) doi:doi.
org/10.1101/2021.02.09.430377
23.  Ying W, Mahata S, Bandyopadhyay GK, Zhou Z, Wollam J, Vu J, Mayoral R, Chi N-W, Webster NJG, Corti A, et 
al. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses 
Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. Diabetes (2018) 67:841–848. doi:10.2337/
db17-0788
24.  Kojima M, Ozawa N, Mori Y, Takahashi Y, Watanabe-Kominato K, Shirai R, Watanabe R, Sato K, Matsuyama T-A, 
Ishibashi-Ueda H, et al. Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury–Induced 
Neointimal Hyperplasia Atherosclerosis and Ischaemic Disease 182. Thromb Haemost (2018) 118:182–194. 
doi:10.1160/TH17-05-0349
25.  Ying W, Tang K, Avolio E, Schilling JM, Pasqua T, Liu MA, Mahata S, Bandyopadhyay G, Das S, Sahoo D, et al. 
Catestatin (CST) is a key mediator of the immunoendocrine regulation of cardiovascular function. Hypertension 
(2021) 77:1670–1682. doi:10.1161/HYPERTENSIONAHA.120.16809
26.  Dasgupta A, Bandyopadhyay GK, Ray I, Bandyopadhyay K, Chowdhury N, De RK, Mahata SK. Catestatin improves 
insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation. Comput Struct 
Biotechnol J (2020) 18:464–481. doi:10.1016/j.csbj.2020.02.005




28.  Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback 
control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic 
antagonist. J Clin Invest (1997) 100:1623–1633. doi:10.1172/jci119686
29.  Gramlich OW, Lorenz K, Grus FH, Kriechbaum M, Ehrlich D, Humpel C, Fischer-Colbrie R, Bechrakis NE, Troger J. 
Catestatin-like immunoreactivity in the rat eye. Neuropeptides (2014) 48:7–13. doi:10.1016/j.npep.2013.11.003
30.  Sahu BS, Mahata S, Bandyopadhyay K, Mahata M, Avolio E, Pasqua T, Sahu C, Bandyopadhyay GK, Bartolomucci 
A, Webster NJG, et al. Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic 
(PACAPergic) stimulation in PC12 cells. Cell Tissue Res (2019) 376:51–70. doi:10.1007/s00441-018-2956-1
31.  Borovac JA, Glavas D, Susilovic Grabovac Z, Supe Domic D, D’Amario D, Bozic J. Catestatin in Acutely 
Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study. J Clin Med (2019) 8:1132. 
doi:10.3390/jcm8081132
32.  Izci S, Acar E, Inanir M. Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism. 
Arch Med Sci - Atheroscler Dis (2020) 5:49–56. doi:10.5114/amsad.2020.95562
33.  Gaede AH, Pilowsky PM. Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates 
sympathetic barosensitivity and the chemoreflex in rat CVLM. Am J Physiol - Regul Integr Comp Physiol (2012) 
302:365–372. doi:10.1152/ajpregu.00409.2011
34.  Gayen JR, Gu Y, O’Connor DT, Mahata SK. Global Disturbances in Autonomic Function Yield Cardiovascular 
Instability and Hypertension in the Chromogranin A Null Mouse. Endocrinology (2009) 150:5027–5035. 
doi:10.1210/en.2009-0429
35.  Dev NB, Gayen JR, O’Connor DT, Mahata SK. Chromogranin A and the autonomic system: Decomposition of 
heart rate variability and rescue by its catestatin fragment. Endocrinology (2010) 151:2760–2768. doi:10.1210/
en.2009-1110
36.  Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O’Connor DT. Catecholamine Secretory 
Vesicle Stimulus-Transcription Coupling in Vivo. J Biol Chem (2003) 278:32058–32067. doi:10.1074/jbc.
m305545200
37.  Simunovic M, Supe-Domic D, Karin Z, Degoricija M, Paradzik M, Bozic J, Unic I, Skrabic V. Serum catestatin 
concentrations are decreased in obese children and adolescents. Pediatr Diabetes (2019) 20:549–555. 
doi:10.1111/pedi.12825
38.  O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine 
release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens (2002) 20:1335–
1345. doi:10.1097/00004872-200207000-00020
39.  Woowiec L, Rogowicz D, Banach J, Gilewski W, Sinkiewicz W, Grzesk G. Catestatin as a New Prognostic Marker 
in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up. Dis Markers (2020) 
2020: doi:10.1155/2020/8847211
40.  Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Catestatin-A Novel Predictor of Left Ventricular Remodeling after 
Acute Myocardial Infarction. Sci Rep (2017) 7:1–9. doi:10.1038/srep44168
41.  Chen Y, Wang X, Yang C, Su X, Yang W, Dai Y, Han H, Jiang J, Lu L, Wang H, et al. Decreased circulating catestatin 
levels are associated with coronary artery disease: The emerging anti-inflammatory role. Atherosclerosis (2019) 
281:78–88. doi:10.1016/j.atherosclerosis.2018.12.025
200
Chapter 8 - General discussion
42.  Borovac JA, Dogas Z, Supe-Domic D, Galic T, Bozic J. Catestatin serum levels are increased in male patients with 
obstructive sleep apnea. Sleep Breath (2019) 23:473–481. doi:10.1007/s11325-018-1703-x
43.  Dai F, Dalla Costa E, Cannas S, Heinzl EUL, Minero M, Mazzola SM. May salivary chromogranin a act as a 
physiological index of stress in transported donkeys? A pilot study. Animals (2020) 10:1–8. doi:10.3390/
ani10060972
44.  Srithunyarat T, Hagman R, Höglund O V., Stridsberg M, Hanson J, Lagerstedt AS, Pettersson A. Catestatin, 
vasostatin, cortisol, and visual analog scale scoring for stress assessment in healthy dogs. Res Vet Sci (2018) 
117:74–80. doi:10.1016/j.rvsc.2017.11.015
45.  Srithunyarat T, Höglund O V., Hagman R, Olsson U, Stridsberg M, Lagerstedt AS, Pettersson A. Catestatin, 
vasostatin, cortisol, temperature, heart rate, respiratory rate, scores of the short form of the Glasgow 
composite measure pain scale and visual analog scale for stress and pain behavior in dogs before and after 
ovariohysterectomy. BMC Res Notes (2016) 9:1–9. doi:10.1186/s13104-016-2193-1
46.  Yoo BB, Mazmanian SK. The Enteric Network: Interactions between the Immune system and Nervous Systems of 
the Gut. (2017) 46:910–926. doi:10.1016/j.immuni.2017.05.011
47.  Meroni E, Stakenborg N, Viola MF, Boeckxstaens GE. Intestinal macrophages and their interaction with the 
enteric nervous system in health and inflammatory bowel disease. Acta Physiol (2019) 225:1–11. doi:10.1111/
apha.13163
48.  Stakenborg N, Viola MF, Boeckxstaens GE. Intestinal neuro-immune interactions: focus on macrophages, mast 
cells and innate lymphoid cells. Curr Opin Neurobiol (2020) 62:68–75. doi:10.1016/j.conb.2019.11.020
49.  Bohórquez D V., Shahid RA, Erdmann A, Kreger AM, Wang Y, Calakos N, Wang F, Liddle RA. Neuroepithelial circuit 
formed by innervation of sensory enteroendocrine cells. J Clin Invest (2015) 125:782–786. doi:10.1172/JCI78361
50.  Dockray GJ. Gastrointestinal hormones and the dialogue between gut and brain. J Physiol (2014) 592:2927–
2941. doi:10.1113/jphysiol.2014.270850
51.  Kulkarni S, Ganz J, Bayrer J, Becker L, Bogunovic M, Rao M. Advances in enteric neurobiology: The “brain” in the 
gut in health and disease. J Neurosci (2018) 38:9346–9354. doi:10.1523/JNEUROSCI.1663-18.2018
52.  Liddle RA. Neuropods. Cmgh (2019) 7:739–747. doi:10.1016/j.jcmgh.2019.01.006
53.  Atif SM, Gibbings SL, Jakubzick C V. Cre Driver Mice Targeting Macrophages Jiayuan. (2019) 1784:69–76. 
doi:10.1007/978-1-4939-7837-3
54.  Murphy DE, de Jong OG, Brouwer M, Wood MJ, Lavieu G, Schiffelers RM, Vader P. Extracellular vesicle-based 
therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med (2019) 51: doi:10.1038/s12276-
019-0223-5
55.  Biswas N, Gayen J, Mahata M, Su Y, Mahata SK, O’Connor DT. Novel Peptide Isomer Strategy for Stable Inhibition 
of Catecholamine Release: Application to Hypertension. Hypertension (2012) 60:1552–1559. doi:10.1161/
hypertensionaha.112.202127
56.  Tsigelny IF, Kouznetsova VL, Biswas N, Mahata SK, O’Connor DT. Development of a pharmacophore model 
for the catecholamine release-inhibitory peptide catestatin: Virtual screening and functional testing identify 









Appendices - Nederlandse samenvatting
Nederlandse samenvatting
Dit proefschrift gaat over de effecten van catestatin op ontsteking in de darm en de rol 
van MHC-I in de verdediging tegen tumoren en virussen.
De rol van catestatin tijdens ontsteking
Het hormoon chromogranine A wordt 
geproduceerd door verschillende 
gespecialiseerde cellen in het lichaam, 
zoals in de eilandjes van Langerhans 
in de alvleesklier. Na productie kan dit 
hormoon in de volgende actieve stukjes 
worden geknipt (Fig. 1); pancreastatin 
(PST: hCgA250-301), WE-14 (hCgA324-
337), vasostatin (hCgA1-76), catestatin 
(CST: hCgA352-372), chromofungin 
(hCgA47-66) en serpinin (hCgA411-436), 
deze stukjes noemen we peptiden.
Op dit moment is er veel belangstelling voor de peptide catestatin, omdat deze een 
belangrijke rol lijkt te spelen in het onderdrukken van ontsteking in het lichaam. 
Zo zijn er zelfs afwijkende hoeveelheden van catestatin in het bloed gemeten van 
patiënten met een hartafwijking, stofwisselingsziekte of chronische ontsteking zoals 
in de ziekte van Crohn, collitis ulcerosa, diabetes en reumatoïde artritis. 
De effecten van catestatin op de darmwand
Patienten met ziektes als IBD (ziekte van Crohn en collitis ulcerosa), 
prikkelbaredarmsyndroom en coeliakie hebben patiënten vaak last van ontsteking en 
een ‘lekkende’ darmwand. De darmwand, bestaande uit een laag cellen met daarop 
een slijmlaag, beschermt in een normale situatie het lichaam tegen indringers 
zoals bacteriën en virussen. Maar wanneer de beschermende laag beschadigd 
wordt, kunnen bacteriën door de darmwand heen. Dit leidt tot een zogeheten 
ontstekingsreactie waarbij witte bloedcellen naar de darm komen om de bacteriën uit 
te schakelen en ze op te ruimen. Bij een chronische darmontsteking kan de ontsteking 
niet opgelost worden, waardoor patiënten last blijven houden van hun darmen en 
vaak levenslang medicatie nodig hebben.
 
Fig. 1. Productie van chromogranine A door 
cellen in de darmwand, dat na productie in zes 
actieve stukjes geknipt kan worden.
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Catestatin beïnvloedt de barrièrefunctie en slijmlaag van de 
darmwand
In hoofdstuk 2 bekijken we de effecten van catestatin en pancreastatin op de 
regulatie van de darmwand. We komen tot de volgende vier bevindingen: 
1)  Na onderzoek op bloed van patiënten met de ziekte van Crohn en collitis ulcerosa 
blijkt dat de hoeveelheden chromogranine A en catestatin in deze patiënten hoger 
zijn dan bij de gezonde controlegroep 
2)  De darm van muizen die geen catestatin kunnen maken, bevat minder soorten 
bacteriën. Interessant genoeg wordt ditzelfde patroon in de bacteriën ook gezien 
voor IBD-patiënten 
3)  We kijken naar de zogeheten tight junctions (alsof de cellen elkaars handen 
vasthouden), dit zijn de connecties tussen de eenlagige darmcelwand. Deze blijken 
langer te zijn in muizen die geen catestatin kunnen produceren. De tight junctions 
lijken bovendien op de connecties tussen darmwandcellen van IBD-patiënten 
4)  Het ‘lekken’ van de darm is erger in muizen die geen catestatin kunnen maken. 
Door middel van het toedienen van pancrestatin of catestatin aan muizen zonder 
chromogranine A zien we dat het lekken van de darm zelfs tegenovergesteld 
gereguleerd wordt. Het toedienen van pancreastatin leidt tot meer ‘lekken’, terwijl 
het toedienen van catestatin juist tot minder darmlekkage leidt. 
We concluderen hieruit dat chromogranine A en zijn actieve peptiden belangrijk zijn 
voor de functie van de darmwand. Catestatin speelt een belangrijke rol in dit proces 
door zijn effecten op de tight junctions, de aanwezige bacteriën en het transport over 
de darmwand. 
Naast de barrièrefunctie van de darmwand kijken we naar de regulatie van de slijmlaag 
in hoofdstuk 3. Hier laten we zien dat catestatin, geproduceerd door immuuncellen 
uit het beenmerg, de slijmlaag reguleert. Daarnaast hebben IBD-patiënten afwijkende 
hoeveelheden catestatin in hun ontlasting. Hieruit leiden we af dat de verdwijnende 
slijmlaag in ontstoken delen van de darm gereguleerd wordt door catestatin.
Het effect van catestatin op de migratie van immuuncelmigratie
In hoofdstuk 4 kijken we naar het effect van catestatin op de zogeheten 
immuuncelmigratie (verplaatsing) tijdens ontsteking. Hier maaken we gebruik van 
verschillende technieken waarbij we bijvoorbeeld de omgeving konden controleren 
of de cellen live volgen in de muis na stimulatie met catestatin. Hiermee laten we 
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zien dat catestatin normaal gesproken immuuncellen aantrekt, maar de migratie van 
immuuncellen naar een ontstoken omgeving blokkeert. Deze bevindingen zijn in lijn 
met het idee dat catestatin helpt tijdens een ontsteking.  
Het werkingsmechanisme van catestatin 
Gedurende dit onderzoek kwamen we erachter dat catestatin niet alleen wordt 
geproduceerd door gespecialiseerde cellen in de celwand, maar ook door 
immuuncellen met een oorsprong in het beenmerg. In de discussie van dit proefschrift, 
hoofdstuk 8, speculeren we daarom over: 1) De bijdrage van deze verschillende 
cellen op de anti-inflammatoire werking van catestatin; 2) De interactie tussen het 
zenuwstelsel en het immuunsysteem via catestatin; 3) Mogelijke behandelingsopties 
voor de toekomst met oraal toedienbare catestatin; 4) Opties voor vervolgonderzoek 
om het precieze werkingsmechanisme te achterhalen.
De interactie tussen immuuncellen ter verdedigen tegen tumoren 
en virusinfecties.
In het tweede deel van dit proefschrift komt de interactie tussen speciale 
immuuncellen, dendritische cellen en macrofagen, om de verdediging tegen tumoren 
en virale infecties te activeren aanbod. In hoofdstuk 5 beschrijven we al het huidige 
onderzoek naar de rol van verscheidene macrofagen uit het bloed en uit weefsel (o.a. 
lever, vet en lymfeklier) in het doorgeven van informatie aan de T-cellen. De T-cellen 
kunnen met deze informatie de gevaarlijke cellen, zoals een tumorcel, uitschakelen. 
Het was al bekent dat macrofagen lokaal helpen bij het oplossen van een ontsteking 
door bv. bacteriën op te eten, maar dat ze net als dendritische cellen ook informatie 
kunnen overdragen aan T-cellen is nieuw. Dit maakt macrofagen interessant om te 
gebruiken voor de behandeling van virusinfecties of kanker.
De functie en interactie van MHC-I in de verdediging tegen 
tumoren en virusinfectie
Hierna bespreken we in hoofdstuk 6 de rol van de receptor MHC-I in de verdediging 
tegen kanker en virussen. MHC-I is aanwezig op immuuncellen zoals macrofagen, 
dendritische cellen en T-cellen, maar ook op andere soorten cellen zoals gladde 
spiercellen, endotheel en tumorcellen. Activatie van MHC-I zet signalering aan die kan 
leiden tot het doodgaan van de cel of doodmaken van andere cellen, tot celdeling 
of celmigratie naar een andere plek. In hoofdstuk 7, bestuderen we de effecten 
van MHC-I op de interactie tussen de dendritische cel en de T-cel. Deze immuuncel 
interactie maakten we zichtbaar met behulp van een elektronenmicroscoop die zeer 
kleine structuren in de cel zichtbaar maakt. Vervolgens laten we met behulp van 
metalen bolletjes beplakt met MHC-I zien, dat MHC-I ervoor zorgt dat structuren in 
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de dendritische cel verplaatsen en leiden tot cytokinen productie. Deze cytokinen 
activeren vervolgens de T-cel, die op zijn beurt de tumor of geïnfecteerde cel kan 
uitschakelen. 
Conclusies
Catestatin beinvloedt de bacteriën, darmwand en migratie van cellen tijdens 
ontsteking. Ondanks dat we niet precies weten hoe catestatin voor deze effecten zorgt, 
kunnen we wel verschillen meten in de catestatinwaarden in het bloed en ontlasting 
van patiënten. Hierdoor is catestatin interessant als indicator om de ziekteprogressie 
te meten. Daarnaast zorgde het toedienen van catestatin voor het terugdraaien van 
de ontsteking. Dit maakt catestatin interessant voor de ontwikkeling van toekomstige 
behandelingen voor patienten met een chronische ontsteking.
Het activeren van T-cellen is nodig voor het uitschakelen van gevaarlijke cellen. Om de 
huidige therapieën te verbeteren zouden naast dendritische cellen ook macrofagen 
gebruikt kunnen worden voor T-cel activatie. Daarnaast speelt MHC-I een belangrijke 
rol in de immuuncelinteractie die leidt tot de activatie van T-cellen. Het begrijpen van 
dit mechanisme helpt om de werking van het immuunsysteem verder te ontrafelen.
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Appendices - Layman summary
Layman summary (published in Fair journal)
The hormone Chromogranin A balances gut wall function
Introduction
In diseases related to chronic 
inflammation such as; inflammatory 
bowel disease (IBD), irritable bowel 
syndrome, and celiac disease, patients 
suffer from a ‘leaky’ gut wall. Normally, the 
gut wall consists of a one-layer cell-wall 
with a mucus layer on top that protects 
you against invaders in the gut, such as 
pathogenic bacteria. If this protection 
is damaged, the bacteria are no longer 
kept outside and can now enter our body. 
This triggers an inflammatory reaction where white blood cells move towards the gut 
to kill the invaders and repair the damaged or ‘leaky’ gut wall. In the case of chronic 
gut inflammation this damage cannot be repaired, which results in ongoing bacterial 
invasion and damage of the gut. As a result, these patients suffer from complications 
due to ongoing gut inflammation and need lifelong treatment. 
In search for a treatment, we focussed on understanding how the gut wall is kept intact 
at steady-state (also called homeostasis). Here, we took a closer look at the locally 
produced hormone chromogranin A (Fig. 1). After production by specialized cells in 
the gut wall, chromogranin A is cut into six small active pieces; pancreastatin, WE-14, 
vasostatin, catestatin, chromofungin and serpinin. All these active pieces, which are 
called peptides, play a role in regulating health and disease. 
Interestingly, the two peptides catestatin and pancreastatin seem to have opposing 
effects; where catestatin plays a role in suppressing inflammation and pancreastatin 
seems to stimulate inflammation. However, we do not currently know much about 
their function in controlling gut homeostasis. Therefore, we investigated the role of 
the active peptides catestatin and pancreastatin on the ‘leaky’ gut wall. 
Findings 
To be able to study the specific role of the complete hormone chromogranin A and 
its peptide catestatin in a physiological setting, we made so-called chromogranin A 
knockout (full hormone-KO) and catestatin knockout (peptide-KO) mice, meaning that 
 
Fig. 1. Chromogranin A production and cutting 
resulting in the active peptides.
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we removed the genes that codes for the hormone or its peptide. The full hormone-
KO mouse could no longer make chromogranin A, while the peptide-KO mouse could 
still make chromogranin A, but it could no longer cut it into the peptide catestatin. 
Additionally, we could feed normal or knockout mice a fluid containing only the full 
hormone or peptide to study its effect as a kind of medication. By using both mouse 
types and peptides as supplementation we could create specific situations necessary 
to study the role of chromogranin A and catestatin on the gut wall function.
First, we looked at the so called ‘tight junctions’, which are structures in the gut cells 
that keep them tightly together in one line (like the cells are holding hands). By using 
an ultrastructural microscope, that is able to enlarge even the most tiny structures 
inside the cells, we could see that the tight junctions in the CST-KO mouse were longer 
and looked similar as in inflammatory bowel disease patients. 
Secondly, we studied how ‘leaky’ the gut-wall was by measuring how much sugar made 
it to the other side of the gut-wall (the sugar was labelled with a green dye to be able 
to see it). Here, detection of green on the other side means ‘leaky’, because in a healthy 
situation the gut-wall is intact and we would not expect to detect green sugar on the 
other side. We learnt that the peptide catestatin is important for maintaining the gut 
barrier since the mice without catestatin showed a very ‘leaky’ gut. By treating the full 
hormone-KO mouse with either catestatin or pancreastatin, we could even see that 
the leakiness of the gut is oppositely regulated by these two peptides; meaning that in 
presence of catestatin the gut-wall seems intact, while after addition of pancreastatin 
the wall seems ‘leaky’.
Thirdly, we identified the bacteria types present in the gut. In the peptide-KO mouse 
we found a higher amount of Firmicutes and a lower amount of Bacteroidetes than in 
the normal mouse. Normally, Firmicutes are necessary for energy uptake from food, 
whereas Bacteroidetes produce acids to keep a good environment in the gut for food 
uptake. However, these bacteria populations need to be balanced to be able to take 
up food and keep the gut in a steady-state. Interestingly, the same shift in bacteria 
groups we found in the peptide-KO mouse is also observed in inflammatory bowel 
disease patients. This shows us that the presence of catestatin is necessary to maintain 
a healthy balance in the gut bacteria that is present. 
Finally, we measured that chromogranin A hormone and catestatin peptide levels in 




Altogether, the hormone chromogranin A and its active peptides play an important 
role in maintaining the gut wall function. Especially the peptide catestatin plays a 
role in making the gut wall less ‘leaky’ by affecting the length of the tight junction, 
the presence of bacteria, and the transport over the gut-wall barrier. Additionally, 
catestatin seems to exert its effect by opposing another peptide pancreastatin. 
Although we now know a great deal more about how these molecules affect gut 
homeostasis, more research is still necessary to define the exact working mechanism. 
Our research is important to understand how gut homeostasis is regulated in health 
and disease. Additionally, blood catestatin levels might be used as a biomarker in 
the future to indicate the presence of inflammation in inflammatory bowel disease 
patients. Finally, catestatin and pancreastatin might be interesting in the future to 
develop treatments for inflammatory bowel disease and other gut-related diseases.
Reviewed by Jonas N. Søndergaard (editor at the Fair Journal).
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Research data management
All primary research data as presented in this thesis were archived according to the 
FAIR (Findable, Accessible, Interoperable and Reusable) principles. All data are stored 
digitally on a local server of the Tumor Immunology department of the Radboud 
University Medical Center (RadboudUMC) and experiments are described in the online 
lab book system Labguru. All data and documents stored on the local server are 
accessible to the supervisors and associated scientific staff. All raw data of research 
performed in the RadboudUMC as used in Chapter 2 is also available through the 
open-source repository Zenodo. The raw data of Chapter 3, 4 and 7 will be available on 
Zenodo upon publication. 
The research with human blood samples at the Department of Tumor Immunology 
complies with all institutional and national ethics regulations and has been approved 
by the ethics committee of Sanquin blood bank. All blood donors were informed of 
the research and have granted their consent. For chapter 2 and 3, informed consent 
was obtained and the study was conducted in accordance with the Institutional 
Board Review of the University Medical Center Utrecht. All samples were collected in 
compliance with the Declaration of Helsinki.
All procedures relating to the WT and KO mice were approved by the Institutional 
Animal Care and Use Committee (UCSD) and all procedures, housing and handling 
of the animals were in accordance with National Institutes of Health animal care 
guidelines. Experiments in chapter 4 using male and female C57BL/6J (Taconic, 
Denmark) and Cx3cr1
GFP mice were approved by the Regional Animal Ethics committee 
in Uppsala, Sweden.  
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